{"doc_id": 0, "doc": {"person_id": 115967211, "visit_occurrence_id": 51248592, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2012-10-19 00:00:00", "visit_end_datetime": "2012-10-19 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-19 00:00:00, ended at 2012-10-19 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 89, "patient_first_visit_date": "2011-05-09 12:40:00", "patient_last_visit_date": "2015-02-18 00:00:00", "end_obs_date": "2013-10-19", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "recurrent", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 27, "cumulated_visit_num": 27, "cumulated_approximate_token_count": 12529, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room Visit, started at 2011-05-09 12:40:00, ended at 2011-05-09 19:32:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hematuria syndrome\n- Headache\n- Blepharitis\n- Posttraumatic stress disorder\n- Visual disturbance\n- Keratitis\n- Myopia\n\n### Drug\n- hypromellose 2 MG/ML Ophthalmic Solution, through Intraocular route, started on 2011-05-09, presumably until 2011-06-08, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes 4 times a day.\n- erythromycin 0.005 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2011-05-09, presumably until 2011-06-08, with intended 0 refill(s). Instructions: instill 0.5 cm to both eyes 2 times a day. For 5 days in each eye\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-05-21 08:00:34, ended at 2011-05-21 09:57:57\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 14 (millimeter mercury column)\n- Intraocular pressure of right eye: 14 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Heteronymous bilateral visual field defects\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-29 12:55:00, ended at 2011-05-29 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Finding of head and neck region\n- Heteronymous bilateral visual field defects\n- Swelling / lump finding\n- Disorder of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-31 00:00:00, ended at 2011-05-31 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm of uncertain behavior of pituitary gland\n- Heteronymous bilateral visual field defects\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-06-14 09:01:04, ended at 2011-06-14 17:43:03\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- atomoxetine 40 MG Oral Capsule, through Oral route, presumably until 2011-07-26. Instructions: take 40 mg by mouth 2 times a day.\n- aripiprazole 2 MG Oral Tablet, through Oral route, presumably until 2011-07-26. Instructions: take 2 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-06-14 09:40:28, ended at 2011-06-14 17:43:53\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- hydrocortisone 10 MG Oral Tablet, through Oral route, started on 2011-06-14, presumably until 2011-07-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth as directed. Take 2 tablets every morning and 1 tablet every afternoon\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-14 11:56:00, ended at 2011-06-14 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Prolactin [Mass/volume] in Serum or Plasma: 76 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.03 (micro-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 12 (microgram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.60 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.52 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.15 (thousand per microliter)\n- Testosterone [Mass/volume] in Serum or Plasma: 33 (nanogram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.5 (percent)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.8 (percent)\n- MCH [Entitic mass] by Automated count: 32.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.7 (nanogram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.1 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of pituitary gland\n- Heteronymous bilateral visual field defects\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-06-15 00:00:00, ended at 2011-06-15 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Panhypopituitarism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2011-06-15, presumably until 2011-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-16 08:44:00, ended at 2011-06-16 08:47:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomography, head or brain; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Disorder of brain\n- Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-16 08:48:00, ended at 2011-06-16 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-22 01:00:00, ended at 2011-06-22 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation\n\n### Condition\n- Finding of head and neck region\n- Benign neoplasm of pituitary gland and craniopharyngeal duct\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-06-22 10:30:48, ended at 2011-06-22 17:57:17\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- simvastatin 10 MG Oral Tablet, through Oral route, presumably until 2011-07-26. Instructions: take 10 mg by mouth every bedtime.\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, presumably until 2011-07-26. Instructions: 1 Puff by Nasal route Every Day.\n- NDA021457 200 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, presumably until 2011-07-26. Instructions: 2 Puffs by Inhalation route as needed.\n- clonazepam 1 MG Oral Tablet, through Oral route, presumably until 2011-07-26. Instructions: take 1 mg by mouth 3 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-06-23 06:05:00, ended at 2011-07-26 14:23:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Base deficit in Blood: 1.0 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 366 (picogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.41 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 288 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 138 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.5 (percent)\n- Prothrombin time (PT): N/A (second)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.7 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 39.0 (millimeter mercury column)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 94 (millimeter mercury column)\n- Oxygen [Partial pressure] in Blood: 51 (millimeter mercury column)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- Osmolality of Serum or Plasma: 332 (milliosmole per kilogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Body height: 5' 2.992\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 7.8 (microgram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: N/A (second)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.23 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.5 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.6 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.12 (micro-international unit per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.00 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: N/A (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 46.6 (millimeter mercury column)\n- Erythrocyte sedimentation rate: 8 (millimeter per hour)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.18 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 166 (milligram per deciliter)\n- Valproate [Mass/volume] in Serum or Plasma: 78.6 (microgram per milliliter)\n- Base excess in Blood by calculation: 9.0 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 32.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.6 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.0 (gram per deciliter)\n\n### Procedure\n- Computed tomography, head or brain; without contrast material, followed by contrast material(s) and further sections\n- Osteoplasty of cranium with flap of bone\n- Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Computer assisted surgery with MR/MRA\n- Evaluation of speech, language, voice, communication, and/or auditory processing\n- Insertion of endotracheal tube\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Percutaneous endoscopic gastrostomy\n- Occupational therapy evaluation\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Other exploration and decompression of spinal canal\n- Evaluation of oral and pharyngeal swallowing function\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Collection of venous blood by venipuncture\n- Venous catheterization, not elsewhere classified\n- Partial excision of pituitary gland by transsphenoidal approach\n- Computed tomography, head or brain; without contrast material\n- Controlled ventilation procedure and therapy, initiation and management\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Arterial puncture, withdrawal of blood for diagnosis\n- Radiologic examination, chest; single view, frontal\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Insertion of catheter into artery\n- Continuous invasive mechanical ventilation for 96 consecutive hours or more\n\n### Condition\n- Asthma\n- Cachexia\n- Disorder of nasal cavity\n- Disorder of pituitary gland\n- Obesity\n- Blind or low vision - both eyes\n- Diabetes insipidus\n- Heteronymous bilateral visual field defects\n- Swelling / lump finding\n- Atelectasis\n- Episodic mood disorder\n- Pleural effusion\n- Visual disturbance\n- Acute respiratory failure\n- Finding of head and neck region\n- Panhypopituitarism\n- Abnormal findings on diagnostic imaging of skull and head\n- Bipolar affective disorder, currently manic, severe, with psychosis\n- Disturbance of consciousness\n- Hyperosmolality and or hypernatremia\n- Lung field abnormal\n- Malnutrition (calorie)\n- Neoplasm of uncertain behavior of pituitary gland\n- Organic anxiety disorder\n- Pulmonary congestion and hypostasis\n- Acquired hypothyroidism\n- Fever\n- Homonymous hemianopia\n- Anxiety state\n- Adrenal cortical hypofunction\n- Bipolar I disorder, single manic episode\n- Disorder of posterior pituitary\n- Blindness AND/OR vision impairment level\n- Pneumonitis due to inhaled substance\n- Tobacco dependence syndrome\n\n### Drug\n- hydrocortisone 5 MG Oral Tablet, through Oral route, started on 2011-07-14, presumably until 2012-04-17, with intended 0 refill(s). Instructions: take 3 Tabs by mouth every morning.\n- hydrocortisone 100 MG Injection, started on 2011-06-23, presumably until 2011-07-04\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-06-24, presumably until 2011-07-07\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- aripiprazole 5 MG Oral Tablet, through Oral route, started on 2011-07-12, presumably until 2011-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning.\n- desmopressin acetate 0.2 MG Oral Tablet, through Oral route, started on 2011-07-08, presumably until 2011-07-09\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-11-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2011-06-28, presumably until 2011-07-02\n- valproic acid 250 MG Oral Capsule, through Oral route, started on 2011-07-08, presumably until 2011-11-15, with intended 0 refill(s). Instructions: take 2 Caps by mouth every bedtime.\n- levothyroxine sodium 0.2 MG Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-07-05\n- olanzapine 10 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24\n- gabapentin 50 MG/ML Oral Solution, through Oral route, started on 2011-06-27, presumably until 2011-06-27\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2011-06-29, presumably until 2011-06-29\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2011-07-26, presumably until 2012-07-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed.\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route, started on 2011-06-25, presumably until 2012-07-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- simvastatin 10 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-07-26, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime.\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2011-06-29, presumably until 2011-07-05\n- haloperidol 5 MG/ML Injectable Solution, started on 2011-06-23, presumably until 2011-07-05\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2011-06-24, presumably until 2011-06-30\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2011-06-24, presumably until 2011-06-25\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-06-25, presumably until 2011-06-25\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2011-06-24, presumably until 2011-07-26. Instructions: 1 Puff by Nasal route Every Day.\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2011-07-26, presumably until 2012-01-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed for Insomnia.\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2011-07-01, presumably until 2011-07-06\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-06-25, presumably until 2011-07-16\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-07-07, presumably until 2011-07-21\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2011-07-03, presumably until 2011-07-03\n- olanzapine 5 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-25\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-06-29, presumably until 2011-07-22\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-06-28, presumably until 2011-06-30\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2011-06-23, presumably until 2011-06-23\n- hydrocortisone 10 MG Oral Tablet, through Oral route, started on 2011-07-04, presumably until 2012-04-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily before dinner.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2011-06-25, presumably until 2011-06-25\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-06-25, presumably until 2011-07-23\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-06-24, presumably until 2012-07-25, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- ramelteon 8 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- olanzapine 10 MG Injection, through Intramuscular route, started on 2011-06-24, presumably until 2011-06-30\n- hydrocortisone 20 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-07-13\n- 10 ML furosemide 10 MG/ML Injection, started on 2011-06-30, presumably until 2011-07-03\n- midodrine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-07-01, presumably until 2011-07-26\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- NDA021457 200 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2011-07-15, presumably until 2011-07-15, with intended 0 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed.\n- 50 ML clindamycin 12 MG/ML Injection, through Intravenous route, started on 2011-06-23, presumably until 2011-06-26\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2011-06-24, presumably until 2011-06-25\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2011-06-23, presumably until 2011-07-03\n- 1 ML vitamin K1 10 MG/ML Injection, through Intravenous route, started on 2011-06-28, presumably until 2011-07-02\n- valproic acid 50 MG/ML Oral Solution, through Oral route, started on 2011-06-27, presumably until 2011-07-08\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-06-25, presumably until 2011-06-27\n- cefepime 2000 MG Injection, through Intravenous route, started on 2011-06-27, presumably until 2011-07-07\n- atomoxetine 40 MG Oral Capsule, through Oral route, started on 2011-06-24, presumably until 2011-06-27. Instructions: take 40 mg by mouth 2 times a day.\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-06-23, presumably until 2011-06-28\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- lorazepam 2 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24\n- oxybutynin chloride 5 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2011-06-26, presumably until 2011-06-28\n- desmopressin acetate 0.004 MG/ML Injectable Solution, through Intravenous route, started on 2011-06-23, presumably until 2011-07-06\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-07-04\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2011-06-29, presumably until 2011-06-29\n- clonazepam 1 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24. Instructions: take 1 mg by mouth 3 times a day.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2011-07-05, presumably until 2011-07-06\n- midazolam 1 MG/ML Injectable Solution, started on 2011-06-30, presumably until 2011-06-30\n- aripiprazole 2 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-07-11. Instructions: take 2 mg by mouth Every Day.\n- sodium chloride 6.5 MG/ML Nasal Spray, through Nasal route, started on 2011-07-02, presumably until 2012-07-14, with intended 0 refill(s). Instructions: 2 Sprays by Nasal route every 2 hours.\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-07-04, presumably until 2011-07-15\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2011-06-29, presumably until 2011-06-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-08-13 13:26:26, ended at 2011-08-13 14:48:05\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2011-08-13 17:32:00, ended at 2011-08-14 01:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.2 (percent)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.08 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.04 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 56.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.29 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 256 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Bipolar disorder\n- Neoplasm of uncertain behavior of pituitary gland\n- Visual disturbance\n- Postprocedural state finding\n- Essential hypertension\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-08-13, presumably until 2011-08-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-13 10:31:31, ended at 2011-09-13 12:56:18\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Panhypopituitarism\n\n### Drug\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route, presumably until 2012-04-17. Instructions: take  by mouth. 0.1 mg qhs, 0.05 mg in morning \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-13 10:31:48, ended at 2011-09-13 12:58:33\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-13 13:22:00, ended at 2011-09-13 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.4 (nanogram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 34 (nanogram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Panhypopituitarism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-15 10:10:00, ended at 2011-11-15 14:42:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Disorder of pituitary gland\n- Finding of head and neck region\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-15 12:56:54, ended at 2011-11-15 15:37:29\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Panhypopituitarism\n\n### Drug\n- aripiprazole 5 MG Oral Tablet, through Oral route. Instructions: take  by mouth.\n- fluoxetine 20 MG Oral Capsule, through Oral route. Instructions: take  by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-15 12:57:10, ended at 2011-11-15 16:07:51\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Panhypopituitarism\n- Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2011-11-15 14:43:00, ended at 2011-11-16 15:45:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.44 (million per microliter)\n- Potassium [Moles/volume] in Blood: 3.9 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.23 (milli-international unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 57.3 (millimeter mercury column)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.70 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Sodium [Moles/volume] in Blood: 143 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Prothrombin time (PT): 12.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 39 (percent)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 143 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 5.0 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 31.0 (milliequivalent per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 13.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- Oxygen [Partial pressure] in Blood: 28 (millimeter mercury column)\n- Body height: 5' 3\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.7 (nanogram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 57 (nanogram per deciliter)\n\n### Procedure\n- Radiologic examination, chest; single view, frontal\n- Insertion of temporary indwelling bladder catheter; simple (eg, Foley)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Diagnostic interview and evaluation, not otherwise specified\n\n### Condition\n- Edema\n- Seizure\n- Anxiety state\n- Neoplasm of uncertain behavior of pituitary gland\n- Organic anxiety disorder\n- Psychotic disorder\n- Acquired hypothyroidism\n- Blind or low vision - both eyes\n- Dysthymia\n- Low blood pressure\n- Panhypopituitarism\n- Insomnia\n- Diabetes insipidus\n- Hyperlipidemia\n- Visual disturbance\n- Cough\n- Disorder of pituitary gland\n- Failure to thrive\n- Heteronymous bilateral visual field defects\n- Adrenal cortical hypofunction\n- Bipolar I disorder, single manic episode\n\n### Drug\n- hydrocortisone 5 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take 3 Tabs by mouth every morning.\n- aripiprazole 5 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take  by mouth.\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2012-01-03, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily.\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take  by mouth.\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16\n- 24 HR divalproex sodium 250 MG Extended Release Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take 1 Tab by mouth 2 times a day.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take 1 Cap by mouth 2 times a day.\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route. Instructions: take 20 mg by mouth daily.\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route. Instructions: take 1 Tab by mouth every bedtime.\n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2011-11-16, presumably until 2011-11-16\n- 24 HR divalproex sodium 500 MG Extended Release Oral Tablet, through Oral route. Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-01-03 10:16:11, ended at 2012-01-03 11:43:09\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Panhypopituitarism\n\n### Drug\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, presumably until 2012-04-17. Instructions: take 100 mcg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-01-03 11:51:00, ended at 2012-01-03 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 70 (nanogram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Panhypopituitarism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-04-17 14:02:05, ended at 2012-04-17 17:12:17\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Panhypopituitarism\n- Adrenal cortical hypofunction\n- Disorder of pituitary gland\n- Diabetes insipidus\n\n### Drug\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route. Instructions: take 0.1 mg by mouth as directed. 0.05 mg po qAM, 0.1 mg po qhs \n- hydrocortisone 10 MG Oral Tablet, through Oral route. Instructions: take 10 mg by mouth 2 times a day.  \n- levothyroxine sodium 0.125 MG Oral Tablet, through Oral route, presumably until 2015-02-17. Instructions: take  by mouth.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-04-17 15:50:00, ended at 2012-04-18 12:30:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 70 (nanogram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.78 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.41 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 147 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.35 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 42.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.7 (gram per deciliter)\n- Prolactin [Mass/volume] in Serum or Plasma: <1 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: <0.01 (milli-international unit per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.2 (nanogram per deciliter)\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences\n- Hospital discharge day management; 30 minutes or less\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Blindness AND/OR vision impairment level\n- Diabetes insipidus\n- Disorder of nasal cavity\n- Disorder of visual pathways\n- Panhypopituitarism\n- Severe visual impairment\n- Essential hypertension\n\n### Drug\n- aripiprazole 5 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- hydrocortisone 10 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- ramelteon 8 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2012-04-17, presumably until 2012-04-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-19 00:00:00, ended at 2012-10-19 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2011-05-09 12:40:00, ended at 2011-05-09 19:32:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Erythrocyte sedimentation rate: 2 (millimeter per hour)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hematuria syndrome\n- Headache\n- Blepharitis\n- Posttraumatic stress disorder\n- Visual disturbance\n- Keratitis\n- Myopia\n\n### Drug\n- hypromellose 2 MG/ML Ophthalmic Solution, through Intraocular route, started on 2011-05-09, presumably until 2011-06-08, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes 4 times a day.\n- erythromycin 0.005 MG/MG Ophthalmic Ointment, through Intraocular route, started on 2011-05-09, presumably until 2011-06-08, with intended 0 refill(s). Instructions: instill 0.5 cm to both eyes 2 times a day. For 5 days in each eye\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-05-21 08:00:34, ended at 2011-05-21 09:57:57\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 14 (millimeter mercury column)\n- Intraocular pressure of right eye: 14 (millimeter mercury column)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Heteronymous bilateral visual field defects\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-05-29 12:55:00, ended at 2011-05-29 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Finding of head and neck region\n- Heteronymous bilateral visual field defects\n- Swelling / lump finding\n- Disorder of brain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-05-31 00:00:00, ended at 2011-05-31 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm of uncertain behavior of pituitary gland\n- Heteronymous bilateral visual field defects\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-06-14 09:01:04, ended at 2011-06-14 17:43:03\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- atomoxetine 40 MG Oral Capsule, through Oral route, presumably until 2011-07-26. Instructions: take 40 mg by mouth 2 times a day.\n- aripiprazole 2 MG Oral Tablet, through Oral route, presumably until 2011-07-26. Instructions: take 2 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-06-14 09:40:28, ended at 2011-06-14 17:43:53\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- hydrocortisone 10 MG Oral Tablet, through Oral route, started on 2011-06-14, presumably until 2011-07-26, with intended 3 refill(s). Instructions: take 1 Tab by mouth as directed. Take 2 tablets every morning and 1 tablet every afternoon\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-14 11:56:00, ended at 2011-06-14 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Prolactin [Mass/volume] in Serum or Plasma: 76 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 2.03 (micro-international unit per milliliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Cortisol [Mass/volume] in Serum or Plasma: 12 (microgram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.60 (million per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.52 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.15 (thousand per microliter)\n- Testosterone [Mass/volume] in Serum or Plasma: 33 (nanogram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 23.5 (percent)\n- MCHC [Mass/volume] by Automated count: 34.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 97 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.8 (percent)\n- MCH [Entitic mass] by Automated count: 32.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 199 (thousand per microliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.7 (nanogram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 64.1 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of pituitary gland\n- Heteronymous bilateral visual field defects\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-06-15 00:00:00, ended at 2011-06-15 00:00:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Panhypopituitarism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2011-06-15, presumably until 2011-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-16 08:44:00, ended at 2011-06-16 08:47:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, head, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n- Computed tomography, head or brain; without contrast material, followed by contrast material(s) and further sections\n\n### Condition\n- Disorder of brain\n- Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-16 08:48:00, ended at 2011-06-16 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-06-22 01:00:00, ended at 2011-06-22 23:59:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging guidance for needle placement (eg, for biopsy, needle aspiration, injection, or placement of localization device) radiological supervision and interpretation\n\n### Condition\n- Finding of head and neck region\n- Benign neoplasm of pituitary gland and craniopharyngeal duct\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-06-22 10:30:48, ended at 2011-06-22 17:57:17\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- simvastatin 10 MG Oral Tablet, through Oral route, presumably until 2011-07-26. Instructions: take 10 mg by mouth every bedtime.\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, presumably until 2011-07-26. Instructions: 1 Puff by Nasal route Every Day.\n- NDA021457 200 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, presumably until 2011-07-26. Instructions: 2 Puffs by Inhalation route as needed.\n- clonazepam 1 MG Oral Tablet, through Oral route, presumably until 2011-07-26. Instructions: take 1 mg by mouth 3 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-06-23 06:05:00, ended at 2011-07-26 14:23:00\nThe patient in this visit was 52 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 13 (unit per liter)\n- Base deficit in Blood: 1.0 (millimole per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 366 (picogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 9.7 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.41 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 288 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 2.3 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 34 (millimole per liter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 138 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 91.5 (percent)\n- Prothrombin time (PT): N/A (second)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.7 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: <5 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 39.0 (millimeter mercury column)\n- MCH [Entitic mass] by Automated count: 33.0 (picogram)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 94 (millimeter mercury column)\n- Oxygen [Partial pressure] in Blood: 51 (millimeter mercury column)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- Osmolality of Serum or Plasma: 332 (milliosmole per kilogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 31 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Body height: 5' 2.992\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 98 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 7.8 (microgram per milliliter)\n- aPTT in Platelet poor plasma by Coagulation assay: N/A (second)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: <0.2 (milligram per deciliter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.23 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 35.5 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.6 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 1.15 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.12 (micro-international unit per milliliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 9.00 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: N/A (millimole per liter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 46.6 (millimeter mercury column)\n- Erythrocyte sedimentation rate: 8 (millimeter per hour)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.18 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.1 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 166 (milligram per deciliter)\n- Valproate [Mass/volume] in Serum or Plasma: 78.6 (microgram per milliliter)\n- Base excess in Blood by calculation: 9.0 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 32.3 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.6 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 5.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.0 (gram per deciliter)\n\n### Procedure\n- Computed tomography, head or brain; without contrast material, followed by contrast material(s) and further sections\n- Osteoplasty of cranium with flap of bone\n- Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s)\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Computer assisted surgery with MR/MRA\n- Evaluation of speech, language, voice, communication, and/or auditory processing\n- Insertion of endotracheal tube\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Treatment of swallowing dysfunction and/or oral function for feeding\n- Percutaneous endoscopic gastrostomy\n- Occupational therapy evaluation\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Other exploration and decompression of spinal canal\n- Evaluation of oral and pharyngeal swallowing function\n- Manipulation chest wall, such as cupping, percussing, and vibration to facilitate lung function; initial demonstration and/or evaluation\n- Collection of venous blood by venipuncture\n- Venous catheterization, not elsewhere classified\n- Partial excision of pituitary gland by transsphenoidal approach\n- Computed tomography, head or brain; without contrast material\n- Controlled ventilation procedure and therapy, initiation and management\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n- Insertion of peripherally inserted central venous catheter (PICC), without subcutaneous port or pump, without imaging guidance; age 5 years or older\n- Arterial puncture, withdrawal of blood for diagnosis\n- Radiologic examination, chest; single view, frontal\n- Therapeutic procedure, 1 or more areas, each 15 minutes; gait training (includes stair climbing)\n- Insertion of catheter into artery\n- Continuous invasive mechanical ventilation for 96 consecutive hours or more\n\n### Condition\n- Asthma\n- Cachexia\n- Disorder of nasal cavity\n- Disorder of pituitary gland\n- Obesity\n- Blind or low vision - both eyes\n- Diabetes insipidus\n- Heteronymous bilateral visual field defects\n- Swelling / lump finding\n- Atelectasis\n- Episodic mood disorder\n- Pleural effusion\n- Visual disturbance\n- Acute respiratory failure\n- Finding of head and neck region\n- Panhypopituitarism\n- Abnormal findings on diagnostic imaging of skull and head\n- Bipolar affective disorder, currently manic, severe, with psychosis\n- Disturbance of consciousness\n- Hyperosmolality and or hypernatremia\n- Lung field abnormal\n- Malnutrition (calorie)\n- Neoplasm of uncertain behavior of pituitary gland\n- Organic anxiety disorder\n- Pulmonary congestion and hypostasis\n- Acquired hypothyroidism\n- Fever\n- Homonymous hemianopia\n- Anxiety state\n- Adrenal cortical hypofunction\n- Bipolar I disorder, single manic episode\n- Disorder of posterior pituitary\n- Blindness AND/OR vision impairment level\n- Pneumonitis due to inhaled substance\n- Tobacco dependence syndrome\n\n### Drug\n- hydrocortisone 5 MG Oral Tablet, through Oral route, started on 2011-07-14, presumably until 2012-04-17, with intended 0 refill(s). Instructions: take 3 Tabs by mouth every morning.\n- hydrocortisone 100 MG Injection, started on 2011-06-23, presumably until 2011-07-04\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2011-06-24, presumably until 2011-07-07\n- 50 ML sodium bicarbonate 84 MG/ML Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- aripiprazole 5 MG Oral Tablet, through Oral route, started on 2011-07-12, presumably until 2011-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning.\n- desmopressin acetate 0.2 MG Oral Tablet, through Oral route, started on 2011-07-08, presumably until 2011-07-09\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-11-16, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- vancomycin 1000 MG Injection, through Intravenous route, started on 2011-06-28, presumably until 2011-07-02\n- valproic acid 250 MG Oral Capsule, through Oral route, started on 2011-07-08, presumably until 2011-11-15, with intended 0 refill(s). Instructions: take 2 Caps by mouth every bedtime.\n- levothyroxine sodium 0.2 MG Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-07-05\n- olanzapine 10 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24\n- gabapentin 50 MG/ML Oral Solution, through Oral route, started on 2011-06-27, presumably until 2011-06-27\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2011-06-29, presumably until 2011-06-29\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2011-07-26, presumably until 2012-07-25, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 4 hours as needed.\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route, started on 2011-06-25, presumably until 2012-07-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- simvastatin 10 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-07-26, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime.\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2011-06-29, presumably until 2011-07-05\n- haloperidol 5 MG/ML Injectable Solution, started on 2011-06-23, presumably until 2011-07-05\n- lorazepam 2 MG/ML Injectable Solution, through Intravenous route, started on 2011-06-24, presumably until 2011-06-30\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2011-06-24, presumably until 2011-06-25\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2011-07-18, presumably until 2011-09-13, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily.\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-06-25, presumably until 2011-06-25\n- 500 ML glucose 50 MG/ML Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- fluticasone propionate 0.05 MG/ACTUAT Metered Dose Nasal Spray, through Nasal route, started on 2011-06-24, presumably until 2011-07-26. Instructions: 1 Puff by Nasal route Every Day.\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2011-07-26, presumably until 2012-01-22, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime as needed for Insomnia.\n- docusate sodium 10 MG/ML Oral Solution, through Oral route, started on 2011-07-01, presumably until 2011-07-06\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-06-25, presumably until 2011-07-16\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-07-07, presumably until 2011-07-21\n- potassium chloride 20 MEQ Powder for Oral Solution, through Oral route, started on 2011-07-03, presumably until 2011-07-03\n- olanzapine 5 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-25\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2011-06-29, presumably until 2011-07-22\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2011-06-28, presumably until 2011-06-30\n- albuterol 0.833 MG/ML / ipratropium bromide 0.167 MG/ML Inhalation Solution, through Inhalation, started on 2011-06-23, presumably until 2011-06-23\n- hydrocortisone 10 MG Oral Tablet, through Oral route, started on 2011-07-04, presumably until 2012-04-17, with intended 0 refill(s). Instructions: take 1 Tab by mouth daily before dinner.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2011-06-25, presumably until 2011-06-25\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-06-25, presumably until 2011-07-23\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-06-24, presumably until 2012-07-25, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- ramelteon 8 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every bedtime.\n- olanzapine 10 MG Injection, through Intramuscular route, started on 2011-06-24, presumably until 2011-06-30\n- hydrocortisone 20 MG Oral Tablet, through Oral route, started on 2011-07-05, presumably until 2011-07-13\n- 10 ML furosemide 10 MG/ML Injection, started on 2011-06-30, presumably until 2011-07-03\n- midodrine hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-07-01, presumably until 2011-07-26\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- NDA021457 200 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2011-07-15, presumably until 2011-07-15, with intended 0 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed.\n- 50 ML clindamycin 12 MG/ML Injection, through Intravenous route, started on 2011-06-23, presumably until 2011-06-26\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2011-06-24, presumably until 2011-06-25\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2011-06-23, presumably until 2011-07-03\n- 1 ML vitamin K1 10 MG/ML Injection, through Intravenous route, started on 2011-06-28, presumably until 2011-07-02\n- valproic acid 50 MG/ML Oral Solution, through Oral route, started on 2011-06-27, presumably until 2011-07-08\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-06-25, presumably until 2011-06-27\n- cefepime 2000 MG Injection, through Intravenous route, started on 2011-06-27, presumably until 2011-07-07\n- atomoxetine 40 MG Oral Capsule, through Oral route, started on 2011-06-24, presumably until 2011-06-27. Instructions: take 40 mg by mouth 2 times a day.\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2011-06-23, presumably until 2011-06-28\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-06-29\n- lorazepam 2 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24\n- oxybutynin chloride 5 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24\n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2011-06-26, presumably until 2011-06-28\n- desmopressin acetate 0.004 MG/ML Injectable Solution, through Intravenous route, started on 2011-06-23, presumably until 2011-07-06\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2011-06-29, presumably until 2011-07-04\n- succinylcholine chloride 20 MG/ML Injectable Solution, started on 2011-06-29, presumably until 2011-06-29\n- clonazepam 1 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-06-24. Instructions: take 1 mg by mouth 3 times a day.\n- 2 ML metoclopramide 5 MG/ML Injection, started on 2011-07-05, presumably until 2011-07-06\n- midazolam 1 MG/ML Injectable Solution, started on 2011-06-30, presumably until 2011-06-30\n- aripiprazole 2 MG Oral Tablet, through Oral route, started on 2011-06-24, presumably until 2011-07-11. Instructions: take 2 mg by mouth Every Day.\n- sodium chloride 6.5 MG/ML Nasal Spray, through Nasal route, started on 2011-07-02, presumably until 2012-07-14, with intended 0 refill(s). Instructions: 2 Sprays by Nasal route every 2 hours.\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-07-04, presumably until 2011-07-15\n- lidocaine hydrochloride 20 MG/ML Injectable Solution, started on 2011-06-29, presumably until 2011-06-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-08-13 13:26:26, ended at 2011-08-13 14:48:05\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2011-08-13 17:32:00, ended at 2011-08-14 01:00:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.6 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.2 (percent)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.08 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.04 (million per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.6 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 56.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Anion gap in Serum or Plasma: 12 (millimole per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.29 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 256 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Bipolar disorder\n- Neoplasm of uncertain behavior of pituitary gland\n- Visual disturbance\n- Postprocedural state finding\n- Essential hypertension\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-08-13, presumably until 2011-08-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-13 10:31:31, ended at 2011-09-13 12:56:18\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Panhypopituitarism\n\n### Drug\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route, presumably until 2012-04-17. Instructions: take  by mouth. 0.1 mg qhs, 0.05 mg in morning \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-09-13 10:31:48, ended at 2011-09-13 12:58:33\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-09-13 13:22:00, ended at 2011-09-13 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.4 (nanogram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 34 (nanogram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 116 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Panhypopituitarism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-11-15 10:10:00, ended at 2011-11-15 14:42:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material, followed by contrast material(s) and further sequences\n\n### Condition\n- Disorder of pituitary gland\n- Finding of head and neck region\n- Swelling / lump finding\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-15 12:56:54, ended at 2011-11-15 15:37:29\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Panhypopituitarism\n\n### Drug\n- aripiprazole 5 MG Oral Tablet, through Oral route. Instructions: take  by mouth.\n- fluoxetine 20 MG Oral Capsule, through Oral route. Instructions: take  by mouth.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-11-15 12:57:10, ended at 2011-11-15 16:07:51\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Panhypopituitarism\n- Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2011-11-15 14:43:00, ended at 2011-11-16 15:45:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.2 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.44 (million per microliter)\n- Potassium [Moles/volume] in Blood: 3.9 (millimole per liter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 0.23 (milli-international unit per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 45 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] in Blood: 57.3 (millimeter mercury column)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.70 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Sodium [Moles/volume] in Blood: 143 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Prothrombin time (PT): 12.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 39 (percent)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.3 (percent)\n- Platelets [#/volume] in Blood by Automated count: 143 (thousand per microliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Base excess in Blood by calculation: 5.0 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 31.0 (milliequivalent per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 13.3 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.8 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.5 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.58 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.30 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 35.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.24 (thousand per microliter)\n- Oxygen [Partial pressure] in Blood: 28 (millimeter mercury column)\n- Body height: 5' 3\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 119 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.7 (nanogram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 57 (nanogram per deciliter)\n\n### Procedure\n- Radiologic examination, chest; single view, frontal\n- Insertion of temporary indwelling bladder catheter; simple (eg, Foley)\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Diagnostic interview and evaluation, not otherwise specified\n\n### Condition\n- Edema\n- Seizure\n- Anxiety state\n- Neoplasm of uncertain behavior of pituitary gland\n- Organic anxiety disorder\n- Psychotic disorder\n- Acquired hypothyroidism\n- Blind or low vision - both eyes\n- Dysthymia\n- Low blood pressure\n- Panhypopituitarism\n- Insomnia\n- Diabetes insipidus\n- Hyperlipidemia\n- Visual disturbance\n- Cough\n- Disorder of pituitary gland\n- Failure to thrive\n- Heteronymous bilateral visual field defects\n- Adrenal cortical hypofunction\n- Bipolar I disorder, single manic episode\n\n### Drug\n- hydrocortisone 5 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take 3 Tabs by mouth every morning.\n- aripiprazole 5 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take  by mouth.\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2012-01-03, with intended 3 refill(s). Instructions: take 2 Tabs by mouth daily.\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take  by mouth.\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16\n- 24 HR divalproex sodium 250 MG Extended Release Oral Tablet, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take 1 Tab by mouth 2 times a day.\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-11-16, presumably until 2011-11-16. Instructions: take 1 Cap by mouth 2 times a day.\n- omeprazole 20 MG Delayed Release Oral Capsule, through Oral route. Instructions: take 20 mg by mouth daily.\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route. Instructions: take 1 Tab by mouth every bedtime.\n- 0.5 ML Streptococcus pneumoniae type 1 capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 10A capsular polysaccharide antigen 0.05 MG/ML / Streptococcus pneumoniae type 11A capsular polysaccharide antigen 0.05 MG/ML / Streptococ..., started on 2011-11-16, presumably until 2011-11-16\n- 24 HR divalproex sodium 500 MG Extended Release Oral Tablet, through Oral route. Instructions: take 1 Tab by mouth 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-01-03 10:16:11, ended at 2012-01-03 11:43:09\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Panhypopituitarism\n\n### Drug\n- levothyroxine sodium 0.1 MG Oral Tablet, through Oral route, presumably until 2012-04-17. Instructions: take 100 mcg by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-01-03 11:51:00, ended at 2012-01-03 23:59:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.0 (nanogram per deciliter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 70 (nanogram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Panhypopituitarism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2012-04-17 14:02:05, ended at 2012-04-17 17:12:17\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Panhypopituitarism\n- Adrenal cortical hypofunction\n- Disorder of pituitary gland\n- Diabetes insipidus\n\n### Drug\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route. Instructions: take 0.1 mg by mouth as directed. 0.05 mg po qAM, 0.1 mg po qhs \n- hydrocortisone 10 MG Oral Tablet, through Oral route. Instructions: take 10 mg by mouth 2 times a day.  \n- levothyroxine sodium 0.125 MG Oral Tablet, through Oral route, presumably until 2015-02-17. Instructions: take  by mouth.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-04-17 15:50:00, ended at 2012-04-18 12:30:00\nThe patient in this visit was 53 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.2 (percent)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Triiodothyronine (T3) [Mass/volume] in Serum or Plasma: 70 (nanogram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.78 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.41 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 147 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 15.0 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.3 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 8.0 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 43.6 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.35 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 42.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 3.2 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.8 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 34.7 (gram per deciliter)\n- Prolactin [Mass/volume] in Serum or Plasma: <1 (nanogram per milliliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: <0.01 (milli-international unit per liter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.2 (nanogram per deciliter)\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, orbit, face, and/or neck; without contrast material(s), followed by contrast material(s) and further sequences\n- Hospital discharge day management; 30 minutes or less\n- Initial hospital care, per day, for the evaluation and management of a patient, which requires these 3 key components: A comprehensive history; A comprehensive examination; and Medical decision making of high complexity. Counseling and/or coordination of \n\n### Condition\n- Blindness AND/OR vision impairment level\n- Diabetes insipidus\n- Disorder of nasal cavity\n- Disorder of visual pathways\n- Panhypopituitarism\n- Severe visual impairment\n- Essential hypertension\n\n### Drug\n- aripiprazole 5 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- desmopressin acetate 0.1 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- fluoxetine 20 MG Oral Capsule, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- hydrocortisone 10 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- ramelteon 8 MG Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- divalproex sodium 500 MG Delayed Release Oral Tablet, through Oral route, started on 2012-04-18, presumably until 2012-04-18\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2012-04-17, presumably until 2012-04-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-10-19 00:00:00, ended at 2012-10-19 00:00:00\nThe patient in this visit was 54 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of pituitary gland\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "e162d0a191d016a0fc6e7d0027afeb800783fe539f5b769d774b71f4ea97370c", "prompt_hash": "a4469a01394cd642809108c8308f2e4c13b69fb3672ca444838df5a54d00879b", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 1, "doc": {"person_id": 115967545, "visit_occurrence_id": 168111161, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2020-10-28 00:00:00", "visit_end_datetime": "2020-10-28 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-28 00:00:00, ended at 2020-10-28 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 91, "patient_first_visit_date": "2017-08-08 00:00:00", "patient_last_visit_date": "2021-12-21 10:38:54", "end_obs_date": "2021-10-28", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 43, "cumulated_visit_num": 43, "cumulated_approximate_token_count": 10330, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-08 00:00:00, ended at 2017-08-08 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-08 13:48:42, ended at 2017-08-08 15:19:30\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.323\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Primary diagnosis: Disorder of kidney and/or ureter\n- Sleep apnea\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (40 mg total) by mouth daily\n- atorvastatin 80 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (80 mg total) by mouth daily\n- rivaroxaban 20 MG Oral Tablet, started on 2017-05-14, presumably until 2017-05-14, with intended 1 refill(s). Instructions: every day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-08 15:32:00, ended at 2017-08-08 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.50 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 165 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-25 10:56:00, ended at 2017-09-25 13:48:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Kidney imaging morphology; with vascular flow and function, single study, with pharmacological intervention (eg, angiotensin converting enzyme inhibitor and/or diuretic)\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-09-25, presumably until 2017-09-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-25 13:49:00, ended at 2017-09-25 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-09 00:00:00, ended at 2017-10-09 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cirrhosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-10 00:00:00, ended at 2017-10-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 08:01:39, ended at 2017-11-12 08:54:26\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.32\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hepatic fibrosis\n- Disorder of kidney and/or ureter\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 12:31:12, ended at 2017-11-12 14:23:32\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Urogenital finding\n- Primary diagnosis: Hydronephrosis\n- Acute renal failure syndrome\n- Chronic kidney disease stage 3\n- Urinary tract obstruction\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-15 00:00:00, ended at 2017-11-15 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-27 00:00:00, ended at 2017-11-27 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-07 00:00:00, ended at 2017-12-07 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sleep apnea\n- Acute non-ST segment elevation myocardial infarction\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-12 07:14:00, ended at 2017-12-12 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.08 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 157 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 208 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.27 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.1 (percent)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.38 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.20 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-12 07:56:19, ended at 2017-12-12 09:36:26\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.93\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Thromboembolism of vein\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-28 00:00:00, ended at 2017-12-28 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-28 00:00:00, ended at 2017-12-28 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-28 07:20:00, ended at 2017-12-28 07:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 56.8 (percent)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Atherosclerosis of coronary artery without angina pectoris\n- Impaired fasting glycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-28 09:30:00, ended at 2017-12-28 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cholesterol [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.7 (ratio)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 69 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 67 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.4 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 69 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Impaired fasting glycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-10 00:00:00, ended at 2018-01-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-10 00:00:00, ended at 2018-01-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, started on 2018-01-10, presumably until 2018-02-06, with intended 0 refill(s). Instructions: One syringe subcu 01/15/2018 q 12 hours.  Last syringe 01/16/2018 in am.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-10 09:57:45, ended at 2018-01-10 12:06:21\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of kidney\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-10 12:13:00, ended at 2018-01-10 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.0 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Prothrombin time (PT): 15.3 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.37 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.99 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.39 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.1 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of kidney and/or ureter\n- Mild intermittent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-10 13:00:12, ended at 2018-01-10 14:06:34\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mild intermittent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-17 00:00:00, ended at 2018-01-17 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Anesthesia for extraperitoneal procedures in lower abdomen, including urinary tract; renal procedures, including upper one-third of ureter, or donor nephrectomy\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hydronephrosis\n- Disorder of kidney and/or ureter\n- Hyperlipidemia\n- Essential hypertension\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- calcium gluconate 100 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- cefazolin 1000 MG Injection, started on 2018-01-17, presumably until 2018-01-17\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- ketamine 100 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-01-17 00:00:00, ended at 2018-01-17 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n- iothalamic acid, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2018-01-17, presumably until 2018-01-17\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2018-01-17, presumably until 2018-01-17\n- iothalamate, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-17 06:01:00, ended at 2018-01-20 13:20:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.05 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 152 (thousand per microliter)\n- Bicarbonate [Moles/volume] in Specimen: 21.5 (millimole per liter)\n- Body height: 5' 7\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 179 (milligram per deciliter)\n- Base excess in Arterial blood by calculation: -2.9 (millimole per liter)\n- Oxygen [Partial pressure] in Arterial blood: 178.0 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.33 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Carbon dioxide [Partial pressure] in Arterial blood: 38.5 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 145 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.3 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.70 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.2 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Ultrasonic guidance, intraoperative\n- Resection of Right Kidney, Percutaneous Endoscopic Approach\n- Excision of Right Kidney, Percutaneous Endoscopic Approach, Diagnostic\n- Laparoscopy, surgical; pyeloplasty\n- Cystourethroscopy, with ureteral catheterization, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service\n- Robotic Assisted Procedure of Trunk Region, Percutaneous Endoscopic Approach\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Laparoscopy, surgical; nephrectomy, including partial ureterectomy\n\n### Condition\n- Aortocoronary bypass graft present\n- Coagulation factor deficiency syndrome\n- Hydronephrosis\n- Anesthesia of skin\n- Disorder of kidney and/or ureter\n- Hyperlipidemia\n- Uncomplicated asthma\n- Obstructive sleep apnea syndrome\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic kidney disease stage 3\n- Old myocardial infarction\n- Chronic kidney disease due to hypertension\n- Illness\n- Primary malignant neoplasm of kidney\n\n### Drug\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2018-01-17, presumably until 2018-01-20\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-01-18, presumably until 2018-01-20\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-01-17, presumably until 2018-01-19\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-01-20, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2018-01-17, presumably until 2018-01-18\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-19\n- rivaroxaban 20 MG Oral Tablet, through Oral route, started on 2018-01-18, presumably until 2018-01-19\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-01-17, presumably until 2018-01-19\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-02-03 00:00:00, ended at 2018-02-03 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of urinary system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-06 00:00:00, ended at 2018-02-06 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cellulitis of abdominal wall\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2018-02-06, presumably until 2018-02-13, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-06 09:57:06, ended at 2018-02-06 12:47:03\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Kidney, NOS\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 13:02:00, ended at 2018-02-06 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.83 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.45 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.26 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.4 (percent)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.34 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cellulitis of abdominal wall\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-06 14:24:01, ended at 2018-02-06 14:57:17\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 07:13:00, ended at 2018-05-08 07:13:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 07:14:00, ended at 2018-05-08 10:13:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 10:14:00, ended at 2018-05-08 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.50 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.25 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.5 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 148 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-08 10:31:15, ended at 2018-05-08 12:28:13\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of kidney\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:05:00, ended at 2018-12-26 07:20:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 168 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.66 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.83 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.13 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.33 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:21:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n- Computed tomography, abdomen and pelvis; without contrast material\n\n### Condition\n- Absent kidney\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:21:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n- Absent kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-26 09:41:30, ended at 2018-12-26 10:32:44\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.93\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of kidney and/or ureter\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-30 00:00:00, ended at 2019-09-30 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-25 06:59:00, ended at 2019-12-25 06:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; without contrast material\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Non-toxic multinodular goiter\n- Absent kidney\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-24 00:00:00, ended at 2020-06-24 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-28 00:00:00, ended at 2020-10-28 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-08-08 00:00:00, ended at 2017-08-08 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-08-08 13:48:42, ended at 2017-08-08 15:19:30\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.323\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Primary diagnosis: Disorder of kidney and/or ureter\n- Sleep apnea\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (40 mg total) by mouth daily\n- atorvastatin 80 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: Take 1 tablet (80 mg total) by mouth daily\n- rivaroxaban 20 MG Oral Tablet, started on 2017-05-14, presumably until 2017-05-14, with intended 1 refill(s). Instructions: every day \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-08-08 15:32:00, ended at 2017-08-08 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.50 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 165 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-25 10:56:00, ended at 2017-09-25 13:48:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Kidney imaging morphology; with vascular flow and function, single study, with pharmacological intervention (eg, angiotensin converting enzyme inhibitor and/or diuretic)\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- 10 ML furosemide 10 MG/ML Injection, started on 2017-09-25, presumably until 2017-09-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-09-25 13:49:00, ended at 2017-09-25 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-09 00:00:00, ended at 2017-10-09 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cirrhosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-10-10 00:00:00, ended at 2017-10-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Chronic kidney disease stage 3\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 08:01:39, ended at 2017-11-12 08:54:26\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7.32\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hepatic fibrosis\n- Disorder of kidney and/or ureter\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-11-12 12:31:12, ended at 2017-11-12 14:23:32\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Urogenital finding\n- Primary diagnosis: Hydronephrosis\n- Acute renal failure syndrome\n- Chronic kidney disease stage 3\n- Urinary tract obstruction\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-15 00:00:00, ended at 2017-11-15 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Primary diagnosis: Chronic ischemic heart disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-11-27 00:00:00, ended at 2017-11-27 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-07 00:00:00, ended at 2017-12-07 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sleep apnea\n- Acute non-ST segment elevation myocardial infarction\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-12 07:14:00, ended at 2017-12-12 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Erythrocytes [#/volume] in Blood by Automated count: 5.08 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 157 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.1 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 39 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 208 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.7 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.27 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 78 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 15.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.1 (percent)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 29 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.38 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.3 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.20 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2017-12-12 07:56:19, ended at 2017-12-12 09:36:26\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.93\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Thromboembolism of vein\n- Primary diagnosis: Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-28 00:00:00, ended at 2017-12-28 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2017-12-28 00:00:00, ended at 2017-12-28 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-28 07:20:00, ended at 2017-12-28 07:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 56.8 (percent)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; supervision only, without interpretation and report\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; tracing only, without interpretation and report\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation \n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardiovascular stress test using maximal or submaximal treadmill or bicycle exercise, continuous electrocardiographic monitoring, and/or pharmacological stress; interpretation and report only\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n- Atherosclerosis of coronary artery without angina pectoris\n- Impaired fasting glycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2017-12-28 09:30:00, ended at 2017-12-28 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cholesterol [Mass/volume] in Serum or Plasma: 109 (milligram per deciliter)\n- Cholesterol.total/Cholesterol in HDL [Mass Ratio] in Serum or Plasma: 2.7 (ratio)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 40 (milligram per deciliter)\n- Cholesterol non HDL [Mass/volume] in Serum or Plasma: 69 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay: 67 (milligram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.4 (percent)\n- Triglyceride [Moles/volume] in Serum or Plasma: 69 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Impaired fasting glycemia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-10 00:00:00, ended at 2018-01-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-01-10 00:00:00, ended at 2018-01-10 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Resistance to activated protein C due to Factor V Leiden\n\n### Drug\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, started on 2018-01-10, presumably until 2018-02-06, with intended 0 refill(s). Instructions: One syringe subcu 01/15/2018 q 12 hours.  Last syringe 01/16/2018 in am.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-10 09:57:45, ended at 2018-01-10 12:06:21\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of kidney\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-01-10 12:13:00, ended at 2018-01-10 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 115 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 86.9 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.0 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- Erythrocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 3 (per high power field)\n- MCH [Entitic mass] by Automated count: 29.9 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.74 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Prothrombin time (PT): 15.3 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.37 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.99 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.4 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.5 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.39 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 31.1 (second)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.12 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 164 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.2 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Leukocytes [#/area] in Urine sediment by Microscopy high power field: 0 - 2 (per high power field)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 25 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of kidney and/or ureter\n- Mild intermittent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-01-10 13:00:12, ended at 2018-01-10 14:06:34\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 7\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Mild intermittent asthma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-17 00:00:00, ended at 2018-01-17 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound guidance for vascular access requiring ultrasound evaluation of potential access sites, documentation of selected vessel patency, concurrent realtime ultrasound visualization of vascular needle entry, with permanent recording and reporting (Lis\n- Anesthesia for extraperitoneal procedures in lower abdomen, including urinary tract; renal procedures, including upper one-third of ureter, or donor nephrectomy\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hydronephrosis\n- Disorder of kidney and/or ureter\n- Hyperlipidemia\n- Essential hypertension\n\n### Drug\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- calcium gluconate 100 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- cefazolin 1000 MG Injection, started on 2018-01-17, presumably until 2018-01-17\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- 2 ML ondansetron 2 MG/ML Injection, started on 2018-01-17, presumably until 2018-01-17\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- ketamine 100 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2018-01-17 00:00:00, ended at 2018-01-17 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2018-01-17, presumably until 2018-01-17\n- iothalamic acid, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- thrombin, bovine 2000 UNT/ML Topical Solution, through Topical route, started on 2018-01-17, presumably until 2018-01-17\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2018-01-17, presumably until 2018-01-17\n- iothalamate, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2018-01-17 06:01:00, ended at 2018-01-20 13:20:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Potassium [Moles/volume] in Serum or Plasma: 4.8 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.05 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 152 (thousand per microliter)\n- Bicarbonate [Moles/volume] in Specimen: 21.5 (millimole per liter)\n- Body height: 5' 7\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 179 (milligram per deciliter)\n- Base excess in Arterial blood by calculation: -2.9 (millimole per liter)\n- Oxygen [Partial pressure] in Arterial blood: 178.0 (millimeter mercury column)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 37 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.33 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Carbon dioxide [Partial pressure] in Arterial blood: 38.5 (millimeter mercury column)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 145 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 89.3 (femtoliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.70 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.2 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Ultrasonic guidance, intraoperative\n- Resection of Right Kidney, Percutaneous Endoscopic Approach\n- Excision of Right Kidney, Percutaneous Endoscopic Approach, Diagnostic\n- Laparoscopy, surgical; pyeloplasty\n- Cystourethroscopy, with ureteral catheterization, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service\n- Robotic Assisted Procedure of Trunk Region, Percutaneous Endoscopic Approach\n- Pressurized or nonpressurized inhalation treatment for acute airway obstruction for therapeutic purposes and/or for diagnostic purposes such as sputum induction with an aerosol generator, nebulizer, metered dose inhaler or intermittent positive pressure b\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Laparoscopy, surgical; nephrectomy, including partial ureterectomy\n\n### Condition\n- Aortocoronary bypass graft present\n- Coagulation factor deficiency syndrome\n- Hydronephrosis\n- Anesthesia of skin\n- Disorder of kidney and/or ureter\n- Hyperlipidemia\n- Uncomplicated asthma\n- Obstructive sleep apnea syndrome\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic kidney disease stage 3\n- Old myocardial infarction\n- Chronic kidney disease due to hypertension\n- Illness\n- Primary malignant neoplasm of kidney\n\n### Drug\n- 14 ACTUAT fluticasone propionate 0.1 MG/ACTUAT / salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler, through Inhalation, started on 2018-01-17, presumably until 2018-01-20\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2018-01-18, presumably until 2018-01-20\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-01-17, presumably until 2018-01-19\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 2 Caps by mouth 2 times a day\n- tramadol hydrochloride 50 MG Oral Tablet, through Oral route, started on 2018-01-20, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2018-01-17, presumably until 2018-01-18\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Cap by mouth 3 times a day\n- 100 ML magnesium sulfate 10 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-17\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2018-01-17, presumably until 2018-02-06, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-19\n- rivaroxaban 20 MG Oral Tablet, through Oral route, started on 2018-01-18, presumably until 2018-01-19\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-01-17, presumably until 2018-01-19\n- cefazolin 2000 MG Injection, through Intravenous route, started on 2018-01-17, presumably until 2018-01-18\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-02-03 00:00:00, ended at 2018-02-03 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of urinary system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-02-06 00:00:00, ended at 2018-02-06 00:00:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Cellulitis of abdominal wall\n\n### Drug\n- cephalexin 500 MG Oral Capsule, through Oral route, started on 2018-02-06, presumably until 2018-02-13, with intended 0 refill(s). Instructions: take 1 Cap by mouth 4 times a day for 7 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-06 09:57:06, ended at 2018-02-06 12:47:03\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.929\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Kidney, NOS\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-02-06 13:02:00, ended at 2018-02-06 23:59:00\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.3 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 91 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 88.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 34 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 32 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.83 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.45 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.44 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.26 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.3 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 57.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 208 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 8.4 (gram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.4 (percent)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 1.01 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.34 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Cellulitis of abdominal wall\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-02-06 14:24:01, ended at 2018-02-06 14:57:17\nThe patient in this visit was 64 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 07:13:00, ended at 2018-05-08 07:13:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 07:14:00, ended at 2018-05-08 10:13:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-05-08 10:14:00, ended at 2018-05-08 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.16 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.50 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.3 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.25 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 21.5 (percent)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 8.1 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.45 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 90.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 106 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 2.4 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.8 (picogram)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 148 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-05-08 10:31:15, ended at 2018-05-08 12:28:13\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of kidney\n- Disorder of kidney and/or ureter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:05:00, ended at 2018-12-26 07:20:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 10 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.4 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 168 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.33 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.66 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 153 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.83 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 32 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.9 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 26.3 (percent)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 59.2 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 89 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.13 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.4 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 2.33 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.61 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:21:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n- Computed tomography, abdomen and pelvis; without contrast material\n\n### Condition\n- Absent kidney\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n- Non-toxic multinodular goiter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2018-12-26 07:21:00, ended at 2018-12-26 23:59:00\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n- Absent kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-12-26 09:41:30, ended at 2018-12-26 10:32:44\nThe patient in this visit was 65 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 6.93\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of kidney and/or ureter\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-30 00:00:00, ended at 2019-09-30 00:00:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-25 06:59:00, ended at 2019-12-25 06:59:00\nThe patient in this visit was 66 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; without contrast material\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Non-toxic multinodular goiter\n- Absent kidney\n- Acquired absence of organ\n- Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-24 00:00:00, ended at 2020-06-24 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-10-28 00:00:00, ended at 2020-10-28 00:00:00\nThe patient in this visit was 67 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of kidney\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "c7f2e67e959f3f68ead2d889c2f719e43217c79c5dd92f832286f7421c6d6d8e", "prompt_hash": "a79e84d913bc8fc81c02030c6b2e3d829b9ceceaa8c2f41286bb2f12570d91bf", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 2, "doc": {"person_id": 115967648, "visit_occurrence_id": 180405753, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2021-06-06 00:00:00", "visit_end_datetime": "2021-06-06 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-06 00:00:00, ended at 2021-06-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 94, "patient_first_visit_date": "2019-12-21 00:00:00", "patient_last_visit_date": "2023-01-16 00:00:00", "end_obs_date": "2022-06-06", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 83, "cumulated_visit_num": 83, "cumulated_approximate_token_count": 13523, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-21 00:00:00, ended at 2019-12-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 11:43:13, ended at 2019-12-21 13:57:21\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2019-03-04, presumably until 2020-12-16, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:00:00, ended at 2019-12-21 14:42:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Persistent atrial fibrillation\n- Chronic atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:43:00, ended at 2019-12-21 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-24 00:00:00, ended at 2019-12-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-28 00:00:00, ended at 2020-01-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-29 07:00:00, ended at 2020-01-29 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Ventricular tachycardia\n- Atrial flutter\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily Start on 05/10 and continue until prescription is completed.\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (1 g total) by mouth 4 times a day Start medication on 05/22/2020 and continue until completed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-18 10:42:00, ended at 2020-05-18 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)\n\n### Condition\n- Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-19 12:43:14, ended at 2020-05-19 13:10:48\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-04-20, presumably until 2020-12-11, with intended 0 refill(s). Instructions: take 75 mg by mouth 4 times a day \n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, started on 2020-03-27, presumably until 2021-06-05, with intended 0 refill(s). Instructions: INHALE 2 PUFFS BY MOUTH EVERY 4 TO 6 HOURS AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-21 10:02:38, ended at 2020-05-21 10:02:53\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- mepivacaine hydrochloride 20 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for cardiac electrophysiologic procedures including radiofrequency ablation\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hypothyroidism\n- Chronic kidney disease stage 2\n- Persistent atrial fibrillation\n- Chronic kidney disease due to hypertension\n- Prediabetes\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- remifentanil 2 MG Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- midazolam 1 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 05:31:00, ended at 2020-05-25 11:37:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Activated clotting time (ACT) of Blood by Coagulation assay: 392 (second)\n- Body height: 5' 10.276\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 79.5 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: 0.38 (unit per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 153 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 14.50 (micro-international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.63 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Prothrombin time (PT): 17.6 (second)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Collection of venous blood by venipuncture\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac \n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n\n### Condition\n- Disorder of cardiovascular system\n- Lumbar radiculopathy\n- Metabolic syndrome X\n- Essential hypertension\n- Hypothyroidism\n- Postoperative state\n- Chronic kidney disease due to hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Atrial fibrillation\n- Paroxysmal atrial fibrillation\n- Primary diagnosis: Persistent atrial fibrillation\n- Abnormal results of cardiovascular function studies\n- Chronic kidney disease stage 2\n- Prediabetes\n- Electrocardiogram abnormal\n- Polyp of colon\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-05-25\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- benazepril hydrochloride 40 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-08-31, with intended 0 refill(s). Instructions: inject 1 mg/kg subcutaneous (under the skin) daily\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-05-25\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n- amiodarone hydrochloride 400 MG Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-06-08, with intended 3 refill(s). Instructions: take 400 mg by mouth 2 times a day for 7 days, THEN 200 mg 2 times a day for 7 days, THEN 200 mg daily.\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.91 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-27 00:00:00, ended at 2020-05-27 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-05-27, presumably until 2020-09-22, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-28 00:00:00, ended at 2020-05-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bisacodyl 5 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-29, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2020-05-29, presumably until 2020-05-29, with intended 0 refill(s). Instructions: take 1 Packet (17 g total) by mouth One Time for 1 dose\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-07 00:00:00, ended at 2020-06-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-08 00:00:00, ended at 2020-06-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-06-08, presumably until 2020-08-15, with intended 11 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Electrocardiogram abnormal\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-09 11:25:00, ended at 2020-06-09 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-10 00:00:00, ended at 2020-06-10 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-11 00:00:00, ended at 2020-06-11 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH ONCE DAILY START ON 05/10 AND CONTINUE UNTIL PRESCRIPTION IS COMPLETED.\n- sucralfate 1000 MG Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH 4 TIMES A DAY START MEDICATION ON 05/22/2020 AND CONTINUE UNTIL COMPLETED.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-13 06:00:00, ended at 2020-06-13 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 08:52:48, ended at 2020-06-16 10:12:11\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (international unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Thyroglobulin Ab [Units/volume] in Serum or Plasma: 2.6 (international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 160 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (international unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 255 (picogram per milliliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: 7 (international unit per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 2.6 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 32.6 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Cholesterol in VLDL [Mass/volume] in Serum or Plasma by calculation: 24 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma by Detection limit <= 0.05 mIU/L: 12.770 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.11 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Body height: 5' 10.25\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 1.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (international unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 95 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Hyperlipidemia\n- Vitamin B deficiency\n- Vitamin D deficiency\n- Atrial fibrillation\n- Proteinuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-20 11:30:00, ended at 2020-06-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Respiratory flow volume loop\n\n### Condition\n- Pulmonary function studies abnormal\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-01 00:00:00, ended at 2020-07-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Retinal disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-04 00:00:00, ended at 2020-07-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-07 00:00:00, ended at 2020-07-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-08 00:00:00, ended at 2020-07-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-20 14:35:26, ended at 2020-07-20 14:50:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Prediabetes\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-08-15, presumably until 2020-12-05, with intended 0 refill(s). Instructions: take 0.5 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-29 00:00:00, ended at 2020-08-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-30 10:00:00, ended at 2020-08-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-31 10:18:59, ended at 2020-08-31 11:01:03\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2020-08-31, presumably until 2021-09-05, with intended 12 refill(s). Instructions: take 1 Tab (5 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-22 09:31:38, ended at 2020-09-22 09:59:53\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-09-22, presumably until 2021-03-30, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-30 07:30:00, ended at 2020-09-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n- Persistent atrial fibrillation\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-16 12:57:09, ended at 2020-11-16 13:31:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Long QT syndrome\n- Electrocardiogram abnormal\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-18 11:00:00, ended at 2020-11-18 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-01 00:00:00, ended at 2020-12-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-01 09:02:00, ended at 2020-12-01 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-05 00:00:00, ended at 2020-12-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-16 00:00:00, ended at 2020-12-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-12-16, presumably until 2021-03-09, with intended 0 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-19 10:19:56, ended at 2020-12-19 10:30:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism caused by drug\n- Prediabetes\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-09 00:00:00, ended at 2021-01-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-17 09:59:16, ended at 2021-01-17 11:01:22\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Paroxysmal atrial fibrillation\n- Coronary atherosclerosis\n- Blood glucose abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-01-17, presumably until 2021-03-09, with intended 11 refill(s). Instructions: take 12.5 mg by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-20 06:45:00, ended at 2021-01-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-09 00:00:00, ended at 2021-02-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-02-09, presumably until 2021-03-03, with intended 3 refill(s). Instructions: take 1 Tab (25 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-13 00:00:00, ended at 2021-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Complete atrioventricular block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-15 08:30:00, ended at 2021-02-15 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-22 08:32:00, ended at 2021-02-22 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-03, presumably until 2021-03-10, with intended 1 refill(s). Instructions: take 1 Tab (1 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-03-03 15:11:00, ended at 2021-03-03 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, started on 2021-03-09, presumably until 2021-08-15, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-10 00:00:00, ended at 2021-03-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-03-10, presumably until 2021-03-20, with intended 1 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-20 00:00:00, ended at 2021-03-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-20, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth as directed (Take 1mg in the morning and 2mg at night)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-30 00:00:00, ended at 2021-03-30 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-03-30, presumably until 2021-11-20, with intended 3 refill(s). Instructions: TAKE 1 TAB (50 MCG TOTAL) BY MOUTH EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-04 00:00:00, ended at 2021-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-04, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-19 00:00:00, ended at 2021-04-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-19, presumably until 2021-06-05, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every morning AND 1.5 Tabs (3 mg total) Daily at night.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-19 11:34:11, ended at 2021-04-19 12:12:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-20 06:15:00, ended at 2021-04-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-25 10:16:13, ended at 2021-04-25 11:00:40\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-04-25, presumably until 2021-08-21, with intended 11 refill(s). Instructions: take 12.5 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-26 16:08:55, ended at 2021-04-26 16:09:05\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Atrial fibrillation\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 00:00:00, ended at 2021-04-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Prediabetes\n- Paroxysmal atrial fibrillation\n- Essential hypertension\n- Hypothyroidism\n\n### Drug\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2021-04-28, presumably until 2021-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 07:16:00, ended at 2021-04-28 11:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 42 (percent)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.3 (gram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.1 (millimole per liter)\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardioversion, elective, electrical conversion of arrhythmia; external\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Hypothyroidism\n- Rheumatic tricuspid valve regurgitation\n- Atrial fibrillation\n- Typical atrial flutter\n- Atrial flutter\n- Atrial premature complex\n- Persistent atrial fibrillation\n- Lumbar radiculopathy\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Ventricular premature complex\n- Atherosclerosis of coronary artery without angina pectoris\n- Electrocardiogram abnormal\n- Essential hypertension\n- Prediabetes\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-14 14:29:00, ended at 2021-05-14 18:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.6 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.7 (percent)\n- MCV [Entitic volume] by Automated count: 93.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.28 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Tachycardia\n- Essential hypertension\n- Hypothyroidism\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-14\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-15 00:00:00, ended at 2021-05-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-16 00:00:00, ended at 2021-05-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-16, presumably until 2021-06-29, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth 2 times a day as needed For AFib episodes\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-23 00:00:00, ended at 2021-05-23 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Atrial fibrillation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-06-13, presumably until 2021-11-28, with intended 0 refill(s). Instructions: take 1 Tablet (40 mg total) by mouth daily Start 4 days pre-procedure, and continue 30 days after, no refills. First dose 08/14/2021\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-31 13:29:00, ended at 2021-05-31 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-02 00:00:00, ended at 2021-06-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-06 00:00:00, ended at 2021-06-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-21 00:00:00, ended at 2019-12-21 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 11:43:13, ended at 2019-12-21 13:57:21\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2019-03-04, presumably until 2020-12-16, with intended 0 refill(s). Instructions: take 10 mg by mouth every bedtime \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:00:00, ended at 2019-12-21 14:42:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Left ventricular Ejection fraction: 60.0 (percent)\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Persistent atrial fibrillation\n- Chronic atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-21 14:43:00, ended at 2019-12-21 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-24 00:00:00, ended at 2019-12-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-28 00:00:00, ended at 2020-01-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-29 07:00:00, ended at 2020-01-29 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Ventricular tachycardia\n- Atrial flutter\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily Start on 05/10 and continue until prescription is completed.\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-22, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (1 g total) by mouth 4 times a day Start medication on 05/22/2020 and continue until completed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-18 10:42:00, ended at 2020-05-18 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, heart, with contrast material, for evaluation of cardiac structure and morphology (including 3D image postprocessing, assessment of cardiac function, and evaluation of venous structures, if performed)\n\n### Condition\n- Persistent atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-19 12:43:14, ended at 2020-05-19 13:10:48\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2020-04-20, presumably until 2020-12-11, with intended 0 refill(s). Instructions: take 75 mg by mouth 4 times a day \n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, started on 2020-03-27, presumably until 2021-06-05, with intended 0 refill(s). Instructions: INHALE 2 PUFFS BY MOUTH EVERY 4 TO 6 HOURS AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-21 10:02:38, ended at 2020-05-21 10:02:53\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronavirus infection\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- mepivacaine hydrochloride 20 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n- heparin sodium, porcine 1000 UNT/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 00:00:00, ended at 2020-05-24 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for cardiac electrophysiologic procedures including radiofrequency ablation\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n\n### Condition\n- Hypothyroidism\n- Chronic kidney disease stage 2\n- Persistent atrial fibrillation\n- Chronic kidney disease due to hypertension\n- Prediabetes\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 5 ML protamine sulfate (USP) 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 250 ML norepinephrine 0.016 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- remifentanil 2 MG Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-24, presumably until 2020-05-24\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-24, presumably until 2020-05-24\n- midazolam 1 MG/ML Injectable Solution, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-24 05:31:00, ended at 2020-05-25 11:37:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Activated clotting time (ACT) of Blood by Coagulation assay: 392 (second)\n- Body height: 5' 10.276\" (inch (US))\n- Glucose [Mass/volume] in Serum or Plasma: 111 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.1 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 79.5 (second)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (unit per liter)\n- Heparin unfractionated [Units/volume] in Platelet poor plasma: 0.38 (unit per milliliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 153 (thousand per microliter)\n- Thyrotropin [Units/volume] in Serum or Plasma: 14.50 (micro-international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.63 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.87 (milligram per deciliter)\n- Prothrombin time (PT): 17.6 (second)\n\n### Procedure\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- Collection of venous blood by venipuncture\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Intracardiac electrophysiologic 3-dimensional mapping (List separately in addition to code for primary procedure)\n- Additional linear or focal intracardiac catheter ablation of the left or right atrium for treatment of atrial fibrillation remaining after completion of pulmonary vein isolation (List separately in addition to code for primary procedure)\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Comprehensive electrophysiologic evaluation including transseptal catheterizations, insertion and repositioning of multiple electrode catheters with intracardiac catheter ablation of atrial fibrillation by pulmonary vein isolation, including intracardiac \n- Intracardiac echocardiography during therapeutic/diagnostic intervention, including imaging supervision and interpretation (List separately in addition to code for primary procedure)\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n\n### Condition\n- Disorder of cardiovascular system\n- Lumbar radiculopathy\n- Metabolic syndrome X\n- Essential hypertension\n- Hypothyroidism\n- Postoperative state\n- Chronic kidney disease due to hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Atrial fibrillation\n- Paroxysmal atrial fibrillation\n- Primary diagnosis: Persistent atrial fibrillation\n- Abnormal results of cardiovascular function studies\n- Chronic kidney disease stage 2\n- Prediabetes\n- Electrocardiogram abnormal\n- Polyp of colon\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 1 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-05-25\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- benazepril hydrochloride 40 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- hydralazine hydrochloride 50 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- 0.8 ML enoxaparin sodium 150 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2020-05-25, presumably until 2020-08-31, with intended 0 refill(s). Instructions: inject 1 mg/kg subcutaneous (under the skin) daily\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-05-25\n- sucralfate 1000 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-25\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n- amiodarone hydrochloride 400 MG Oral Tablet, through Oral route, started on 2020-05-25, presumably until 2020-06-08, with intended 3 refill(s). Instructions: take 400 mg by mouth 2 times a day for 7 days, THEN 200 mg 2 times a day for 7 days, THEN 200 mg daily.\n- citalopram 10 MG Oral Tablet, through Oral route, started on 2020-05-24, presumably until 2020-05-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-25 00:00:00, ended at 2020-05-25 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 0.91 (nanogram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-27 00:00:00, ended at 2020-05-27 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-05-27, presumably until 2020-09-22, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-05-28 00:00:00, ended at 2020-05-28 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bisacodyl 5 MG Delayed Release Oral Tablet, through Oral route, started on 2020-05-29, presumably until 2020-08-31, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily as needed\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2020-05-29, presumably until 2020-05-29, with intended 0 refill(s). Instructions: take 1 Packet (17 g total) by mouth One Time for 1 dose\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-07 00:00:00, ended at 2020-06-07 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-08 00:00:00, ended at 2020-06-08 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-06-08, presumably until 2020-08-15, with intended 11 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n- Electrocardiogram abnormal\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-09 00:00:00, ended at 2020-06-09 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-09 11:25:00, ended at 2020-06-09 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-10 00:00:00, ended at 2020-06-10 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-06-11 00:00:00, ended at 2020-06-11 00:00:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH ONCE DAILY START ON 05/10 AND CONTINUE UNTIL PRESCRIPTION IS COMPLETED.\n- sucralfate 1000 MG Oral Tablet, started on 2020-06-13, presumably until 2020-06-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET BY MOUTH 4 TIMES A DAY START MEDICATION ON 05/22/2020 AND CONTINUE UNTIL COMPLETED.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-13 06:00:00, ended at 2020-06-13 23:59:00\nThe patient in this visit was 75 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-06-16 08:52:48, ended at 2020-06-16 10:12:11\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 62 (international unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.12 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 100 (milligram per deciliter)\n- Thyroglobulin Ab [Units/volume] in Serum or Plasma: 2.6 (international unit per milliliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 24 (millimole per liter)\n- Cholesterol [Mass/volume] in Serum or Plasma: 160 (milligram per deciliter)\n- Triglyceride [Moles/volume] in Serum or Plasma: 122 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (international unit per liter)\n- Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma: 255 (picogram per milliliter)\n- Thyroperoxidase Ab [Units/volume] in Serum or Plasma: 7 (international unit per milliliter)\n- Triiodothyronine (T3) Free [Mass/volume] in Serum or Plasma: 2.6 (picogram per milliliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 32.6 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Cholesterol in VLDL [Mass/volume] in Serum or Plasma by calculation: 24 (milligram per deciliter)\n- Thyrotropin [Units/volume] in Serum or Plasma by Detection limit <= 0.05 mIU/L: 12.770 (micro-international unit per milliliter)\n- Thyroxine (T4) free [Mass/volume] in Serum or Plasma: 1.11 (nanogram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Body height: 5' 10.25\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Cholesterol in HDL [Mass/volume] in Serum or Plasma: 41 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 1.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 17 (international unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation: 95 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.2 (gram per deciliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 6.1 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n- Hyperlipidemia\n- Vitamin B deficiency\n- Vitamin D deficiency\n- Atrial fibrillation\n- Proteinuria\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-06-20 11:30:00, ended at 2020-06-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Respiratory flow volume loop\n\n### Condition\n- Pulmonary function studies abnormal\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-01 00:00:00, ended at 2020-07-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Retinal disorder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-04 00:00:00, ended at 2020-07-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-07-07 00:00:00, ended at 2020-07-07 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-08 00:00:00, ended at 2020-07-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-20 14:35:26, ended at 2020-07-20 14:50:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n- Prediabetes\n- Primary diagnosis: Hypothyroidism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-29 00:00:00, ended at 2020-07-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 00:00:00, ended at 2020-08-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-08-15, presumably until 2020-12-05, with intended 0 refill(s). Instructions: take 0.5 Tabs (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-26 00:00:00, ended at 2020-08-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-29 00:00:00, ended at 2020-08-29 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Electrocardiogram abnormal\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-30 10:00:00, ended at 2020-08-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-31 10:18:59, ended at 2020-08-31 11:01:03\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Bradycardia\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- apixaban 5 MG Oral Tablet, through Oral route, started on 2020-08-31, presumably until 2021-09-05, with intended 12 refill(s). Instructions: take 1 Tab (5 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-22 09:31:38, ended at 2020-09-22 09:59:53\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2020-09-22, presumably until 2021-03-30, with intended 4 refill(s). Instructions: take 1 Tab (50 mcg total) by mouth every morning before breakfast\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-09-30 07:30:00, ended at 2020-09-30 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 21 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial flutter\n- Persistent atrial fibrillation\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-16 12:57:09, ended at 2020-11-16 13:31:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-18 00:00:00, ended at 2020-11-18 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Long QT syndrome\n- Electrocardiogram abnormal\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-18 11:00:00, ended at 2020-11-18 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-21 00:00:00, ended at 2020-11-21 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-01 00:00:00, ended at 2020-12-01 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-01 09:02:00, ended at 2020-12-01 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-05 00:00:00, ended at 2020-12-05 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-12-16 00:00:00, ended at 2020-12-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2020-12-16, presumably until 2021-03-09, with intended 0 refill(s). Instructions: take 1 Tab (200 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-19 10:19:56, ended at 2020-12-19 10:30:47\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hypothyroidism caused by drug\n- Prediabetes\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-09 00:00:00, ended at 2021-01-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-01-17 09:59:16, ended at 2021-01-17 11:01:22\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n- Paroxysmal atrial fibrillation\n- Coronary atherosclerosis\n- Blood glucose abnormal\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-01-17, presumably until 2021-03-09, with intended 11 refill(s). Instructions: take 12.5 mg by mouth every morning\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-01-20 06:45:00, ended at 2021-01-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n\n### Condition\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-09 00:00:00, ended at 2021-02-09 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2021-02-09, presumably until 2021-03-03, with intended 3 refill(s). Instructions: take 1 Tab (25 mg total) by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-13 00:00:00, ended at 2021-02-13 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Atrial flutter\n- Complete atrioventricular block\n- Electrocardiogram abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-15 08:30:00, ended at 2021-02-15 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-22 08:32:00, ended at 2021-02-22 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-03 00:00:00, ended at 2021-03-03 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-03, presumably until 2021-03-10, with intended 1 refill(s). Instructions: take 1 Tab (1 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-03-03 15:11:00, ended at 2021-03-03 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Persistent atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-08 00:00:00, ended at 2021-03-08 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, started on 2021-03-09, presumably until 2021-08-15, with intended 1 refill(s). Instructions: TAKE 1 TABLET BY MOUTH EVERY DAY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-10 00:00:00, ended at 2021-03-10 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-03-10, presumably until 2021-03-20, with intended 1 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-03-20 00:00:00, ended at 2021-03-20 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 1 MG Oral Tablet, through Oral route, started on 2021-03-20, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (1 mg total) by mouth as directed (Take 1mg in the morning and 2mg at night)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-03-30 00:00:00, ended at 2021-03-30 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypothyroidism\n\n### Drug\n- levothyroxine sodium 0.05 MG Oral Tablet, through Oral route, started on 2021-03-30, presumably until 2021-11-20, with intended 3 refill(s). Instructions: TAKE 1 TAB (50 MCG TOTAL) BY MOUTH EVERY MORNING BEFORE BREAKFAST\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-04-04 00:00:00, ended at 2021-04-04 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-04, presumably until 2021-04-19, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-19 00:00:00, ended at 2021-04-19 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- doxazosin 2 MG Oral Tablet, through Oral route, started on 2021-04-19, presumably until 2021-06-05, with intended 3 refill(s). Instructions: take 1 Tab (2 mg total) by mouth every morning AND 1.5 Tabs (3 mg total) Daily at night.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-19 11:34:11, ended at 2021-04-19 12:12:45\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-20 06:15:00, ended at 2021-04-20 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation\n- External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Atrial flutter\n- Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-04-25 10:16:13, ended at 2021-04-25 11:00:40\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- hydrochlorothiazide 12.5 MG Oral Capsule, through Oral route, started on 2021-04-25, presumably until 2021-08-21, with intended 11 refill(s). Instructions: take 12.5 mg by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-04-26 00:00:00, ended at 2021-04-26 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-26 16:08:55, ended at 2021-04-26 16:09:05\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Paroxysmal atrial fibrillation\n- Atrial fibrillation\n- Atrial flutter\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 00:00:00, ended at 2021-04-28 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Prediabetes\n- Paroxysmal atrial fibrillation\n- Essential hypertension\n- Hypothyroidism\n\n### Drug\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2021-04-28, presumably until 2021-04-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-04-28 07:16:00, ended at 2021-04-28 11:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Hematocrit [Volume Fraction] of Blood: 42 (percent)\n- Sodium [Moles/volume] in Blood: 140 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 14.3 (gram per deciliter)\n- Body height: 5' 10\" (inch (US))\n- Potassium [Moles/volume] in Blood: 4.1 (millimole per liter)\n\n### Procedure\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete\n- Cardioversion, elective, electrical conversion of arrhythmia; external\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n- External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording)\n\n### Condition\n- Hypothyroidism\n- Rheumatic tricuspid valve regurgitation\n- Atrial fibrillation\n- Typical atrial flutter\n- Atrial flutter\n- Atrial premature complex\n- Persistent atrial fibrillation\n- Lumbar radiculopathy\n- Non-rheumatic mitral valve stenosis with regurgitation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n- Ventricular premature complex\n- Atherosclerosis of coronary artery without angina pectoris\n- Electrocardiogram abnormal\n- Essential hypertension\n- Prediabetes\n- Supraventricular tachycardia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2021-05-14 14:29:00, ended at 2021-05-14 18:25:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 49 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.34 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.66 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.86 (million per microliter)\n- Platelets [#/volume] in Blood by Automated count: 180 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 12.4 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.3 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.81 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.1 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 60.6 (percent)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.017 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 20 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.21 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.0 (percent)\n- Hemoglobin [Mass/volume] in Blood: 15.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Albumin [Mass/volume] in Serum or Plasma: 4.5 (gram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 25.7 (percent)\n- MCV [Entitic volume] by Automated count: 93.2 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.4 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.28 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 2.2 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Tachycardia\n- Essential hypertension\n- Hypothyroidism\n- Primary diagnosis: Atrial fibrillation\n\n### Drug\n- amiodarone hydrochloride 200 MG Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-14\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-14, presumably until 2021-05-16, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-15 00:00:00, ended at 2021-05-15 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-16 00:00:00, ended at 2021-05-16 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 24 HR metoprolol succinate 25 MG Extended Release Oral Tablet, through Oral route, started on 2021-05-16, presumably until 2021-06-29, with intended 0 refill(s). Instructions: take 0.5 Tablets (12.5 mg total) by mouth 2 times a day as needed For AFib episodes\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-23 00:00:00, ended at 2021-05-23 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transesophageal, real-time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report\n- Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); follow-up or limited study (List separately in addition to codes for echocardiographic imaging)\n- Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)\n\n### Condition\n- Atrial fibrillation\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2021-06-13, presumably until 2021-11-28, with intended 0 refill(s). Instructions: take 1 Tablet (40 mg total) by mouth daily Start 4 days pre-procedure, and continue 30 days after, no refills. First dose 08/14/2021\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-05-25 00:00:00, ended at 2021-05-25 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Essential hypertension\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-31 13:29:00, ended at 2021-05-31 23:59:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-02 00:00:00, ended at 2021-06-02 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-06-06 00:00:00, ended at 2021-06-06 00:00:00\nThe patient in this visit was 76 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atrial flutter\n- Primary diagnosis: Paroxysmal atrial fibrillation\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "8bcd6b70cb8efffe2e11d04b49180d1e00130b055ee387b1a6780d0ca59f460f", "prompt_hash": "28b25043784709a5f87d46ac5bdecfe6957a12f64447bd806fd8a5658768eeb1", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 3, "doc": {"person_id": 115967699, "visit_occurrence_id": 172123964, "death_date": null, "visit_concept_name": "Pharmacy visit", "visit_start_datetime": "2021-01-26 00:00:00", "visit_end_datetime": "2021-01-26 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-26 00:00:00, ended at 2021-01-26 00:00:00\nThe patient in this visit was 60 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2021-01-27, presumably until 2021-11-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n", "approximate_token_count": 130, "patient_first_visit_date": "2018-07-27 08:09:53", "patient_last_visit_date": "2022-11-11 10:16:14", "end_obs_date": "2022-01-26", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 38, "cumulated_visit_num": 38, "cumulated_approximate_token_count": 5226, "visit_cumulated": "## Visit\nThis visit record, was from Office Visit, started at 2018-07-27 08:09:53, ended at 2018-07-27 09:18:56\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Low grade squamous intraepithelial lesion on cervical Papanicolaou smear\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2019-03-07, with intended 2 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-07-27, presumably until 2019-02-15, with intended 1 refill(s). Instructions: inject 10 Units subcutaneous (under the skin) every bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2019-03-07, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-22 00:00:00, ended at 2018-12-22 00:00:00\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 15.6 (milligram per gram of creatinine)\n- Creatinine [Mass/volume] in Urine: 265.5 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 41.3 (microgram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-31 00:00:00, ended at 2018-12-31 00:00:00\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-15 15:14:21, ended at 2019-02-15 15:46:51\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 300 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-15, presumably until 2019-02-20, with intended 0 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-20 00:00:00, ended at 2019-02-20 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 300 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-20, presumably until 2019-03-01, with intended 0 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-28 00:00:00, ended at 2019-02-28 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 3 ML insulin degludec 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-01, presumably until 2019-03-07, with intended 1 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-05-30 00:00:00, ended at 2019-05-30 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-05-30, presumably until 2019-10-18, with intended 3 refill(s). Instructions: INJECT 15 UNITS UNDER SKIN EVERY EVENING.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-28 00:00:00, ended at 2019-08-28 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-04 00:00:00, ended at 2019-09-04 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-06 11:31:00, ended at 2019-09-06 23:59:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation on X-ray examination made elsewhere, written report\n\n### Condition\n- Mammographic calcification of breast\n- Mammographic microcalcification of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-12 12:25:00, ended at 2019-09-12 23:59:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Lump in upper inner quadrant of right breast\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-09-12, presumably until 2019-09-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-23 00:00:00, ended at 2019-09-23 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2019-09-24, presumably until 2019-11-06, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-26 00:00:00, ended at 2019-09-26 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-06 00:00:00, ended at 2019-11-06 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2019-11-07, presumably until 2020-01-08, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-07 00:00:00, ended at 2020-01-07 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-01-08, presumably until 2020-02-28, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-07 00:00:00, ended at 2020-01-07 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-01-07, presumably until 2020-01-21, with intended 3 refill(s). Instructions: INJECT 15 UNITS UNDER THE SKIN EVERY EVENING\n- atorvastatin 40 MG Oral Tablet, started on 2020-01-07, presumably until 2020-07-13, with intended 1 refill(s). Instructions: TAKE 1 TABLET(40 MG) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-21 15:09:17, ended at 2020-01-21 15:59:07\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.0 (percent)\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Hyperlipidemia\n- Secondary diabetes mellitus\n- Type 2 diabetes mellitus\n- Primary diagnosis: Essential hypertension\n- Mild nonproliferative retinopathy of left eye due to diabetes mellitus\n\n### Drug\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2020-01-21, presumably until 2020-05-20, with intended 3 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-01-21, presumably until 2020-01-28, with intended 3 refill(s). Instructions: 24 Units by abdominal subcutaneous route AM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-04 00:00:00, ended at 2020-02-04 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-02-04, presumably until 2020-02-04, with intended 1 refill(s). Instructions: inject 100 Units subcutaneous (under the skin) daily in the evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-02-28, presumably until 2020-04-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-11 00:00:00, ended at 2020-04-11 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-04-13, presumably until 2020-05-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-12 00:00:00, ended at 2020-07-12 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-07-13, presumably until 2021-01-16, with intended 1 refill(s). Instructions: TAKE 1 TABLET(40 MG) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-21 00:00:00, ended at 2020-09-21 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-06 20:40:00, ended at 2020-10-06 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-08 00:00:00, ended at 2020-10-08 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-30 11:10:00, ended at 2020-10-30 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-12 00:00:00, ended at 2020-11-12 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Lump in upper inner quadrant of right breast\n- Lump in upper outer quadrant of right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-11-12, presumably until 2020-11-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-13 12:00:00, ended at 2020-11-13 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Neoplasm of uncertain behavior of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 07:03:00, ended at 2020-12-02 09:27:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Lump in right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 09:28:00, ended at 2020-12-02 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Disorder of breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-09 15:16:28, ended at 2020-12-09 15:58:22\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-29 15:00:00, ended at 2020-12-29 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including ultrasound guidance\n\n### Condition\n- Benign neoplasm of right breast\n- Neoplasm of uncertain behavior of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-29 15:00:00, ended at 2020-12-29 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Lump in right breast\n- Benign neoplasm of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-12-31 00:00:00, ended at 2020-12-31 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2020-12-31, presumably until 2020-12-31\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2020-12-31, presumably until 2020-12-31\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection, started on 2020-12-31, presumably until 2020-12-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-16 00:00:00, ended at 2021-01-16 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2021-01-16, presumably until 2022-02-18, with intended 3 refill(s). Instructions: take 1 Tab (40 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-26 00:00:00, ended at 2021-01-26 00:00:00\nThe patient in this visit was 60 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2021-01-27, presumably until 2021-11-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Office Visit, started at 2018-07-27 08:09:53, ended at 2018-07-27 09:18:56\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Low grade squamous intraepithelial lesion on cervical Papanicolaou smear\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2019-03-07, with intended 2 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2018-07-27, presumably until 2019-02-15, with intended 1 refill(s). Instructions: inject 10 Units subcutaneous (under the skin) every bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2018-07-27, presumably until 2019-03-07, with intended 1 refill(s). Instructions: take 1 Tab by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2018-12-22 00:00:00, ended at 2018-12-22 00:00:00\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Albumin/Creatinine [Mass Ratio] in Urine: 15.6 (milligram per gram of creatinine)\n- Creatinine [Mass/volume] in Urine: 265.5 (milligram per deciliter)\n- Albumin [Mass/volume] in Urine: 41.3 (microgram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2018-12-31 00:00:00, ended at 2018-12-31 00:00:00\nThe patient in this visit was 57 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-15 15:14:21, ended at 2019-02-15 15:46:51\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 300 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-15, presumably until 2019-02-20, with intended 0 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-02-20 00:00:00, ended at 2019-02-20 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 300 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-02-20, presumably until 2019-03-01, with intended 0 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-02-28 00:00:00, ended at 2019-02-28 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 3 ML insulin degludec 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2019-03-01, presumably until 2019-03-07, with intended 1 refill(s). Instructions: inject 15 Units subcutaneous (under the skin) every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-05-30 00:00:00, ended at 2019-05-30 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-05-30, presumably until 2019-10-18, with intended 3 refill(s). Instructions: INJECT 15 UNITS UNDER SKIN EVERY EVENING.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-28 00:00:00, ended at 2019-08-28 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-04 00:00:00, ended at 2019-09-04 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-06 11:31:00, ended at 2019-09-06 23:59:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation on X-ray examination made elsewhere, written report\n\n### Condition\n- Mammographic calcification of breast\n- Mammographic microcalcification of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-12 12:25:00, ended at 2019-09-12 23:59:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including stereotactic guidance\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Lump in upper inner quadrant of right breast\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-09-12, presumably until 2019-09-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-23 00:00:00, ended at 2019-09-23 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.7 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2019-09-24, presumably until 2019-11-06, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-26 00:00:00, ended at 2019-09-26 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-11-06 00:00:00, ended at 2019-11-06 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2019-11-07, presumably until 2020-01-08, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-07 00:00:00, ended at 2020-01-07 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-01-08, presumably until 2020-02-28, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-07 00:00:00, ended at 2020-01-07 00:00:00\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus\n- Hyperglycemia due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-01-07, presumably until 2020-01-21, with intended 3 refill(s). Instructions: INJECT 15 UNITS UNDER THE SKIN EVERY EVENING\n- atorvastatin 40 MG Oral Tablet, started on 2020-01-07, presumably until 2020-07-13, with intended 1 refill(s). Instructions: TAKE 1 TABLET(40 MG) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-21 15:09:17, ended at 2020-01-21 15:59:07\nThe patient in this visit was 58 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Hemoglobin A1c/Hemoglobin.total in Blood: 10.0 (percent)\n- Body height: 5' 3\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 2 diabetes mellitus\n- Hyperlipidemia\n- Secondary diabetes mellitus\n- Type 2 diabetes mellitus\n- Primary diagnosis: Essential hypertension\n- Mild nonproliferative retinopathy of left eye due to diabetes mellitus\n\n### Drug\n- lisinopril 10 MG Oral Tablet, through Oral route, started on 2020-01-21, presumably until 2020-05-20, with intended 3 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-01-21, presumably until 2020-01-28, with intended 3 refill(s). Instructions: 24 Units by abdominal subcutaneous route AM\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-02-04 00:00:00, ended at 2020-02-04 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-02-04, presumably until 2020-02-04, with intended 1 refill(s). Instructions: inject 100 Units subcutaneous (under the skin) daily in the evening\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-02-28, presumably until 2020-04-13, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-11 00:00:00, ended at 2020-04-11 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2020-04-13, presumably until 2020-05-20, with intended 0 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-07-12 00:00:00, ended at 2020-07-12 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-07-13, presumably until 2021-01-16, with intended 1 refill(s). Instructions: TAKE 1 TABLET(40 MG) BY MOUTH DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-09-21 00:00:00, ended at 2020-09-21 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-06 20:40:00, ended at 2020-10-06 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance imaging, breast, without and with contrast material(s), including computer-aided detection (CAD real-time lesion detection, characterization and pharmacokinetic analysis), when performed; bilateral\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-10-08 00:00:00, ended at 2020-10-08 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-10-30 11:10:00, ended at 2020-10-30 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, breast, unilateral, real time with image documentation, including axilla when performed; limited\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-11-12 00:00:00, ended at 2020-11-12 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including ultrasound guidance\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Lump in upper inner quadrant of right breast\n- Lump in upper outer quadrant of right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-11-12, presumably until 2020-11-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-12 08:36:00, ended at 2020-11-12 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Lump in right breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-13 12:00:00, ended at 2020-11-13 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred material requiring preparation of slides\n- Morphometric analysis, tumor\n\n### Condition\n- Neoplasm of uncertain behavior of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 07:03:00, ended at 2020-12-02 09:27:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Biopsy, breast, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, percutaneous; first lesion, including magnetic resonance guidance\n\n### Condition\n- Abnormal findings on diagnostic imaging of breast\n- Lump in right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-02 09:28:00, ended at 2020-12-02 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Disorder of breast\n- Abnormal findings on diagnostic imaging of breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-09 15:16:28, ended at 2020-12-09 15:58:22\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Benign neoplasm of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-29 15:00:00, ended at 2020-12-29 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Placement of breast localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous; first lesion, including ultrasound guidance\n\n### Condition\n- Benign neoplasm of right breast\n- Neoplasm of uncertain behavior of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-29 15:00:00, ended at 2020-12-29 23:59:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic mammography, including computer-aided detection (CAD) when performed; unilateral\n\n### Condition\n- Lump in right breast\n- Benign neoplasm of right breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-12-31 00:00:00, ended at 2020-12-31 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- 20 ML bupivacaine liposome 13.3 MG/ML Injection, through Infiltration route, started on 2020-12-31, presumably until 2020-12-31\n- water 1000 MG/ML Irrigation Solution, through Topical route, started on 2020-12-31, presumably until 2020-12-31\n- 10 ML bupivacaine hydrochloride 2.5 MG/ML Injection, started on 2020-12-31, presumably until 2020-12-31\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-16 00:00:00, ended at 2021-01-16 00:00:00\nThe patient in this visit was 59 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2021-01-16, presumably until 2022-02-18, with intended 3 refill(s). Instructions: take 1 Tab (40 mg total) by mouth every bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2021-01-26 00:00:00, ended at 2021-01-26 00:00:00\nThe patient in this visit was 60 years old, Asian, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- metformin hydrochloride 1000 MG Oral Tablet, started on 2021-01-27, presumably until 2021-11-01, with intended 3 refill(s). Instructions: TAKE 1 TABLET(1000 MG) BY MOUTH TWICE DAILY\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "1668150d2b3e770bfb3911310bd351686f588bb3374f134c775b7773e328fad2", "prompt_hash": "5d4d5f0b98c3efa385dbcc791cddd6ee7af0a064b7b9618665294a65fcf83bb8", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 4, "doc": {"person_id": 115967769, "visit_occurrence_id": 159320772, "death_date": null, "visit_concept_name": "Pharmacy visit", "visit_start_datetime": "2020-05-17 00:00:00", "visit_end_datetime": "2020-05-17 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, started on 2020-05-17, presumably until 2021-04-09, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH THREE TIMES DAILY \n\n", "approximate_token_count": 123, "patient_first_visit_date": "2012-03-31 14:46:00", "patient_last_visit_date": "2023-02-06 10:56:09", "end_obs_date": "2021-05-17", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 0, "asthma_type": "recurrent", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 1, "chronic_obstructive_pulmonary_disease_type": "recurrent", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 1, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 1, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 1, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 1, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 129, "cumulated_visit_num": 129, "cumulated_approximate_token_count": 24713, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-03-31 14:46:00, ended at 2012-03-31 16:19:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.3 (percent)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 236 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.34 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Chronic pain\n- Dysuria\n- Abdominal pain\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus without complication\n- Congestive heart failure\n- Type 1 diabetes mellitus uncontrolled\n- Chronic kidney disease\n- Chronic obstructive lung disease\n- Neurogenic bladder\n- Nausea\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2012-03-31, presumably until 2012-04-30, with intended 0 refill(s). Instructions: take 4 Tabs by mouth daily as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-20 00:00:00, ended at 2018-10-20 00:00:00\nThe patient in this visit was 45 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-05 12:36:05, ended at 2019-01-05 15:56:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary artery graft present\n- Mixed hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Pulmonary emphysema\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Anemia in chronic kidney disease\n- Chronic nephritic syndrome\n- End-stage renal disease\n- Essential hypertension\n- Vitamin D deficiency\n- Hyperparathyroidism due to renal insufficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-05 15:58:00, ended at 2019-01-05 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C peptide [Mass/volume] in Serum or Plasma: <0.02 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-12 00:00:00, ended at 2019-01-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-18 00:00:00, ended at 2019-01-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 00:00:00, ended at 2019-02-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 08:37:00, ended at 2019-02-23 13:35:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Primary diagnosis: Hearing loss of right ear\n- Atelectasis\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic pain\n- Obesity\n- Type 2 diabetes mellitus\n- Bilateral hearing loss\n- Heart failure\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic obstructive lung disease\n- Sudden hearing loss\n- Disorder of bronchus\n- Hypertensive heart and chronic kidney disease\n- Disorder of nervous system due to type 2 diabetes mellitus\n- End-stage renal disease\n- Hearing loss of left ear\n\n### Drug\n- acyclovir 400 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-03-05, with intended 0 refill(s). Instructions: take 1.5 Tabs (600 mg total) by mouth daily for 10 days\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-04-15, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily for 60 doses Take 6 tabs (60mg) daily for 3 days, then 5 tabs daily for 3 days, then 4 tabs daily for 3 days, then 3 tabs daily for 2 days, then 2 tabs daily for 2 days, then 1 tab daily for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-24 07:30:51, ended at 2019-02-24 12:44:18\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Labyrinthotomy, with perfusion of vestibuloactive drug(s), transcanal\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sudden hearing loss\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 200 mg by mouth\n- atorvastatin 10 MG Oral Tablet, started on 2018-12-19, presumably until 2019-04-15, with intended 0 refill(s)\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-01-14, presumably until 2019-04-15, with intended 0 refill(s)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2018-12-12, presumably until 2019-04-15, with intended 0 refill(s). Instructions: take 81 mg by mouth\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2019-02-19, presumably until 2019-04-15, with intended 0 refill(s)\n- losartan potassium 100 MG Oral Tablet, started on 2019-02-17, presumably until 2019-04-15, with intended 0 refill(s)\n- furosemide 80 MG Oral Tablet, started on 2018-12-21, presumably until 2019-04-15, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-24 07:31:03, ended at 2019-02-24 08:47:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Tympanometry (impedance testing)\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sudden hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-03 09:57:52, ended at 2019-03-03 11:50:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-03 09:58:03, ended at 2019-03-03 11:50:40\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-08 07:24:30, ended at 2019-03-08 09:43:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-08 07:24:41, ended at 2019-03-08 08:42:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-09 07:17:57, ended at 2019-03-09 09:04:26\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-12 00:00:00, ended at 2019-03-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-23 08:42:00, ended at 2019-03-23 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Interstitial lung disease\n- Abnormal findings on diagnostic imaging of lung\n- Fibrosis of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-24 07:21:38, ended at 2019-03-24 10:09:25\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pure tone audiometry (threshold); air only\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-24 07:21:55, ended at 2019-03-24 12:22:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 12:57:53, ended at 2019-03-26 15:17:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 16:52:00, ended at 2019-03-26 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Atherosclerosis of aorta\n- Sensorineural hearing loss, bilateral\n- Opioid dependence in remission\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-15 11:55:31, ended at 2019-04-15 16:21:50\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Complication due to diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Retinal disorder\n- Type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Mixed conductive AND sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Chronic obstructive lung disease\n- Disorder of upper gastrointestinal tract\n- Heart failure\n- End-stage renal disease\n- Illness\n- Bipolar disorder in remission\n- Chronic pain\n- Pure hypercholesterolemia\n- Dependence on supplemental oxygen\n- Mechanical complication of peritoneal dialysis catheter\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-15 16:14:08, ended at 2019-04-15 17:19:35\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: End-stage renal disease\n- Retinal disorder\n- Complication due to diabetes mellitus\n- Pure hypercholesterolemia\n- Chronic pain\n- Mechanical complication of peritoneal dialysis catheter\n- Renal disorder due to type 1 diabetes mellitus\n- Bipolar disorder in remission\n- Dependence on supplemental oxygen\n- Chronic obstructive lung disease\n- Heart failure\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Disorder of upper gastrointestinal tract\n- Type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2019-11-22, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n- vitamin E, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- selenomethionine, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2019-06-07, with intended 11 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily\n- cholecalciferol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- folic acid, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- wheat germ oil, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- alpha tocopherol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2019-07-07, with intended 1 refill(s). Instructions: place 1.5 Tabs under the tongue and let dissolve every day\n- zinc oxide, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-04-15, presumably until 2020-02-28, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-06, with intended 11 refill(s). Instructions: take 1 Tab (81 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 18 units under the skin at bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-26, with intended 11 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2020-04-14, with intended 11 refill(s). Instructions: place 1 Tab (0.4 mg total) under the tongue and let dissolve as needed for Chest pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-19 14:07:51, ended at 2019-04-19 17:41:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 19 (millimeter mercury column)\n- Intraocular pressure of right eye: 17 (millimeter mercury column)\n\n### Procedure\n- Intravitreal injection of a pharmacologic agent (separate procedure)\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n- Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral\n\n### Condition\n- Primary diagnosis: Retinal neovascularization\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-20 12:25:18, ended at 2019-04-20 13:25:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n- Pulmonary hypertension\n- Severe nonproliferative retinopathy due to diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Nonproliferative diabetic retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-04-20, presumably until 2019-05-04, with intended 5 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 14 days\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-20, presumably until 2019-04-26, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1-2 Tabs (4-8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-05-04, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-29 13:05:19, ended at 2019-04-29 15:15:57\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hearing loss\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2019-04-29, presumably until 2019-06-22, with intended 2 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 11:05:35, ended at 2019-05-04 13:44:21\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 13:34:13, ended at 2019-05-04 14:57:46\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- esomeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take by mouth every day\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, presumably until 2019-12-06, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every 6 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-05 13:45:06, ended at 2019-05-05 15:08:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Electrocardiogram abnormal\n- Primary diagnosis: Essential hypertension\n- Pulmonary emphysema\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 00:00:00, ended at 2019-05-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on lower anterior abdominal wall; not otherwise specified\n\n### Condition\n- Mechanical complication of peritoneal dialysis catheter\n- End-stage renal disease\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cefazolin 1000 MG Injection, started on 2019-05-07, presumably until 2019-05-07\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 07:10:00, ended at 2019-05-07 12:08:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.14 (millimole per liter)\n- Base excess in Arterial blood by calculation: 7.5 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 31.5 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Glucose [Mass/volume] in Blood: 320 (milligram per deciliter)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood: 23.7 (millimeter mercury column)\n\n### Procedure\n- Removal of tunneled intraperitoneal catheter\n- Collection of venous blood by venipuncture\n- Removal of Infusion Device from Peritoneal Cavity, Open Approach\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: End-stage renal disease\n- Heart failure\n- Hypertensive heart and chronic kidney disease\n- Mechanical complication of peritoneal dialysis catheter\n- Hyperlipidemia\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-05-07, presumably until 2019-05-11, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-07, presumably until 2019-05-11, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-11 09:13:38, ended at 2019-05-11 13:20:07\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2019-05-11, presumably until 2019-05-16, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2019-05-11, presumably until 2019-05-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-11 12:31:00, ended at 2019-05-11 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Disorder of brain\n- Hearing loss\n- Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-18 10:33:23, ended at 2019-05-18 14:44:56\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-21 14:03:22, ended at 2019-05-21 15:43:17\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n- Pulmonary hypertension\n- End-stage renal disease\n- Essential hypertension\n- Sensorineural hearing loss\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for procedures on external, middle, and inner ear including biopsy; not otherwise specified\n\n### Condition\n- Chronic kidney disease\n- Essential hypertension\n- Sensorineural hearing loss, bilateral\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2019-05-27, presumably until 2019-05-27\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- ketamine 100 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium hyaluronate 10 MG/ML Prefilled Syringe, through Intraocular route, started on 2019-05-27, presumably until 2019-05-27\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 05:58:00, ended at 2019-05-27 12:20:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: 5.5 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.13 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 63.1 (millimeter mercury column)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Arterial blood: 27.3 (millimeter mercury column)\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Oxygen [Partial pressure] in Arterial blood: 93.1 (millimeter mercury column)\n- Glucose [Mass/volume] in Blood: 87 (milligram per deciliter)\n\n### Procedure\n- Cochlear device implantation, with or without mastoidectomy\n- Radiologic examination, skull; less than 4 views\n- Insertion of Single Channel Cochlear Prosthesis into Left Inner Ear, Open Approach\n\n### Condition\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Sarcoidosis\n- Heart failure\n- Old myocardial infarction\n- Retinopathy due to type 1 diabetes mellitus\n- Sensorineural hearing loss, bilateral\n- End-stage renal disease\n- Hypertensive heart and chronic kidney disease\n- Renal disorder due to type 1 diabetes mellitus\n- Uncomplicated asthma\n- Sensorineural hearing loss\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-05-27, presumably until 2019-06-26, with intended 0 refill(s). Instructions: take 1 Boley (10,000 Units total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-05-27, presumably until 2019-05-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-07 00:00:00, ended at 2019-06-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 100 MG Oral Tablet, through Oral route, started on 2019-06-07, presumably until 2020-05-22, with intended 3 refill(s). Instructions: take 1 Tab (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-15 08:37:55, ended at 2019-06-15 10:25:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-15 08:38:27, ended at 2019-06-15 11:04:42\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; with programming\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-17 15:18:47, ended at 2019-06-17 16:25:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Dependence on supplemental oxygen\n- Leukocytosis\n- Sarcoidosis\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Hyperglycemia due to type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Sensorineural hearing loss\n- End-stage renal disease\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-06-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n- oxycodone hydrochloride 5 MG Oral Tablet, started on 2019-05-26, presumably until 2019-07-29, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-18 00:00:00, ended at 2019-06-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.41 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.6 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.57 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 228 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Leukocytosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-22 09:47:01, ended at 2019-06-22 10:28:28\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, presumably until 2019-07-29, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-06-22, presumably until 2019-10-04, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-22 13:45:04, ended at 2019-06-22 16:45:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-24 13:32:00, ended at 2019-06-24 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-06 00:00:00, ended at 2019-07-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-07-06, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily 15 mg (3 x 5 mg) for 1 mo, 10 mg (2 x 5 mg) for 1 mo, 5 mg (1 x 5 mg) for 1 mo then STOP.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-07-07 00:00:00, ended at 2019-07-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-07-07, presumably until 2019-08-05, with intended 0 refill(s). Instructions: DISSOLVE 1&1/2 TABLETS UNDER TONGUE ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-12 11:41:00, ended at 2019-07-12 12:03:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n- Plethysmography for determination of lung volumes and, when performed, airway resistance\n\n### Condition\n- Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-13 11:35:08, ended at 2019-07-13 12:28:27\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-13 11:36:03, ended at 2019-07-13 15:03:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-23 00:00:00, ended at 2019-07-23 12:10:45\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-26 00:00:00, ended at 2019-07-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin E, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol 0.05 MG Oral Tablet, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 1 tablet by oral route once daily\n- selenomethionine, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cefdinir 300 MG Oral Capsule, presumably until 2019-07-29, with intended 0 refill(s). Instructions: cefdinir 300 mg capsule\n- folic acid, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- ergocalciferol 1.25 MG Oral Capsule, started on 2014-03-15, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Take 1 capsule by mouth once a week for 10 weeks\n- wheat germ oil, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- alpha tocopherol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- sucroferric oxyhydroxide 500 MG Chewable Tablet, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Velphoro 500 mg chewable tablet\n- zinc oxide, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- lidocaine 0.05 MG/MG Medicated Patch, started on 2012-08-06, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Apply 1/2 patch to right foot, 1/2 patch to left foot once a day, may wear up to 12 hours.\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2013-09-28, presumably until 2019-11-23, with intended 11 refill(s). Instructions: inject 8 Units subcutaneous (under the skin) 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-29 12:02:28, ended at 2019-07-29 12:55:15\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Chronic ulcer of foot\n- End-stage renal disease\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-07-29, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Kravitz (10,000 Units total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-05 00:00:00, ended at 2019-08-05 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-05, presumably until 2019-08-06, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-06 00:00:00, ended at 2019-08-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-06, presumably until 2019-09-17, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-23 00:00:00, ended at 2019-08-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2019-08-23, presumably until 2019-10-06, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-24 00:00:00, ended at 2019-08-24 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- folic acid, through Oral route, started on 2019-08-24, presumably until 2019-10-06, with intended 3 refill(s). Instructions: take 1 Tab (0.8 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:44:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:59:48\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- amlodipine 5 MG Oral Tablet, started on 2019-09-09, presumably until 2019-09-21, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-24, presumably until 2019-09-24, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-09-17, presumably until 2021-10-13, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, through Sublingual route, started on 2019-09-17, presumably until 2019-10-17, with intended 0 refill(s). Instructions: place 2 Tabs under the tongue and let dissolve daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-22 00:00:00, ended at 2019-09-22 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-23, presumably until 2019-09-23, with intended 0 refill(s). Instructions: Dissolve one and one half under the tongue daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-28 11:52:23, ended at 2019-09-28 18:06:19\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.583\" (inch (US))\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Atherosclerosis of coronary artery without angina pectoris\n- End-stage renal disease\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Essential hypertension\n- Nicotine dependence\n- Nondependent opioid abuse in remission\n- Primary diagnosis: Type 1 diabetes mellitus\n- Opioid abuse\n- Chronic ulcer of foot\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-09-28, presumably until 2019-09-28, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- varenicline 1 MG Oral Tablet, through Oral route, started on 2019-09-28, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 0.5 Tabs (0.5 mg total) by mouth 2 times a day Take daily for first 3 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-30 15:21:18, ended at 2019-09-30 16:33:16\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 20 (millimeter mercury column)\n- Intraocular pressure of right eye: 18 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Primary diagnosis: Retinal neovascularization\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-04 13:40:14, ended at 2019-10-04 14:40:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n- Hypercalcemia\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-10-04, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-10-17 00:00:00, ended at 2019-10-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2019-10-19, presumably until 2020-03-09, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-18 00:00:00, ended at 2019-10-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- biotin, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbate manganese, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbyl tetraisopalmitate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- folic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- zinc ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- potassium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- 6-O-palmitoylascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- magnesium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- calcium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- sodium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-20 12:25:42, ended at 2019-10-20 14:05:54\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-21 13:37:15, ended at 2019-10-21 15:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypersomnia\n- Gastroesophageal reflux disease without esophagitis\n- Nicotine dependence\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n- Cough\n\n### Drug\n- nicotine 2 MG Oral Lozenge, through Buccal route, started on 2019-10-21, presumably until 2021-05-16, with intended 6 refill(s). Instructions: place 2 mg inside cheek or to gum every 4 hours as needed\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2019-10-21, presumably until 2020-01-03, with intended 3 refill(s). Instructions: take 2 Tabs (40 mg total) by mouth daily\n- nicotine bitartrate, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n- nicotine, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-28 12:36:49, ended at 2019-10-28 14:38:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-29 00:00:00, ended at 2019-10-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-10-29, presumably until 2022-07-30, with intended 0 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 7 days\n- furosemide 80 MG Oral Tablet, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q24H\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-08 00:00:00, ended at 2019-11-08 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-09 10:05:00, ended at 2019-11-09 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow)\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-09 10:05:06, ended at 2019-11-09 16:40:03\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-22 11:58:27, ended at 2019-11-22 15:11:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Opioid abuse\n- Pulmonary hypertension\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-23 00:00:00, ended at 2019-11-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Opioid abuse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-26 13:07:20, ended at 2019-11-26 13:47:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Determination of refractive state\n\n### Condition\n- Presbyopia\n- Primary diagnosis: Regular astigmatism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-04 00:00:00, ended at 2019-12-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-06, presumably until 2019-12-15, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-09 12:11:19, ended at 2019-12-09 14:09:17\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-14 08:08:46, ended at 2019-12-14 09:14:42\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-15 00:00:00, ended at 2019-12-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-16, presumably until 2020-03-06, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 12:32:47, ended at 2019-12-21 15:44:55\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n- Retinal disorder\n- End-stage renal disease\n- Type 1 diabetes mellitus\n- Complication due to diabetes mellitus\n- Nicotine dependence\n- Polyneuropathy due to diabetes mellitus\n- Secondary diabetes mellitus\n- Primary diagnosis: Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 00:00:00, ended at 2019-12-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Pulmonary hypertension\n- Lymph node sarcoidosis\n- Gastroesophageal reflux disease without esophagitis\n- Essential hypertension\n- Type 1 diabetes mellitus without complication\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-12-29, presumably until 2019-12-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 07:10:00, ended at 2019-12-29 10:09:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n- Radiologic examination, chest; single view\n\n### Condition\n- Chronic obstructive lung disease\n- Lymph node sarcoidosis\n- Old myocardial infarction\n- Primary diagnosis: Pulmonary hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Nicotine dependence\n- Essential hypertension\n- Heart failure\n- Post-inflammatory pulmonary fibrosis\n- Abnormal findings on diagnostic imaging of lung\n- Hyperlipidemia\n- Interstitial lung disease\n- Disorder of lung\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Pulmonary sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-31 00:00:00, ended at 2019-12-31 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-03 14:07:08, ended at 2020-01-03 15:25:08\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Primary diagnosis: Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-01-04 00:00:00, ended at 2020-01-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-04, presumably until 2020-01-05, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-05 00:00:00, ended at 2020-01-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-05, presumably until 2020-06-08, with intended 2 refill(s). Instructions: take 3 Tabs (15 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:10:00, ended at 2020-01-06 12:24:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 29.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.52 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- MCV [Entitic volume] by Automated count: 102.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocyte sedimentation rate: 29 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 326 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.4 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperosmolarity\n- Hypercalcemia\n- Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:25:00, ended at 2020-01-06 13:06:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Sarcoidosis\n- Closed fracture of second metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of first metatarsal bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:07:00, ended at 2020-01-06 13:19:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Closed fracture of first metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of second metatarsal bone\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Interstitial lung disease\n- Sarcoidosis\n- Dyspnea\n- Hyperosmolarity\n- Secondary diabetes mellitus\n- Hypercalcemia\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-06 14:09:28, ended at 2020-01-06 16:00:44\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-11 09:30:59, ended at 2020-01-11 10:16:22\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-12 10:30:00, ended at 2020-01-12 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Type 2 diabetes mellitus\n- Type 1 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-18 11:42:19, ended at 2020-01-18 12:43:33\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-27 00:00:00, ended at 2020-01-27 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-30 00:00:00, ended at 2020-01-30 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n\n### Drug\n- 24 HR nicotine 0.875 MG/HR Transdermal System, started on 2020-02-01, presumably until 2021-05-16, with intended 2 refill(s). Instructions: APPLY ONE PATCH EXTERNALLY ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-06 00:00:00, ended at 2020-02-06 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium acetate 667 MG Oral Capsule, started on 2020-02-07, presumably until 2020-04-10, with intended 4 refill(s). Instructions: TAKE TWO CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-10 00:00:00, ended at 2020-02-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-02-10, with intended 0 refill(s). Instructions: Take 1 capsule now and then 1 after next 3 dialysis sessions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-11 00:00:00, ended at 2020-02-11 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-11, presumably until 2020-02-24, with intended 0 refill(s). Instructions: APPLY TOPICALLY AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-15 10:15:00, ended at 2020-02-15 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Closed fracture of first metatarsal bone\n- Hyperglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-15 10:38:28, ended at 2020-02-15 11:17:20\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-23 00:00:00, ended at 2020-02-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-24, presumably until 2020-05-08, with intended 3 refill(s). Instructions: apply to affected area topically as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- ascorbate manganese, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbyl tetraisopalmitate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- folic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- zinc ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- potassium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- 6-O-palmitoylascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- magnesium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- calcium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- sodium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- biotin, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2020-02-28, presumably until 2021-02-27, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-05 00:00:00, ended at 2020-03-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2020-03-06, presumably until 2021-03-14, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH TWICE A DAY AS NEEDED FOR NAUSEA \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-09 00:00:00, ended at 2020-03-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-03-09, presumably until 2020-08-04, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-09 12:18:40, ended at 2020-03-09 12:48:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Hyperglycemia due to type 1 diabetes mellitus\n- Nicotine dependence\n- Type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Anemia\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-04-06, with intended 0 refill(s)\n- 3 ML insulin lispro 200 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-09, presumably until 2021-03-15, with intended 11 refill(s). Instructions: inject 6-10 Units subcutaneous (under the skin) before meals\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-03-09, presumably until 2021-03-19, with intended 11 refill(s). Instructions: Inject 30 units under the skin at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-22 00:00:00, ended at 2020-03-22 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-24 13:41:40, ended at 2020-03-24 13:51:46\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-28 09:16:21, ended at 2020-03-28 09:27:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-06 14:27:38, ended at 2020-04-06 15:01:14\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Sarcoidosis\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Type 2 diabetes mellitus\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2020-04-06, presumably until 2020-09-28, with intended 2 refill(s). Instructions: take 4 Tabs (4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-13 14:48:23, ended at 2020-04-13 15:32:30\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-20 10:33:00, ended at 2020-04-20 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Sarcoidosis\n- Primary diagnosis: Interstitial lung disease\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-26 00:00:00, ended at 2020-04-26 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-04-26, presumably until 2021-06-14, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-02 00:00:00, ended at 2020-05-02 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-04 08:28:00, ended at 2020-05-04 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Autonomic neuropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Arthropathy of the ankle AND/OR foot associated with a neurological disorder\n- Type 2 diabetes mellitus\n- Onychomycosis due to dermatophyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-07 00:00:00, ended at 2020-05-07 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-05-08, presumably until 2020-10-10, with intended 11 refill(s). Instructions: APPLY TOPICALLY TO THE AFFECTED AREA AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, started on 2020-05-17, presumably until 2021-04-09, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH THREE TIMES DAILY \n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2012-03-31 14:46:00, ended at 2012-03-31 16:19:00\nThe patient in this visit was 39 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Monocytes/100 leukocytes in Blood by Automated count: 4.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 12.7 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.56 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 14.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.3 (percent)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 236 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 27 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.1 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.9 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 236 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.1 (picogram)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.34 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n\n### Procedure\n- Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine)\n\n### Condition\n- Chronic pain\n- Dysuria\n- Abdominal pain\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus without complication\n- Congestive heart failure\n- Type 1 diabetes mellitus uncontrolled\n- Chronic kidney disease\n- Chronic obstructive lung disease\n- Neurogenic bladder\n- Nausea\n\n### Drug\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2012-03-31, presumably until 2012-04-30, with intended 0 refill(s). Instructions: take 4 Tabs by mouth daily as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2018-10-20 00:00:00, ended at 2018-10-20 00:00:00\nThe patient in this visit was 45 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-01-05 12:36:05, ended at 2019-01-05 15:56:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.228\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Coronary artery graft present\n- Mixed hyperlipidemia\n- Nicotine dependence\n- Old myocardial infarction\n- Pulmonary emphysema\n- Renal disorder due to type 1 diabetes mellitus\n- Bilateral hearing loss\n- Anemia in chronic kidney disease\n- Chronic nephritic syndrome\n- End-stage renal disease\n- Essential hypertension\n- Vitamin D deficiency\n- Hyperparathyroidism due to renal insufficiency\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-01-05 15:58:00, ended at 2019-01-05 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C peptide [Mass/volume] in Serum or Plasma: <0.02 (nanogram per milliliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-01-12 00:00:00, ended at 2019-01-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-01-18 00:00:00, ended at 2019-01-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 00:00:00, ended at 2019-02-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2019-02-23 08:37:00, ended at 2019-02-23 13:35:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Platelets [#/volume] in Blood by Automated count: 281 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 14.62 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 251 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.5 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 90 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.70 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 18.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n- MCV [Entitic volume] by Automated count: 98.4 (femtoliter)\n- Anion gap in Serum or Plasma: 17 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.41 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 63 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.77 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 89 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.2 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.1 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.09 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.2 (percent)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 22 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.34 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Radiologic examination, chest; 2 views\n\n### Condition\n- Primary diagnosis: Hearing loss of right ear\n- Atelectasis\n- Chronic kidney disease due to type 2 diabetes mellitus\n- Chronic pain\n- Obesity\n- Type 2 diabetes mellitus\n- Bilateral hearing loss\n- Heart failure\n- Atherosclerosis of coronary artery without angina pectoris\n- Chronic obstructive lung disease\n- Sudden hearing loss\n- Disorder of bronchus\n- Hypertensive heart and chronic kidney disease\n- Disorder of nervous system due to type 2 diabetes mellitus\n- End-stage renal disease\n- Hearing loss of left ear\n\n### Drug\n- acyclovir 400 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-03-05, with intended 0 refill(s). Instructions: take 1.5 Tabs (600 mg total) by mouth daily for 10 days\n- prednisone 10 MG Oral Tablet, through Oral route, started on 2019-02-23, presumably until 2019-04-15, with intended 1 refill(s). Instructions: take 1 Tab (10 mg total) by mouth daily for 60 doses Take 6 tabs (60mg) daily for 3 days, then 5 tabs daily for 3 days, then 4 tabs daily for 3 days, then 3 tabs daily for 2 days, then 2 tabs daily for 2 days, then 1 tab daily for 2 days\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-02-24 07:30:51, ended at 2019-02-24 12:44:18\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Labyrinthotomy, with perfusion of vestibuloactive drug(s), transcanal\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sudden hearing loss\n\n### Drug\n- docusate sodium 100 MG Oral Capsule, through Oral route, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 200 mg by mouth\n- atorvastatin 10 MG Oral Tablet, started on 2018-12-19, presumably until 2019-04-15, with intended 0 refill(s)\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-01-14, presumably until 2019-04-15, with intended 0 refill(s)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2018-12-12, presumably until 2019-04-15, with intended 0 refill(s). Instructions: take 81 mg by mouth\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2019-02-19, presumably until 2019-04-15, with intended 0 refill(s)\n- losartan potassium 100 MG Oral Tablet, started on 2019-02-17, presumably until 2019-04-15, with intended 0 refill(s)\n- furosemide 80 MG Oral Tablet, started on 2018-12-21, presumably until 2019-04-15, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-02-24 07:31:03, ended at 2019-02-24 08:47:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Tympanometry (impedance testing)\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Sudden hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-03 09:57:52, ended at 2019-03-03 11:50:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-03 09:58:03, ended at 2019-03-03 11:50:40\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-08 07:24:30, ended at 2019-03-08 09:43:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-08 07:24:41, ended at 2019-03-08 08:42:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-09 07:17:57, ended at 2019-03-09 09:04:26\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-03-12 00:00:00, ended at 2019-03-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-23 08:42:00, ended at 2019-03-23 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Interstitial lung disease\n- Abnormal findings on diagnostic imaging of lung\n- Fibrosis of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-24 07:21:38, ended at 2019-03-24 10:09:25\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pure tone audiometry (threshold); air only\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Tympanometry (impedance testing)\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-03-24 07:21:55, ended at 2019-03-24 12:22:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 12:57:53, ended at 2019-03-26 15:17:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-03-26 16:52:00, ended at 2019-03-26 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomographic angiography, abdomen and pelvis, with contrast material(s), including noncontrast images, if performed, and image postprocessing\n\n### Condition\n- Atherosclerosis of aorta\n- Sensorineural hearing loss, bilateral\n- Opioid dependence in remission\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-04-15 11:55:31, ended at 2019-04-15 16:21:50\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Complication due to diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Retinal disorder\n- Type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Mixed conductive AND sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n- Chronic obstructive lung disease\n- Disorder of upper gastrointestinal tract\n- Heart failure\n- End-stage renal disease\n- Illness\n- Bipolar disorder in remission\n- Chronic pain\n- Pure hypercholesterolemia\n- Dependence on supplemental oxygen\n- Mechanical complication of peritoneal dialysis catheter\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-15 16:14:08, ended at 2019-04-15 17:19:35\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.346\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: End-stage renal disease\n- Retinal disorder\n- Complication due to diabetes mellitus\n- Pure hypercholesterolemia\n- Chronic pain\n- Mechanical complication of peritoneal dialysis catheter\n- Renal disorder due to type 1 diabetes mellitus\n- Bipolar disorder in remission\n- Dependence on supplemental oxygen\n- Chronic obstructive lung disease\n- Heart failure\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Disorder of upper gastrointestinal tract\n- Type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2019-11-22, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n- vitamin E, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- selenomethionine, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- losartan potassium 50 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2019-06-07, with intended 11 refill(s). Instructions: take 1 Tab (50 mg total) by mouth daily\n- cholecalciferol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- folic acid, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- wheat germ oil, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- alpha tocopherol, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2019-07-07, with intended 1 refill(s). Instructions: place 1.5 Tabs under the tongue and let dissolve every day\n- zinc oxide, through Oral route, presumably until 2019-07-26, with intended 0 refill(s). Instructions: take 1 Tab by mouth every day\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2019-04-15, presumably until 2020-02-28, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-06, with intended 11 refill(s). Instructions: take 1 Tab (81 mg total) by mouth daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2019-04-15, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 18 units under the skin at bedtime\n- atorvastatin 40 MG Oral Tablet, through Oral route, started on 2019-04-15, presumably until 2020-04-26, with intended 11 refill(s). Instructions: take 1 Tab (40 mg total) by mouth daily\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2019-04-15, presumably until 2020-04-14, with intended 11 refill(s). Instructions: place 1 Tab (0.4 mg total) under the tongue and let dissolve as needed for Chest pain\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-19 14:07:51, ended at 2019-04-19 17:41:30\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 19 (millimeter mercury column)\n- Intraocular pressure of right eye: 17 (millimeter mercury column)\n\n### Procedure\n- Intravitreal injection of a pharmacologic agent (separate procedure)\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n- Fluorescein angiography (includes multiframe imaging) with interpretation and report, unilateral or bilateral\n\n### Condition\n- Primary diagnosis: Retinal neovascularization\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-20 12:25:18, ended at 2019-04-20 13:25:37\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n- Pulmonary hypertension\n- Severe nonproliferative retinopathy due to diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Nonproliferative diabetic retinopathy due to type 1 diabetes mellitus\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-04-20, presumably until 2019-05-04, with intended 5 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 14 days\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-20, presumably until 2019-04-26, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Disintegrating Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1-2 Tabs (4-8 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-04-26 00:00:00, ended at 2019-04-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- ondansetron 4 MG Oral Tablet, through Oral route, started on 2019-04-26, presumably until 2019-05-04, with intended 2 refill(s). Instructions: take 1 Tab (4 mg total) by mouth every 8 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-04-29 13:05:19, ended at 2019-04-29 15:15:57\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hearing loss\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- prednisone 20 MG Oral Tablet, through Oral route, started on 2019-04-29, presumably until 2019-06-22, with intended 2 refill(s). Instructions: take 1 Tab (20 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 11:05:35, ended at 2019-05-04 13:44:21\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-04 13:34:13, ended at 2019-05-04 14:57:46\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- esomeprazole 20 MG Delayed Release Oral Capsule, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take by mouth every day\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, presumably until 2019-12-06, with intended 0 refill(s). Instructions: take 12.5 mg by mouth every 6 hours as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-05 13:45:06, ended at 2019-05-05 15:08:22\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n\n### Condition\n- Type 1 diabetes mellitus\n- Pure hypercholesterolemia\n- Renal disorder due to type 1 diabetes mellitus\n- Sensorineural hearing loss\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Electrocardiogram abnormal\n- Primary diagnosis: Essential hypertension\n- Pulmonary emphysema\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 00:00:00, ended at 2019-05-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for procedures on lower anterior abdominal wall; not otherwise specified\n\n### Condition\n- Mechanical complication of peritoneal dialysis catheter\n- End-stage renal disease\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cefazolin 1000 MG Injection, started on 2019-05-07, presumably until 2019-05-07\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-07, presumably until 2019-05-07\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-07 07:10:00, ended at 2019-05-07 12:08:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.14 (millimole per liter)\n- Base excess in Arterial blood by calculation: 7.5 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 31.5 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Glucose [Mass/volume] in Blood: 320 (milligram per deciliter)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Venous blood: 23.7 (millimeter mercury column)\n\n### Procedure\n- Removal of tunneled intraperitoneal catheter\n- Collection of venous blood by venipuncture\n- Removal of Infusion Device from Peritoneal Cavity, Open Approach\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: End-stage renal disease\n- Heart failure\n- Hypertensive heart and chronic kidney disease\n- Mechanical complication of peritoneal dialysis catheter\n- Hyperlipidemia\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-05-07, presumably until 2019-05-11, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- 2 ML prochlorperazine 5 MG/ML Injection, started on 2019-05-07, presumably until 2019-05-07\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2019-05-07, presumably until 2019-05-07\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-07, presumably until 2019-05-11, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth every 4 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-11 09:13:38, ended at 2019-05-11 13:20:07\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- cephalexin 250 MG Oral Capsule, through Oral route, started on 2019-05-11, presumably until 2019-05-16, with intended 0 refill(s). Instructions: take 1 Cap (250 mg total) by mouth 4 times a day for 5 days\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2019-05-11, presumably until 2019-05-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-11 12:31:00, ended at 2019-05-11 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, brain (including brain stem); without contrast material\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Disorder of brain\n- Hearing loss\n- Abnormal findings on diagnostic imaging of skull and head\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-18 10:33:23, ended at 2019-05-18 14:44:56\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-05-21 14:03:22, ended at 2019-05-21 15:43:17\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Hyperglycemia due to type 1 diabetes mellitus\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n- Pulmonary hypertension\n- End-stage renal disease\n- Essential hypertension\n- Sensorineural hearing loss\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Arterial catheterization or cannulation for sampling, monitoring or transfusion (separate procedure); percutaneous\n- Anesthesia for procedures on external, middle, and inner ear including biopsy; not otherwise specified\n\n### Condition\n- Chronic kidney disease\n- Essential hypertension\n- Sensorineural hearing loss, bilateral\n- Gastroesophageal reflux disease without esophagitis\n\n### Drug\n- hydrocortisone 100 MG Injection, started on 2019-05-27, presumably until 2019-05-27\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- cisatracurium 2 MG/ML Injectable Solution, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- ketamine 100 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 250 ML lidocaine hydrochloride 8 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- midazolam 1 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n- 1 ML sufentanil 0.05 MG/ML Injection, through Intravenous route, started on 2019-05-27, presumably until 2019-05-27\n- dexamethasone phosphate 4 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2019-05-27 00:00:00, ended at 2019-05-27 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- sodium hyaluronate 10 MG/ML Prefilled Syringe, through Intraocular route, started on 2019-05-27, presumably until 2019-05-27\n- epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-05-27 05:58:00, ended at 2019-05-27 12:20:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Base excess in Arterial blood by calculation: 5.5 (millimole per liter)\n- Calcium.ionized [Mass/volume] in Serum or Plasma: 1.13 (millimole per liter)\n- Carbon dioxide [Partial pressure] in Arterial blood: 63.1 (millimeter mercury column)\n- Oxygen [Partial pressure] saturation adjusted to 0.5 in Arterial blood: 27.3 (millimeter mercury column)\n- Bicarbonate [Moles/volume] in Specimen: 31.4 (millimole per liter)\n- Body height: 5' 8\" (inch (US))\n- Oxygen [Partial pressure] in Arterial blood: 93.1 (millimeter mercury column)\n- Glucose [Mass/volume] in Blood: 87 (milligram per deciliter)\n\n### Procedure\n- Cochlear device implantation, with or without mastoidectomy\n- Radiologic examination, skull; less than 4 views\n- Insertion of Single Channel Cochlear Prosthesis into Left Inner Ear, Open Approach\n\n### Condition\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Sarcoidosis\n- Heart failure\n- Old myocardial infarction\n- Retinopathy due to type 1 diabetes mellitus\n- Sensorineural hearing loss, bilateral\n- End-stage renal disease\n- Hypertensive heart and chronic kidney disease\n- Renal disorder due to type 1 diabetes mellitus\n- Uncomplicated asthma\n- Sensorineural hearing loss\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-05-27, presumably until 2019-06-26, with intended 0 refill(s). Instructions: take 1 Boley (10,000 Units total) by mouth daily\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2019-05-27, presumably until 2019-05-27\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2019-05-27, presumably until 2019-05-27\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-07 00:00:00, ended at 2019-06-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- losartan potassium 100 MG Oral Tablet, through Oral route, started on 2019-06-07, presumably until 2020-05-22, with intended 3 refill(s). Instructions: take 1 Tab (100 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-15 08:37:55, ended at 2019-06-15 10:25:51\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sensorineural hearing loss\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-15 08:38:27, ended at 2019-06-15 11:04:42\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; with programming\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-17 15:18:47, ended at 2019-06-17 16:25:29\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Dependence on supplemental oxygen\n- Leukocytosis\n- Sarcoidosis\n- Primary diagnosis: Atherosclerosis of coronary artery without angina pectoris\n- Essential hypertension\n- Hyperglycemia due to type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Sensorineural hearing loss\n- End-stage renal disease\n\n### Drug\n- amlodipine 5 MG Oral Tablet, through Oral route, started on 2019-06-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n- oxycodone hydrochloride 5 MG Oral Tablet, started on 2019-05-26, presumably until 2019-07-29, with intended 0 refill(s)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-06-18 00:00:00, ended at 2019-06-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 10.41 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 76.2 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.2 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.82 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 14.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 98.6 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 10.9 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 6.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.57 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.9 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 2.18 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 228 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.08 (thousand per microliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Leukocytosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-06-22 09:47:01, ended at 2019-06-22 10:28:28\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- C reactive protein [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, presumably until 2019-07-29, with intended 0 refill(s). Instructions: take 100 mg by mouth 2 times a day\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-06-22, presumably until 2019-10-04, with intended 3 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-22 13:45:04, ended at 2019-06-22 16:45:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-06-24 13:32:00, ended at 2019-06-24 23:59:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Sarcoidosis\n- Abnormal findings on diagnostic imaging of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-06 00:00:00, ended at 2019-07-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-07-06, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 1 Tab (5 mg total) by mouth daily 15 mg (3 x 5 mg) for 1 mo, 10 mg (2 x 5 mg) for 1 mo, 5 mg (1 x 5 mg) for 1 mo then STOP.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-07-07 00:00:00, ended at 2019-07-07 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-07-07, presumably until 2019-08-05, with intended 0 refill(s). Instructions: DISSOLVE 1&1/2 TABLETS UNDER TONGUE ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-12 00:00:00, ended at 2019-07-12 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-12 11:41:00, ended at 2019-07-12 12:03:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Gas dilution or washout for determination of lung volumes and, when performed, distribution of ventilation and closing volumes\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Bronchodilation responsiveness, spirometry as in 94010, pre- and post-bronchodilator administration\n- Plethysmography for determination of lung volumes and, when performed, airway resistance\n\n### Condition\n- Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-13 11:35:08, ended at 2019-07-13 12:28:27\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-07-13 11:36:03, ended at 2019-07-13 15:03:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n- Comprehensive audiometry threshold evaluation and speech recognition (92553 and 92556 combined)\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-23 00:00:00, ended at 2019-07-23 12:10:45\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-07-26 00:00:00, ended at 2019-07-26 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- vitamin E, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol 0.05 MG Oral Tablet, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 1 tablet by oral route once daily\n- selenomethionine, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cholecalciferol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- cefdinir 300 MG Oral Capsule, presumably until 2019-07-29, with intended 0 refill(s). Instructions: cefdinir 300 mg capsule\n- folic acid, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- ergocalciferol 1.25 MG Oral Capsule, started on 2014-03-15, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Take 1 capsule by mouth once a week for 10 weeks\n- wheat germ oil, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- alpha tocopherol, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- sucroferric oxyhydroxide 500 MG Chewable Tablet, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Velphoro 500 mg chewable tablet\n- zinc oxide, presumably until 2019-08-02, with intended 0 refill(s). Instructions: Take one tablet by mouth daily\n- lidocaine 0.05 MG/MG Medicated Patch, started on 2012-08-06, presumably until 2019-07-29, with intended 0 refill(s). Instructions: Apply 1/2 patch to right foot, 1/2 patch to left foot once a day, may wear up to 12 hours.\n- 3 ML insulin aspart, human 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2013-09-28, presumably until 2019-11-23, with intended 11 refill(s). Instructions: inject 8 Units subcutaneous (under the skin) 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-07-29 00:00:00, ended at 2019-07-29 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-07-29 12:02:28, ended at 2019-07-29 12:55:15\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Pulmonary hypertension\n- Chronic ulcer of foot\n- End-stage renal disease\n- Primary diagnosis: Type 1 diabetes mellitus\n\n### Drug\n- beta carotene 10000 UNT Oral Capsule, through Oral route, started on 2019-07-29, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Kravitz (10,000 Units total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-05 00:00:00, ended at 2019-08-05 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-05, presumably until 2019-08-06, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-08-06 00:00:00, ended at 2019-08-06 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-08-06, presumably until 2019-09-17, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-08-23 00:00:00, ended at 2019-08-23 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, through Topical route, started on 2019-08-23, presumably until 2019-10-06, with intended 3 refill(s). Instructions: by Topical route as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-08-24 00:00:00, ended at 2019-08-24 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- folic acid, through Oral route, started on 2019-08-24, presumably until 2019-10-06, with intended 3 refill(s). Instructions: take 1 Tab (0.8 mg total) by mouth every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:44:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-09-07 13:11:12, ended at 2019-09-07 15:59:48\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Pure tone audiometry (threshold); air only\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-10, presumably until 2019-09-10, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-09 00:00:00, ended at 2019-09-09 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n\n### Drug\n- amlodipine 5 MG Oral Tablet, started on 2019-09-09, presumably until 2019-09-21, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-24, presumably until 2019-09-24, with intended 0 refill(s). Instructions: DISSOLVE ONE AND ONE-HALF TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-09-17 00:00:00, ended at 2019-09-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n\n### Drug\n- naloxone hydrochloride 40 MG/ML Nasal Spray, started on 2019-09-17, presumably until 2021-10-13, with intended 1 refill(s). Instructions: Spray 0.1 mL (4 mg) into one nostril for suspected overdose. Repeat into other nostril after 2 to 3 minutes if no or minimal response.\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, through Sublingual route, started on 2019-09-17, presumably until 2019-10-17, with intended 0 refill(s). Instructions: place 2 Tabs under the tongue and let dissolve daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-09-22 00:00:00, ended at 2019-09-22 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2.9 MG / naloxone 0.71 MG Sublingual Tablet, started on 2019-09-23, presumably until 2019-09-23, with intended 0 refill(s). Instructions: Dissolve one and one half under the tongue daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-28 11:52:23, ended at 2019-09-28 18:06:19\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.583\" (inch (US))\n\n### Procedure\n- Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Atherosclerosis of coronary artery without angina pectoris\n- End-stage renal disease\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Essential hypertension\n- Nicotine dependence\n- Nondependent opioid abuse in remission\n- Primary diagnosis: Type 1 diabetes mellitus\n- Opioid abuse\n- Chronic ulcer of foot\n\n### Drug\n- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.016 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.005 UNT/ML / Bordetella pertussis toxoid vaccine, inactivated 0.016 MG/ML / diphtheria toxoid vaccine, inacti..., through Intramuscular route, started on 2019-09-28, presumably until 2019-09-28, with intended 0 refill(s). Instructions: inject 0.5 mL into a muscle One Time for 1 dose\n- varenicline 1 MG Oral Tablet, through Oral route, started on 2019-09-28, presumably until 2020-04-06, with intended 0 refill(s). Instructions: take 0.5 Tabs (0.5 mg total) by mouth 2 times a day Take daily for first 3 days.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-09-30 15:21:18, ended at 2019-09-30 16:33:16\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Intraocular pressure of left eye: 20 (millimeter mercury column)\n- Intraocular pressure of right eye: 18 (millimeter mercury column)\n\n### Procedure\n- Scanning computerized ophthalmic diagnostic imaging, posterior segment, with interpretation and report, unilateral or bilateral; retina\n\n### Condition\n- Complication due to diabetes mellitus\n- Proliferative retinopathy due to type 2 diabetes mellitus\n- Primary diagnosis: Retinal neovascularization\n- Type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-04 13:40:14, ended at 2019-10-04 14:40:39\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n- Hypercalcemia\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2019-10-04, presumably until 2020-01-04, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2019-10-17 00:00:00, ended at 2019-10-17 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2019-10-19, presumably until 2020-03-09, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-10-18 00:00:00, ended at 2019-10-18 00:00:00\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- biotin, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbate manganese, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbyl tetraisopalmitate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- folic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- zinc ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- potassium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- 6-O-palmitoylascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- magnesium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- calcium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- sodium ascorbate, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n- ascorbic acid, through Oral route, started on 2019-10-20, presumably until 2020-02-25, with intended 3 refill(s). Instructions: take 1 mg by mouth daily AND 60 mg every day AND 300 mg every day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-20 12:25:42, ended at 2019-10-20 14:05:54\nThe patient in this visit was 46 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n- Primary diagnosis: Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-10-21 13:37:15, ended at 2019-10-21 15:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hypersomnia\n- Gastroesophageal reflux disease without esophagitis\n- Nicotine dependence\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n- Cough\n\n### Drug\n- nicotine 2 MG Oral Lozenge, through Buccal route, started on 2019-10-21, presumably until 2021-05-16, with intended 6 refill(s). Instructions: place 2 mg inside cheek or to gum every 4 hours as needed\n- pantoprazole 20 MG Delayed Release Oral Tablet, through Oral route, started on 2019-10-21, presumably until 2020-01-03, with intended 3 refill(s). Instructions: take 2 Tabs (40 mg total) by mouth daily\n- nicotine bitartrate, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n- nicotine, through Transdermal route, started on 2019-10-21, presumably until 2020-02-01, with intended 3 refill(s). Instructions: apply 14 mg to skin every day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-10-28 12:36:49, ended at 2019-10-28 14:38:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-10-29 00:00:00, ended at 2019-10-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- nitrofurantoin, macrocrystals 25 MG / nitrofurantoin, monohydrate 75 MG Oral Capsule, through Oral route, started on 2019-10-29, presumably until 2022-07-30, with intended 0 refill(s). Instructions: take 1 Cap (100 mg total) by mouth 2 times a day for 7 days\n- furosemide 80 MG Oral Tablet, through Oral route, presumably until 2019-12-21, with intended 0 refill(s). Instructions: take 1 Tab by mouth Q24H\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-08 00:00:00, ended at 2019-11-08 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-11-09 10:05:00, ended at 2019-11-09 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Duplex scan of hemodialysis access (including arterial inflow, body of access and venous outflow)\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-09 10:05:06, ended at 2019-11-09 16:40:03\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-22 11:58:27, ended at 2019-11-22 15:11:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Opioid abuse\n- Pulmonary hypertension\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- 0.5 UNT Doses 3 ML insulin lispro 100 UNT/ML Pen Injector, started on 2019-11-22, presumably until 2020-03-09, with intended 11 refill(s). Instructions: Inject 6 to 10 unit subcutaneously (under the skin) 3 times daily with meals according to sliding scale\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-11-23 00:00:00, ended at 2019-11-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Opioid abuse\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-11-26 13:07:20, ended at 2019-11-26 13:47:51\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Determination of refractive state\n\n### Condition\n- Presbyopia\n- Primary diagnosis: Regular astigmatism\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-04 00:00:00, ended at 2019-12-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-06, presumably until 2019-12-15, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-09 12:11:19, ended at 2019-12-09 14:09:17\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Evaluation of auditory function for surgically implanted device(s) candidacy or postoperative status of a surgically implanted device(s); first hour\n- Diagnostic analysis of cochlear implant, age 7 years or older; subsequent reprogramming\n\n### Condition\n- Sensorineural hearing loss, bilateral\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-14 08:08:46, ended at 2019-12-14 09:14:42\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Interstitial lung disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2019-12-15 00:00:00, ended at 2019-12-15 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, through Oral route, started on 2019-12-16, presumably until 2020-03-06, with intended 0 refill(s). Instructions: take 1 Tab (12.5 mg total) by mouth 2 times a day as needed for Nausea\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2019-12-21 12:32:47, ended at 2019-12-21 15:44:55\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Opioid abuse\n- Retinal disorder\n- End-stage renal disease\n- Type 1 diabetes mellitus\n- Complication due to diabetes mellitus\n- Nicotine dependence\n- Polyneuropathy due to diabetes mellitus\n- Secondary diabetes mellitus\n- Primary diagnosis: Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 00:00:00, ended at 2019-12-29 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for closed chest procedures; (including bronchoscopy) not otherwise specified\n\n### Condition\n- Pulmonary hypertension\n- Lymph node sarcoidosis\n- Gastroesophageal reflux disease without esophagitis\n- Essential hypertension\n- Type 1 diabetes mellitus without complication\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- remifentanil 2 MG Injection, through Intravenous route, started on 2019-12-29, presumably until 2019-12-29\n- 2 ML ondansetron 2 MG/ML Injection, started on 2019-12-29, presumably until 2019-12-29\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2019-12-29 07:10:00, ended at 2019-12-29 10:09:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with transbronchial lung biopsy(s), single lobe\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial or endobronchial biopsy(s), single or multiple sites\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial alveolar lavage\n- Radiologic examination, chest; single view\n\n### Condition\n- Chronic obstructive lung disease\n- Lymph node sarcoidosis\n- Old myocardial infarction\n- Primary diagnosis: Pulmonary hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n- Disorder of nervous system due to type 1 diabetes mellitus\n- Nicotine dependence\n- Essential hypertension\n- Heart failure\n- Post-inflammatory pulmonary fibrosis\n- Abnormal findings on diagnostic imaging of lung\n- Hyperlipidemia\n- Interstitial lung disease\n- Disorder of lung\n- Peripheral circulatory disorder due to type 1 diabetes mellitus\n- Sarcoidosis\n- Pulmonary sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2019-12-31 00:00:00, ended at 2019-12-31 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Interstitial lung disease\n- Dyspnea\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-03 14:07:08, ended at 2020-01-03 15:25:08\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperosmolarity\n- Primary diagnosis: Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-01-04 00:00:00, ended at 2020-01-04 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-04, presumably until 2020-01-05, with intended 1 refill(s). Instructions: take 2 Tabs (10 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-05 00:00:00, ended at 2020-01-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Sarcoidosis\n\n### Drug\n- prednisone 5 MG Oral Tablet, through Oral route, started on 2020-01-05, presumably until 2020-06-08, with intended 2 refill(s). Instructions: take 3 Tabs (15 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:10:00, ended at 2020-01-06 12:24:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- MCH [Entitic mass] by Automated count: 30.4 (picogram)\n- MCHC [Mass/volume] by Automated count: 29.6 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 301 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 152 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 7.52 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 10.3 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 134 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Anion gap in Serum or Plasma: 14 (millimole per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.06 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.9 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.2 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.29 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma: 69 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.8 (percent)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 8.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 29 (milligram per deciliter)\n- 25-hydroxyvitamin D3 [Mass/volume] in Serum or Plasma: 55 (nanogram per milliliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- MCV [Entitic volume] by Automated count: 102.7 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 2.8 (percent)\n- Calciferol (Vit D2) [Mass/volume] in Serum or Plasma: <4 (nanogram per milliliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.3 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Erythrocyte sedimentation rate: 29 (millimeter per hour)\n- Glucose [Mass/volume] in Serum or Plasma: 326 (milligram per deciliter)\n- C reactive protein [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 94 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 10.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.69 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 84.4 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Hyperosmolarity\n- Hypercalcemia\n- Sarcoidosis\n- Secondary diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 12:25:00, ended at 2020-01-06 13:06:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Sarcoidosis\n- Closed fracture of second metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of first metatarsal bone\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:07:00, ended at 2020-01-06 13:19:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; 2 views\n\n### Condition\n- Closed fracture of first metatarsal bone\n- Closed fracture of third metatarsal bone\n- Closed fracture of second metatarsal bone\n- Sarcoidosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Respiratory flow volume loop\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-06 13:20:00, ended at 2020-01-06 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Pulmonary stress testing (eg, 6-minute walk test), including measurement of heart rate, oximetry, and oxygen titration, when performed\n- Diffusing capacity (eg, carbon monoxide, membrane) (List separately in addition to code for primary procedure)\n- Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation\n\n### Condition\n- Interstitial lung disease\n- Sarcoidosis\n- Dyspnea\n- Hyperosmolarity\n- Secondary diabetes mellitus\n- Hypercalcemia\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-06 14:09:28, ended at 2020-01-06 16:00:44\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-11 09:30:59, ended at 2020-01-11 10:16:22\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- Body height: 5' 8.5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Atherosclerosis of coronary artery without angina pectoris\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-01-12 10:30:00, ended at 2020-01-12 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Type 2 diabetes mellitus\n- Type 1 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-01-18 11:42:19, ended at 2020-01-18 12:43:33\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Closed fracture proximal phalanx, toe\n- Hyperglycemia due to type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-27 00:00:00, ended at 2020-01-27 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-01-30 00:00:00, ended at 2020-01-30 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n\n### Drug\n- 24 HR nicotine 0.875 MG/HR Transdermal System, started on 2020-02-01, presumably until 2021-05-16, with intended 2 refill(s). Instructions: APPLY ONE PATCH EXTERNALLY ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-06 00:00:00, ended at 2020-02-06 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- calcium acetate 667 MG Oral Capsule, started on 2020-02-07, presumably until 2020-04-10, with intended 4 refill(s). Instructions: TAKE TWO CAPSULES BY MOUTH THREE TIMES DAILY WITH MEALS\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-10 00:00:00, ended at 2020-02-10 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-02-10, with intended 0 refill(s). Instructions: Take 1 capsule now and then 1 after next 3 dialysis sessions.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-11 00:00:00, ended at 2020-02-11 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-11, presumably until 2020-02-24, with intended 0 refill(s). Instructions: APPLY TOPICALLY AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-15 10:15:00, ended at 2020-02-15 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n- Closed fracture proximal phalanx, toe\n- Closed fracture of first metatarsal bone\n- Hyperglycemia due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-15 10:38:28, ended at 2020-02-15 11:17:20\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 1 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Type 2 diabetes mellitus\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-23 00:00:00, ended at 2020-02-23 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-02-24, presumably until 2020-05-08, with intended 3 refill(s). Instructions: apply to affected area topically as needed\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-25 00:00:00, ended at 2020-02-25 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- ascorbate manganese, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbyl tetraisopalmitate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- folic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- zinc ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- potassium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- 6-O-palmitoylascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- magnesium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- calcium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- sodium ascorbate, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- ascorbic acid, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n- biotin, started on 2020-02-28, presumably until 2020-04-13, with intended 3 refill(s). Instructions: Take 1 tab by mouth daily.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-02-28 00:00:00, ended at 2020-02-28 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- NDA020983 60 ACTUAT albuterol 0.09 MG/ACTUAT Metered Dose Inhaler, through Inhalation, started on 2020-02-28, presumably until 2021-02-27, with intended 11 refill(s). Instructions: 2 Puffs by Inhalation route every 4 hours as needed (SOB, Wheezing)\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-05 00:00:00, ended at 2020-03-05 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- promethazine hydrochloride 12.5 MG Oral Tablet, started on 2020-03-06, presumably until 2021-03-14, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH TWICE A DAY AS NEEDED FOR NAUSEA \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-09 00:00:00, ended at 2020-03-09 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- buprenorphine 2 MG / naloxone 0.5 MG Sublingual Tablet, started on 2020-03-09, presumably until 2020-08-04, with intended 5 refill(s). Instructions: DISSOLVE TWO TABLETS UNDER TONGUE DAILY\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-09 12:18:40, ended at 2020-03-09 12:48:39\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Abnormal findings on diagnostic imaging of lung\n- Hyperglycemia due to type 1 diabetes mellitus\n- Nicotine dependence\n- Type 1 diabetes mellitus\n- Post-inflammatory pulmonary fibrosis\n- Primary diagnosis: Anemia\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 2 diabetes mellitus\n\n### Drug\n- oseltamivir 30 MG Oral Capsule, started on 2020-02-10, presumably until 2020-04-06, with intended 0 refill(s)\n- 3 ML insulin lispro 200 UNT/ML Pen Injector, through Subcutaneous route, started on 2020-03-09, presumably until 2021-03-15, with intended 11 refill(s). Instructions: inject 6-10 Units subcutaneous (under the skin) before meals\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, started on 2020-03-09, presumably until 2021-03-19, with intended 11 refill(s). Instructions: Inject 30 units under the skin at bedtime\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-03-22 00:00:00, ended at 2020-03-22 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Type 1 diabetes mellitus\n- Primary diagnosis: Renal disorder due to type 1 diabetes mellitus\n- Primary diagnosis: Hyperglycemia due to type 1 diabetes mellitus\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-24 13:41:40, ended at 2020-03-24 13:51:46\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-03-28 09:16:21, ended at 2020-03-28 09:27:19\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Opioid dependence\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-06 14:27:38, ended at 2020-04-06 15:01:14\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Primary diagnosis: Sarcoidosis\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Type 2 diabetes mellitus\n\n### Drug\n- prednisone 1 MG Oral Tablet, through Oral route, started on 2020-04-06, presumably until 2020-09-28, with intended 2 refill(s). Instructions: take 4 Tabs (4 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-13 14:48:23, ended at 2020-04-13 15:32:30\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nicotine dependence\n- Dyspnea\n- Interstitial lung disease\n- Primary diagnosis: Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-20 10:33:00, ended at 2020-04-20 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, lower extremity; without contrast material\n\n### Condition\n- Hyperglycemia due to type 1 diabetes mellitus\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Type 2 diabetes mellitus\n- Renal disorder due to type 1 diabetes mellitus\n- Type 1 diabetes mellitus\n- Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-21 00:00:00, ended at 2020-04-21 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Dyspnea\n- Sarcoidosis\n- Primary diagnosis: Interstitial lung disease\n- Post-inflammatory pulmonary fibrosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-04-26 00:00:00, ended at 2020-04-26 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- atorvastatin 40 MG Oral Tablet, started on 2020-04-26, presumably until 2021-06-14, with intended 12 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-02 00:00:00, ended at 2020-05-02 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Pain in left foot\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-04 08:28:00, ended at 2020-05-04 23:59:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiologic examination, foot; complete, minimum of 3 views\n\n### Condition\n- Atherosclerosis of coronary artery without angina pectoris\n- Autonomic neuropathy due to type 2 diabetes mellitus\n- Pain in left foot\n- Neuropathic arthropathy due to type 2 diabetes mellitus\n- Arthropathy of the ankle AND/OR foot associated with a neurological disorder\n- Type 2 diabetes mellitus\n- Onychomycosis due to dermatophyte\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-07 00:00:00, ended at 2020-05-07 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- End-stage renal disease\n\n### Drug\n- lidocaine 25 MG/ML / prilocaine 25 MG/ML Topical Cream, started on 2020-05-08, presumably until 2020-10-10, with intended 11 refill(s). Instructions: APPLY TOPICALLY TO THE AFFECTED AREA AS NEEDED\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2020-05-17 00:00:00, ended at 2020-05-17 00:00:00\nThe patient in this visit was 47 years old, White, Not Hispanic or Latino, FEMALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, started on 2020-05-17, presumably until 2021-04-09, with intended 3 refill(s). Instructions: TAKE ONE TABLET BY MOUTH THREE TIMES DAILY \n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "158c09c66bbc2808a3e20c763d96a3c5eed1be8e0ff71a701fa5d42ab1404da8", "prompt_hash": "aa94fa4e97755cfb3b40e1bfd87cd4531dcd573bf2895e8de53398eb10c31155", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 5, "doc": {"person_id": 115967868, "visit_occurrence_id": 45095824, "death_date": null, "visit_concept_name": "Case Management Visit", "visit_start_datetime": "2011-08-30 00:00:00", "visit_end_datetime": "2011-08-30 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Case Management Visit, started at 2011-08-30 00:00:00, ended at 2011-08-30 00:00:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 94, "patient_first_visit_date": "2009-07-11 13:00:00", "patient_last_visit_date": "2021-07-02 00:00:00", "end_obs_date": "2012-08-29", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "recurrent", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 26, "cumulated_visit_num": 26, "cumulated_approximate_token_count": 5721, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2009-07-11 13:00:00, ended at 2009-07-11 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.685\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, presumably until 2012-03-24. Instructions: take by mouth 2 times a day. \n- valsartan 160 MG Oral Tablet, through Oral route, presumably until 2013-05-04. Instructions: take by mouth 2 times a day. \n- atorvastatin 20 MG Oral Tablet, through Oral route, presumably until 2014-04-05. Instructions: take by mouth daily. \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2009-07-19. Instructions: take by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-07-18 11:30:00, ended at 2009-07-18 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.685\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route. Instructions: take 20 mg by mouth 2 times a day. Call if lightheaded\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-07-20 10:54:00, ended at 2009-07-20 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-07-25 09:45:00, ended at 2009-07-25 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- MCV [Entitic volume] by Automated count: 91.6 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Prothrombin time (PT): 12.3 (second)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 147 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.2 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 80 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n\n### Drug\n- lisinopril 40 MG Oral Tablet, through Oral route, presumably until 2014-04-05. Instructions: take by mouth. \n- atenolol 50 MG Oral Tablet, through Oral route, presumably until 2010-02-20. Instructions: take by mouth. \n- allopurinol 300 MG Oral Tablet, through Oral route, presumably until 2014-04-05. Instructions: take by mouth. \n- terazosin 5 MG Oral Tablet, through Oral route. Instructions: take by mouth. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-07-26 08:45:00, ended at 2009-07-31 12:18:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 96 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 219 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 42.1 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.28 (thousand per microliter)\n- Prothrombin time (PT): 16.0 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 60.5 (millimeter mercury column)\n- Base deficit in Blood: 5.0 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 28.1 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Body height: 5' 11\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.23 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.4 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.66 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 640 (millimeter mercury column)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 203 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Coronary atherosclerosis\n- Aortocoronary bypass graft present\n- Essential hypertension\n- Alcohol abuse\n- Complication of surgical procedure\n- Gout\n- Disorder of lung\n- Drug abuse, continuous\n- Primary malignant neoplasm of lower lobe, bronchus or lung\n- Hyperlipidemia\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-07-27, presumably until 2009-07-31\n- terazosin 5 MG Oral Capsule, through Oral route, started on 2009-07-27, presumably until 2009-07-30\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2009-07-30, presumably until 2009-07-31\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-31\n- nitroglycerin 0.02 MG/MG Topical Ointment, through Transdermal route, started on 2009-07-27, presumably until 2009-07-27\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-31\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2009-07-28, presumably until 2009-07-30\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-28\n- atorvastatin 10 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-30\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-31\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-07-30, presumably until 2010-02-20, with quantity of 100.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2009-07-27, presumably until 2009-07-31\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-27\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2009-07-29, presumably until 2009-07-29\n- valsartan 160 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-31\n- 10 ML furosemide 10 MG/ML Injection, started on 2009-07-26, presumably until 2009-07-26\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-31\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2009-07-30, presumably until 2009-07-31\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2009-07-26, presumably until 2009-07-30\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-27\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2009-07-29, presumably until 2009-07-31\n- morphine sulfate 1 MG/ML Injection, through Intravenous route, started on 2009-07-27, presumably until 2009-07-27\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-26\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-07-28, presumably until 2009-07-31\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-07-31, presumably until 2010-01-27, with quantity of 100.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2009-08-12 13:49:00, ended at 2009-08-12 19:26:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 173 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.08 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.74 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCV [Entitic volume] by Automated count: 90.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.48 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Generalized aches and pains\n- Chest pain\n\n### Drug\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-08-12, presumably until 2009-08-12\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-08-12, presumably until 2009-08-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-08-22 10:30:00, ended at 2009-08-22 10:42:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-08-25 16:07:00, ended at 2009-08-25 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-19 08:55:00, ended at 2010-02-19 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Pleural effusion\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-20 11:14:00, ended at 2010-02-20 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.898\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- aspirin 81 MG Chewable Tablet, through Oral route. Instructions: take by mouth daily. \n- carvedilol 12.5 MG Oral Tablet, through Oral route, presumably until 2014-04-05. Instructions: take by mouth 2 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-08-01 00:00:00, ended at 2010-08-01 00:00:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-21 08:25:00, ended at 2010-08-21 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Disorder of lung\n- Lung field abnormal\n- Pleural effusion\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-28 10:12:00, ended at 2010-08-28 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-29 00:00:00, ended at 2011-01-29 00:00:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-07 16:59:00, ended at 2011-02-07 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-08 13:36:00, ended at 2011-02-08 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n\n### Condition\n- Lumbosacral spondylosis without myelopathy\n- Cervical spondylosis without myelopathy\n- Spinal stenosis of lumbar region\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-11 08:11:00, ended at 2011-02-11 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of lung\n- Pleural effusion\n- Lung field abnormal\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-02-18 09:50:46, ended at 2011-02-18 15:26:56\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis of lumbar region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-26 09:25:00, ended at 2011-02-26 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-01 09:40:00, ended at 2011-03-01 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Pleural effusion\n- Degeneration of intervertebral disc\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-03-06 00:00:00, ended at 2011-03-06 00:00:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-12 14:44:00, ended at 2011-08-12 23:59:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-13 09:23:00, ended at 2011-08-13 23:59:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of lung\n- Lung field abnormal\n- Primary malignant neoplasm of respiratory tract\n- Pleural effusion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-27 09:45:00, ended at 2011-08-27 10:37:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-27 10:38:00, ended at 2011-08-27 23:59:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-08-30 00:00:00, ended at 2011-08-30 00:00:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-07-11 13:00:00, ended at 2009-07-11 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.685\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- metformin hydrochloride 500 MG Oral Tablet, through Oral route, presumably until 2012-03-24. Instructions: take by mouth 2 times a day. \n- valsartan 160 MG Oral Tablet, through Oral route, presumably until 2013-05-04. Instructions: take by mouth 2 times a day. \n- atorvastatin 20 MG Oral Tablet, through Oral route, presumably until 2014-04-05. Instructions: take by mouth daily. \n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, presumably until 2009-07-19. Instructions: take by mouth daily. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-07-18 11:30:00, ended at 2009-07-18 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 9.685\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n\n### Drug\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route. Instructions: take 20 mg by mouth 2 times a day. Call if lightheaded\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-07-20 10:54:00, ended at 2009-07-20 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-07-25 09:45:00, ended at 2009-07-25 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.5 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.69 (million per microliter)\n- MCV [Entitic volume] by Automated count: 91.6 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Prothrombin time (PT): 12.3 (second)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.9 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.9 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 147 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.2 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.8 (gram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.0 (ratio)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 33.2 (second)\n- Glucose [Mass/volume] in Serum or Plasma: 80 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n\n### Drug\n- lisinopril 40 MG Oral Tablet, through Oral route, presumably until 2014-04-05. Instructions: take by mouth. \n- atenolol 50 MG Oral Tablet, through Oral route, presumably until 2010-02-20. Instructions: take by mouth. \n- allopurinol 300 MG Oral Tablet, through Oral route, presumably until 2014-04-05. Instructions: take by mouth. \n- terazosin 5 MG Oral Tablet, through Oral route. Instructions: take by mouth. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-07-26 08:45:00, ended at 2009-07-31 12:18:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Platelets [#/volume] in Blood by Automated count: 96 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 219 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.5 (picogram)\n- aPTT in Platelet poor plasma by Coagulation assay: 42.1 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 6.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.78 (thousand per microliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: <0.1 (nanogram per milliliter)\n- Hemoglobin [Mass/volume] in Blood: 11.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 8.28 (thousand per microliter)\n- Prothrombin time (PT): 16.0 (second)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 60.5 (millimeter mercury column)\n- Base deficit in Blood: 5.0 (millimole per liter)\n- Bicarbonate [Moles/volume] in Specimen: 28.1 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 108 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- MCHC [Mass/volume] by Automated count: 34.6 (gram per deciliter)\n- Body height: 5' 11\" (inch (US))\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.23 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.4 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 1.3 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 89.4 (percent)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.3 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Base excess in Blood by calculation: 1.0 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.66 (million per microliter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 7.0 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 640 (millimeter mercury column)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 203 (unit per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Type 2 diabetes mellitus without complication\n- Coronary atherosclerosis\n- Aortocoronary bypass graft present\n- Essential hypertension\n- Alcohol abuse\n- Complication of surgical procedure\n- Gout\n- Disorder of lung\n- Drug abuse, continuous\n- Primary malignant neoplasm of lower lobe, bronchus or lung\n- Hyperlipidemia\n\n### Drug\n- 200 ACTUAT albuterol 0.09 MG/ACTUAT / ipratropium bromide 0.018 MG/ACTUAT Inhalation Spray, through Inhalation, started on 2009-07-27, presumably until 2009-07-31\n- terazosin 5 MG Oral Capsule, through Oral route, started on 2009-07-27, presumably until 2009-07-30\n- lisinopril 40 MG Oral Tablet, through Oral route, started on 2009-07-30, presumably until 2009-07-31\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-31\n- nitroglycerin 0.02 MG/MG Topical Ointment, through Transdermal route, started on 2009-07-27, presumably until 2009-07-27\n- acetaminophen 500 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-31\n- docusate sodium 100 MG Oral Capsule, through Oral route, started on 2009-07-28, presumably until 2009-07-30\n- cefazolin 1000 MG Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-28\n- atorvastatin 10 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-30\n- hydralazine hydrochloride 25 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-31\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2009-07-30, presumably until 2010-02-20, with quantity of 100.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day. \n- heparin sodium, porcine 10000 UNT/ML Injectable Solution, started on 2009-07-27, presumably until 2009-07-31\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-27\n- lisinopril 20 MG Oral Tablet, through Oral route, started on 2009-07-29, presumably until 2009-07-29\n- valsartan 160 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-31\n- 10 ML furosemide 10 MG/ML Injection, started on 2009-07-26, presumably until 2009-07-26\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-07-27, presumably until 2009-07-31\n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2009-07-30, presumably until 2009-07-31\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2009-07-26, presumably until 2009-07-30\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-27\n- gabapentin 600 MG Oral Tablet, through Oral route, started on 2009-07-29, presumably until 2009-07-31\n- morphine sulfate 1 MG/ML Injection, through Intravenous route, started on 2009-07-27, presumably until 2009-07-27\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2009-07-26, presumably until 2009-07-26\n- oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-07-28, presumably until 2009-07-31\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2009-07-31, presumably until 2010-01-27, with quantity of 100.0, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2009-08-12 13:49:00, ended at 2009-08-12 19:26:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 273 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 92 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.32 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 11.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.5 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.2 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 173 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.7 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 4.08 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.74 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.6 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 33.9 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.68 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 0.00 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.3 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Albumin [Mass/volume] in Serum or Plasma: 3.4 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- MCV [Entitic volume] by Automated count: 90.6 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.48 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 25 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 16 (unit per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 73.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.6 (gram per deciliter)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n\n### Condition\n- Generalized aches and pains\n- Chest pain\n\n### Drug\n- 1000 ML potassium chloride 0.02 MEQ/ML / sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2009-08-12, presumably until 2009-08-12\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-08-12, presumably until 2009-08-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-08-22 10:30:00, ended at 2009-08-22 10:42:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2009-08-25 16:07:00, ended at 2009-08-25 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-19 08:55:00, ended at 2010-02-19 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Pleural effusion\n- Disorder of lung\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-02-20 11:14:00, ended at 2010-02-20 23:59:00\nThe patient in this visit was 75 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 8.898\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- aspirin 81 MG Chewable Tablet, through Oral route. Instructions: take by mouth daily. \n- carvedilol 12.5 MG Oral Tablet, through Oral route, presumably until 2014-04-05. Instructions: take by mouth 2 times a day. \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2010-08-01 00:00:00, ended at 2010-08-01 00:00:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-21 08:25:00, ended at 2010-08-21 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Lymphadenopathy\n- Disorder of lung\n- Lung field abnormal\n- Pleural effusion\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2010-08-28 10:12:00, ended at 2010-08-28 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-01-29 00:00:00, ended at 2011-01-29 00:00:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-07 16:59:00, ended at 2011-02-07 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-08 13:36:00, ended at 2011-02-08 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; cervical\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; lumbar\n- Magnetic resonance (eg, proton) imaging, spinal canal and contents, without contrast material, followed by contrast material(s) and further sequences; thoracic\n\n### Condition\n- Lumbosacral spondylosis without myelopathy\n- Cervical spondylosis without myelopathy\n- Spinal stenosis of lumbar region\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-11 08:11:00, ended at 2011-02-11 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of lung\n- Pleural effusion\n- Lung field abnormal\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2011-02-18 09:50:46, ended at 2011-02-18 15:26:56\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Spinal stenosis of lumbar region\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-02-26 09:25:00, ended at 2011-02-26 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-03-01 09:40:00, ended at 2011-03-01 23:59:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Pleural effusion\n- Degeneration of intervertebral disc\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-03-06 00:00:00, ended at 2011-03-06 00:00:00\nThe patient in this visit was 76 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-12 14:44:00, ended at 2011-08-12 23:59:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-13 09:23:00, ended at 2011-08-13 23:59:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of lung\n- Lung field abnormal\n- Primary malignant neoplasm of respiratory tract\n- Pleural effusion\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-27 09:45:00, ended at 2011-08-27 10:37:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2011-08-27 10:38:00, ended at 2011-08-27 23:59:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2011-08-30 00:00:00, ended at 2011-08-30 00:00:00\nThe patient in this visit was 77 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of respiratory tract\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "3e234eef2f4784129299218fc963ede935b7b9ed6a95e0bf1129d432342fe88c", "prompt_hash": "6c34089e83a2f8a62760e0f6fad64490625eb5c8a9304432007296f1265d0614", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 6, "doc": {"person_id": 115967924, "visit_occurrence_id": 85358796, "death_date": null, "visit_concept_name": "Hospital", "visit_start_datetime": "2016-04-24 00:00:00", "visit_end_datetime": "2016-04-24 00:00:00", "visit_length_in_hours": 0.0, "integrated_visit_record": "## Visit\nThis visit record, was from Hospital, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2016-04-24, presumably until 2016-04-24\n\n", "approximate_token_count": 99, "patient_first_visit_date": "2014-10-03 14:30:00", "patient_last_visit_date": "2018-07-08 11:13:00", "end_obs_date": "2017-04-24", "hypertension_type": "new", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "recurrent", "intestinal_cancer_one_year_diagnosis": 1, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 17, "cumulated_visit_num": 17, "cumulated_approximate_token_count": 4295, "visit_cumulated": "## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-03 14:30:00, ended at 2014-10-03 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Primary malignant neoplasm of rectosigmoid junction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-13 12:12:00, ended at 2014-10-13 14:02:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n- Pure hypercholesterolemia\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day.\n- ranitidine 150 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 150 mg by mouth 2 times a day.\n- sucralfate 1000 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 1 g by mouth 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-13 14:03:00, ended at 2014-10-13 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.7 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-02 13:32:00, ended at 2014-11-02 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-11-03 00:00:00, ended at 2014-11-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-17 00:00:00, ended at 2015-01-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-02 12:36:00, ended at 2015-02-02 14:29:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of rectum\n- Neoplasm defined only by topography: Rectum, NOS\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-02-02, presumably until 2015-02-03, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-02 14:30:00, ended at 2015-02-02 23:59:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of rectum\n- Digestive symptom\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-07 10:30:00, ended at 2015-03-07 13:29:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.094\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- atorvastatin 10 MG Oral Tablet, through Oral route, presumably until 2015-09-21, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day.\n- esomeprazole 40 MG Delayed Release Oral Capsule, through Oral route, presumably until 2015-03-30, with intended 0 refill(s). Instructions: take 40 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-13 00:00:00, ended at 2015-03-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-03-13, presumably until 2015-03-15, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-03-15 00:00:00, ended at 2015-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- ertapenem 1000 MG Injection, started on 2015-03-15, presumably until 2015-03-15\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- midazolam 1 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-03-15 00:00:00, ended at 2015-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2015-03-15, presumably until 2015-03-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-03-15 07:36:00, ended at 2015-03-17 13:47:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 157 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.49 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.9 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 149 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Body height: 5' 4\" (inch (US))\n- Glucose [Mass/volume] in Blood: 131 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- MCH [Entitic mass] by Automated count: 34.2 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Other anterior resection of rectum\n- Anastomosis of large intestine to large intestine\n\n### Condition\n- Pure hypercholesterolemia\n- Primary malignant neoplasm of rectum\n- Gastroesophageal reflux disease\n- Intestinal disaccharidase deficiency\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-03-15, presumably until 2015-03-16\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2015-03-16, presumably until 2015-03-16\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-16\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2015-03-16, presumably until 2015-03-17\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2015-03-16, presumably until 2015-03-16\n- atorvastatin 10 MG Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-16\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-03-15, presumably until 2015-03-15\n- alvimopan 12 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-16\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2015-03-16, presumably until 2015-09-13, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-30 13:08:00, ended at 2015-03-30 23:59:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.094\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-21 11:06:42, ended at 2015-09-21 11:41:05\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.37\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-09-21, presumably until 2015-09-21, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n- prochlorperazine 10 MG Oral Tablet, started on 2015-06-14, presumably until 2015-06-14, with intended 0 refill(s)\n- psyllium 6000 MG Powder for Oral Suspension, through Oral route, started on 2015-09-21, presumably until 2015-09-21. Instructions: take 1 Packet by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-11 00:00:00, ended at 2016-03-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2016-03-11, presumably until 2016-03-11, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2016-04-24, presumably until 2016-04-24\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-03 14:30:00, ended at 2014-10-03 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n\n### Condition\n- Primary malignant neoplasm of rectosigmoid junction\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-13 12:12:00, ended at 2014-10-13 14:02:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n- Pure hypercholesterolemia\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day.\n- ranitidine 150 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 150 mg by mouth 2 times a day.\n- sucralfate 1000 MG Oral Tablet, through Oral route, presumably until 2015-03-07, with intended 0 refill(s). Instructions: take 1 g by mouth 4 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-10-13 14:03:00, ended at 2014-10-13 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 21 (unit per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 44.0 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 113 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Carcinoembryonic Ag [Mass/volume] in Serum or Plasma: 2 (nanogram per milliliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.64 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 5.5 (thousand per microliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.0 (percent)\n- Platelets [#/volume] in Blood by Automated count: 192 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.7 (femtoliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 11 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-11-02 13:32:00, ended at 2014-11-02 23:59:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Lymphadenopathy\n- Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-11-03 00:00:00, ended at 2014-11-03 00:00:00\nThe patient in this visit was 55 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2015-01-17 00:00:00, ended at 2015-01-17 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-02 12:36:00, ended at 2015-02-02 14:29:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.354\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of rectum\n- Neoplasm defined only by topography: Rectum, NOS\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-02-02, presumably until 2015-02-03, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-02-02 14:30:00, ended at 2015-02-02 23:59:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of rectum\n- Digestive symptom\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-07 10:30:00, ended at 2015-03-07 13:29:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.094\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- atorvastatin 10 MG Oral Tablet, through Oral route, presumably until 2015-09-21, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day.\n- esomeprazole 40 MG Delayed Release Oral Capsule, through Oral route, presumably until 2015-03-30, with intended 0 refill(s). Instructions: take 40 mg by mouth Every Day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Pharmacy visit, started at 2015-03-13 00:00:00, ended at 2015-03-13 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-03-13, presumably until 2015-03-15, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-03-15 00:00:00, ended at 2015-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; not otherwise specified\n\n### Condition\n- Primary malignant neoplasm of rectum\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- ertapenem 1000 MG Injection, started on 2015-03-15, presumably until 2015-03-15\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2015-03-15, presumably until 2015-03-15\n- midazolam 1 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2015-03-15 00:00:00, ended at 2015-03-15 00:00:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- bupivacaine hydrochloride 2.5 MG/ML Injectable Solution, started on 2015-03-15, presumably until 2015-03-15\n- sodium chloride 0.154 MEQ/ML Irrigation Solution, through Topical route, started on 2015-03-15, presumably until 2015-03-15\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2015-03-15 07:36:00, ended at 2015-03-17 13:47:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 157 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.33 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.46 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 5.49 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.3 (percent)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 85.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 99.9 (femtoliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 149 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 8 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.0 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.00 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 8.0 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Body height: 5' 4\" (inch (US))\n- Glucose [Mass/volume] in Blood: 131 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- MCH [Entitic mass] by Automated count: 34.2 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.0 (percent)\n\n### Procedure\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Collection of venous blood by venipuncture\n- Other anterior resection of rectum\n- Anastomosis of large intestine to large intestine\n\n### Condition\n- Pure hypercholesterolemia\n- Primary malignant neoplasm of rectum\n- Gastroesophageal reflux disease\n- Intestinal disaccharidase deficiency\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2015-03-15, presumably until 2015-03-16\n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2015-03-16, presumably until 2015-03-16\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-16\n- 0.4 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2015-03-16, presumably until 2015-03-17\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2015-03-16, presumably until 2015-03-16\n- atorvastatin 10 MG Oral Tablet, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-17\n- celecoxib 200 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-15\n- 2 ML ondansetron 2 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-15\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2015-03-15, presumably until 2015-03-16\n- 1 ML hydromorphone hydrochloride 2 MG/ML Prefilled Syringe, started on 2015-03-15, presumably until 2015-03-15\n- alvimopan 12 MG Oral Capsule, through Oral route, started on 2015-03-15, presumably until 2015-03-16\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2015-03-16, presumably until 2015-09-13, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2015-03-30 13:08:00, ended at 2015-03-30 23:59:00\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.094\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2015-09-21 11:06:42, ended at 2015-09-21 11:41:05\nThe patient in this visit was 56 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 4.37\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of rectum\n\n### Drug\n- rosuvastatin calcium 10 MG Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 10 mg by mouth Every Day\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2015-09-21, presumably until 2015-09-21, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n- prochlorperazine 10 MG Oral Tablet, started on 2015-06-14, presumably until 2015-06-14, with intended 0 refill(s)\n- psyllium 6000 MG Powder for Oral Suspension, through Oral route, started on 2015-09-21, presumably until 2015-09-21. Instructions: take 1 Packet by mouth 3 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2016-03-11 00:00:00, ended at 2016-03-11 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- polyethylene glycol 3350 236000 MG / potassium chloride 2970 MG / sodium bicarbonate 6740 MG / sodium chloride 5860 MG / sodium sulfate 22740 MG Powder for Oral Solution, through Oral route, started on 2016-03-11, presumably until 2016-03-11, with intended 0 refill(s). Instructions: take 4,000 mL by mouth One Time\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2016-04-24 00:00:00, ended at 2016-04-24 00:00:00\nThe patient in this visit was 57 years old, unknown race, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- midazolam 1 MG/ML Injectable Solution, started on 2016-04-24, presumably until 2016-04-24\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "2f8946aab9035e9ecc732786397cf833bf4a5cccd6d30e12f3f10b40affe0d8c", "prompt_hash": "185c1dd321e41c1cb66d82f403e006aae4f460dd9a8b4f1d63900458496be39a", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 7, "doc": {"person_id": 115968081, "visit_occurrence_id": 180687774, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2021-05-08 06:57:00", "visit_end_datetime": "2021-05-08 23:59:00", "visit_length_in_hours": 17.033333333333335, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-08 06:57:00, ended at 2021-05-08 23:59:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Cirrhosis of liver\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 118, "patient_first_visit_date": "2011-01-09 10:37:00", "patient_last_visit_date": "2023-02-04 11:16:39", "end_obs_date": "2022-05-08", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "recurrent", "obesity_one_year_diagnosis": 1, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 1, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 1, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "recurrent", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "recurrent", "liver_cancer_one_year_diagnosis": 1, "visit_sequence_number": 37, "cumulated_visit_num": 37, "cumulated_approximate_token_count": 9832, "visit_cumulated": "## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-01-09 10:37:00, ended at 2011-01-29 15:45:00\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 52.7 (millimeter mercury column)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 415 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 1.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.03 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.47 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 55 (percent)\n- Platelets [#/volume] in Blood by Automated count: 97 (thousand per microliter)\n- Prothrombin time (PT): 27.7 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 1.51 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 32.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.6 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 96 (millimeter mercury column)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.73 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 32.2 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 147 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 61.8 (second)\n- Base excess in Blood by calculation: 8.0 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Manual count: 1.3 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 13.2 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 6.8 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 1.4 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Body height: 5' 6\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Base deficit in Blood: 9.0 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.4 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.9 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 15 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 20.9 (microgram per milliliter)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Aortocoronary bypass of two coronary arteries\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, chest; single view, frontal\n- Catheterization of both left and right heart\n- Operative external blood circulation\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Collection of venous blood by venipuncture\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Coronary angiography\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Insertion of intra-aortic balloon counterpulsation\n- Single internal mammary-coronary artery bypass\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Controlled ventilation procedure and therapy, initiation and management\n- Occupational therapy evaluation\n\n### Condition\n- Congestive heart failure\n- Obesity\n- Obstructive sleep apnea syndrome\n- Postprocedural state finding\n- Acute respiratory failure\n- Peripheral vascular disease\n- Pulmonary congestion and hypostasis\n- Brachial radiculitis\n- Coronary arteriosclerosis\n- Essential hypertension\n- Glaucoma\n- Leukocytosis\n- Primary diagnosis: Acute myocardial infarction\n- Aortocoronary bypass graft present\n- Cardiomegaly\n- Hyperlipidemia\n- Acute combined systolic and diastolic heart failure\n- Cardiac arrhythmia\n- Chronic systolic heart failure\n- Hemorrhoids\n- Nuclear senile cataract\n- Sequelae of cardiovascular disorders\n- Type 2 diabetes mellitus without complication\n- Acute myocardial infarction of anterolateral wall\n- Chronic ischemic heart disease\n- Pleural effusion\n\n### Drug\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2011-01-28, presumably until 2011-02-15, with quantity of 15.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours. \n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2011-01-20, presumably until 2011-01-20\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2011-01-18, presumably until 2011-01-21\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2011-01-28, presumably until 2011-01-28\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2011-01-11, presumably until 2011-01-11\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-01-16, presumably until 2011-01-26\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-04-19. Instructions: take 25 mg by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-01-26, presumably until 2011-01-26\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-22, presumably until 2011-01-27\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2011-01-20, presumably until 2011-01-20\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2011-01-19, presumably until 2011-01-23\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-14\n- nitroglycerin 0.02 MG/MG Topical Ointment, through Transdermal route, started on 2011-01-12, presumably until 2011-01-28\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2011-01-27, presumably until 2011-04-19, with quantity of 1.0, with intended 0 refill(s). Instructions: insert into the rectum as needed for Anorectal itching/discomfort. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-01-10, presumably until 2012-01-29, with quantity of 120.0, with intended 0 refill(s). Instructions: take 4 Tabs by mouth 2 times a day. \n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-01-09, presumably until 2011-01-09\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-01-12, presumably until 2011-01-28\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-01-14, presumably until 2012-01-29, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed \n- furosemide 40 MG Oral Tablet, through Oral route, started on 2011-01-27, presumably until 2012-01-29, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- insulin detemir 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-01-13, presumably until 2020-04-28. Instructions: inject subcutaneous (under the skin). \n- citalopram 20 MG Oral Tablet, through Oral route, started on 2011-01-16, presumably until 2011-01-29. Instructions: take by mouth.\n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2011-01-17, presumably until 2011-01-29\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- 10 ML furosemide 10 MG/ML Injection, started on 2011-01-13, presumably until 2011-01-26\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-14\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2011-01-22, presumably until 2011-01-27\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2011-01-09, presumably until 2011-01-13\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-01-28. Instructions: take 20 mg by mouth daily.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2011-01-11, presumably until 2011-01-14\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-01-09, presumably until 2022-08-20. Instructions: inject subcutaneous (under the skin) 4 times a day before meals and bedtime. \n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, started on 2011-01-20, presumably until 2011-01-26\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-01-17, presumably until 2011-01-28\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-02-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-13\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-11\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2011-01-14, presumably until 2011-01-14\n- sodium polystyrene sulfonate 250 MG/ML Oral Suspension, through Oral route, started on 2011-01-13, presumably until 2011-01-13\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2011-01-26, presumably until 2011-02-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- warfarin sodium 2 MG Oral Tablet, through Oral route, started on 2011-01-29, presumably until 2011-01-29, with quantity of 90.0, with intended 0 refill(s). Instructions: take 3 Tabs by mouth daily. Please have INR levels checked on Monday 02/01/2011 \n- pravastatin sodium 10 MG Oral Tablet, through Oral route, presumably until 2011-02-15. Instructions: take 20 mg by mouth daily. \n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2011-01-17, presumably until 2011-01-28\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2011-01-25, presumably until 2011-01-25\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2011-01-13, presumably until 2011-04-19, with quantity of 60.0, with intended 2 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed \n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2011-01-11, presumably until 2011-01-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2011-01-10, presumably until 2011-02-15, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast. \n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-01-12, presumably until 2011-01-12\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-23, presumably until 2011-04-19, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain. \n- 500 ML heparin sodium, porcine 2 UNT/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-10 14:38:57, ended at 2011-01-10 15:15:45\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Precordial pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-18 09:29:44, ended at 2011-01-18 10:42:10\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Coronary arteriosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-29 10:00:00, ended at 2011-01-29 23:59:00\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-29 00:00:00, ended at 2020-01-29 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cancer Ag 19-9 [Units/volume] in Serum or Plasma: 2 (unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-01 08:29:50, ended at 2020-02-01 10:34:41\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2020-01-28, presumably until 2020-01-28, with intended 0 refill(s). Instructions: take 1 Tablet (300 mg total) by mouth daily\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2019-10-23, presumably until 2019-10-23, with intended 0 refill(s). Instructions: take 1 Tablet (20 mg total) by mouth AM\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2019-04-12, presumably until 2022-11-09, with intended 0 refill(s). Instructions: take 250 mg by mouth 2 times a day\n- omeprazole 40 MG Delayed Release Oral Capsule, through Oral route, started on 2019-10-25, presumably until 2022-03-01, with intended 0 refill(s). Instructions: take 40 mg by mouth daily\n- vitamin B complex, through Oral route, started on 2012-07-25, presumably until 2012-07-25, with intended 0 refill(s). Instructions: take 1 Capsule by mouth daily\n- 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet, through Oral route, started on 2019-07-23, presumably until 2019-07-23, with intended 0 refill(s). Instructions: take 1 Tablet (150 mg total) by mouth AM\n- dorzolamide 20 MG/ML Ophthalmic Solution, through Intraocular route, started on 2019-08-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes 2 times a day\n- spironolactone 25 MG Oral Tablet, started on 2017-08-15, presumably until 2017-08-15, with intended 0 refill(s). Instructions: Take one tablet by mouth one time daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2017-08-19, presumably until 2017-08-19, with intended 0 refill(s). Instructions: inject 60 Units subcutaneous (under the skin) 2 times a day\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, through Oral route, started on 2019-12-30, presumably until 2019-12-30, with intended 0 refill(s). Instructions: take 500 mg by mouth 2 times a day\n- 0.5 ML dulaglutide 1.5 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-01-07, presumably until 2020-01-07, with intended 0 refill(s). Instructions: inject subcutaneous (under the skin) every 7 days Every Mondays\n- rosuvastatin calcium 20 MG Oral Tablet, started on 2019-08-24, presumably until 2019-08-24, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY\n- losartan potassium 25 MG Oral Tablet, through Oral route, started on 2019-11-15, presumably until 2019-11-15, with intended 0 refill(s). Instructions: take 1 Tablet (25 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-01 10:33:00, ended at 2020-02-01 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.9 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 13 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.38 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.43 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 46 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.3 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.67 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.21 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 69.0 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 72 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Prothrombin time (PT): 13.9 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-18 00:00:00, ended at 2020-02-18 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 07:12:00, ended at 2020-03-31 08:24:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone and/or joint imaging; whole body\n\n### Condition\n- Liver cell carcinoma\n- Lumbar spondylosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 08:25:00, ended at 2020-03-31 10:25:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 13:22:00, ended at 2020-03-31 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-04 00:00:00, ended at 2020-04-04 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cirrhosis of liver\n- Nonalcoholic steatohepatitis\n- Portal vein thrombosis\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-04 00:00:00, ended at 2020-04-04 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-15 00:00:00, ended at 2020-04-15 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-18 00:00:00, ended at 2020-04-18 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-18 10:04:44, ended at 2020-04-18 10:16:59\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-22 07:47:00, ended at 2020-04-22 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, abdominal, real time with image documentation; complete\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n\n### Condition\n- Postoperative state\n- Steatosis of liver\n- Disorder of digestive system\n- Hepatosplenomegaly\n- Liver cell carcinoma\n- Acquired absence of organ\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-28 09:33:22, ended at 2020-04-28 10:35:04\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Malignant neoplasm of liver\n- Traumatic or non-traumatic injury\n- Obstructive sleep apnea syndrome\n- Generalized ischemic myocardial dysfunction\n- Hyperlipidemia\n- Primary diagnosis: COVID-19\n- Liver cell carcinoma\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, presumably until 2020-11-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 1 Tablet (81 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Liver cell carcinoma\n- Essential hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- cefazolin 1000 MG Injection, started on 2020-05-01, presumably until 2020-05-01\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-05-01, presumably until 2020-05-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-01 08:40:00, ended at 2020-05-01 19:30:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.32 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.16 (million per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 58 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 27.5 (picogram)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Body height: 5' 6\" (inch (US))\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 223 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n\n### Procedure\n- Ablation, 1 or more liver tumor(s), percutaneous, radiofrequency\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography guidance for, and monitoring of, parenchymal tissue ablation\n- Collection of venous blood by venipuncture\n\n### Condition\n- Aortocoronary bypass graft present\n- Steatosis of liver\n- Hyperlipidemia\n- Old myocardial infarction\n- Supraventricular tachycardia\n- Chronic systolic heart failure\n- Primary diagnosis: Liver cell carcinoma\n- Generalized ischemic myocardial dysfunction\n- Chronic congestive heart failure\n- Hypertensive heart failure\n- Obesity\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-24 00:00:00, ended at 2020-06-24 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-04 10:32:19, ended at 2020-07-04 10:56:47\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nonalcoholic steatohepatitis\n- Cirrhosis of liver\n- Primary diagnosis: Liver cell carcinoma\n- Portal vein thrombosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-05 07:00:00, ended at 2020-08-05 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-06 08:46:06, ended at 2020-08-06 09:13:34\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-07 00:00:00, ended at 2020-08-07 00:00:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 10:36:58, ended at 2020-08-15 11:02:37\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm defined only by topography: Liver\n- Portal vein thrombosis\n- Cirrhosis of liver\n- Nonalcoholic steatohepatitis\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-05 07:10:00, ended at 2020-11-05 23:59:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-14 09:54:20, ended at 2020-11-14 10:11:20\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n- Nonalcoholic steatohepatitis\n- Cirrhosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-12 00:00:00, ended at 2021-01-12 00:00:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 0.56 (nanogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-06 00:00:00, ended at 2021-02-06 00:00:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-12 12:59:00, ended at 2021-02-12 23:59:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Portal hypertension\n- Splenomegaly\n- Liver cell carcinoma\n- Cirrhosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-13 10:28:20, ended at 2021-02-13 10:49:11\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nonalcoholic steatohepatitis\n- Cirrhosis of liver\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-08 06:57:00, ended at 2021-05-08 23:59:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Cirrhosis of liver\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n"}, "target": "Yes", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Emergency Room and Inpatient Visit, started at 2011-01-09 10:37:00, ended at 2011-01-29 15:45:00\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 94 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Carbon dioxide [Partial pressure] adjusted to patient's actual temperature in Blood: 52.7 (millimeter mercury column)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 415 (unit per liter)\n- Eosinophils [#/volume] in Blood by Manual count: 1.5 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 3.03 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Manual count: 7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 9.47 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 55 (percent)\n- Platelets [#/volume] in Blood by Automated count: 97 (thousand per microliter)\n- Prothrombin time (PT): 27.7 (second)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 74 (unit per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 1.51 (thousand per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 49.1 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 32.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 89.2 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 82.6 (percent)\n- Oxygen [Partial pressure] adjusted to patient's actual temperature in Blood: 96 (millimeter mercury column)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 70 (unit per liter)\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.25 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.6 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 93 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 9.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.73 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.2 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Basophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Bicarbonate [Moles/volume] in Specimen: 32.2 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.2 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 3.4 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 147 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 61.8 (second)\n- Base excess in Blood by calculation: 8.0 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.11 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 33 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 99 (millimole per liter)\n- Monocytes [#/volume] in Blood by Manual count: 1.3 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Manual count: 13.2 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 6.8 (millimole per liter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 1.4 (nanogram per milliliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 33 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Basophils [#/volume] in Blood by Manual count: 0.2 (thousand per microliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.4 (milligram per deciliter)\n- Body height: 5' 6\" (inch (US))\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.7 (percent)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 3.7 (milligram per deciliter)\n- Base deficit in Blood: 9.0 (millimole per liter)\n- Hemoglobin A1c/Hemoglobin.total in Blood: 9.4 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 2.9 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 15 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 1.55 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 9.9 (percent)\n- Oxygen saturation Calculated from oxygen partial pressure in Blood: 99 (percent)\n- Vancomycin [Mass/volume] in Serum or Plasma --trough: 20.9 (microgram per milliliter)\n- INR in Platelet poor plasma by Coagulation assay: N/A (ratio)\n- MCH [Entitic mass] by Automated count: 29.5 (picogram)\n\n### Procedure\n- Radiologic examination, chest, 2 views, frontal and lateral\n- Aortocoronary bypass of two coronary arteries\n- Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes\n- Radiologic examination, chest; single view, frontal\n- Catheterization of both left and right heart\n- Operative external blood circulation\n- Limited bilateral noninvasive physiologic studies of upper or lower extremity arteries, (eg, for lower extremity: ankle/brachial indices at distal posterior tibial and anterior tibial/dorsalis pedis arteries plus bidirectional, Doppler waveform recording \n- Collection of venous blood by venipuncture\n- Physical therapy evaluation\n- Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility\n- Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report\n- Coronary angiography\n- Self-care/home management training (eg, activities of daily living (ADL) and compensatory training, meal preparation, safety procedures, and instructions in use of assistive technology devices/adaptive equipment) direct one-on-one contact, each 15 minutes\n- Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes\n- Insertion of intra-aortic balloon counterpulsation\n- Single internal mammary-coronary artery bypass\n- Catheter placement in coronary artery(s) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation\n- Continuous positive airway pressure ventilation (CPAP), initiation and management\n- Controlled ventilation procedure and therapy, initiation and management\n- Occupational therapy evaluation\n\n### Condition\n- Congestive heart failure\n- Obesity\n- Obstructive sleep apnea syndrome\n- Postprocedural state finding\n- Acute respiratory failure\n- Peripheral vascular disease\n- Pulmonary congestion and hypostasis\n- Brachial radiculitis\n- Coronary arteriosclerosis\n- Essential hypertension\n- Glaucoma\n- Leukocytosis\n- Primary diagnosis: Acute myocardial infarction\n- Aortocoronary bypass graft present\n- Cardiomegaly\n- Hyperlipidemia\n- Acute combined systolic and diastolic heart failure\n- Cardiac arrhythmia\n- Chronic systolic heart failure\n- Hemorrhoids\n- Nuclear senile cataract\n- Sequelae of cardiovascular disorders\n- Type 2 diabetes mellitus without complication\n- Acute myocardial infarction of anterolateral wall\n- Chronic ischemic heart disease\n- Pleural effusion\n\n### Drug\n- amoxicillin 500 MG / clavulanate 125 MG Oral Tablet, through Oral route, started on 2011-01-28, presumably until 2011-02-15, with quantity of 15.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 8 hours. \n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2011-01-20, presumably until 2011-01-20\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- warfarin sodium 5 MG Oral Tablet, through Oral route, started on 2011-01-18, presumably until 2011-01-21\n- warfarin sodium 6 MG Oral Tablet, through Oral route, started on 2011-01-28, presumably until 2011-01-28\n- chlorhexidine gluconate 1.2 MG/ML Mouthwash, through Submucosal route, started on 2011-01-11, presumably until 2011-01-11\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2011-01-16, presumably until 2011-01-26\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-04-19. Instructions: take 25 mg by mouth daily. \n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-01-26, presumably until 2011-01-26\n- zolpidem tartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-22, presumably until 2011-01-27\n- warfarin sodium 3 MG Oral Tablet, through Oral route, started on 2011-01-20, presumably until 2011-01-20\n- magnesium citrate 58.2 MG/ML Oral Solution, through Oral route, started on 2011-01-19, presumably until 2011-01-23\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-14\n- nitroglycerin 0.02 MG/MG Topical Ointment, through Transdermal route, started on 2011-01-12, presumably until 2011-01-28\n- hydrocortisone 25 MG/ML Topical Cream, through Topical route, started on 2011-01-27, presumably until 2011-04-19, with quantity of 1.0, with intended 0 refill(s). Instructions: insert into the rectum as needed for Anorectal itching/discomfort. \n- cefazolin 1000 MG Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- Microencapsulated potassium chloride 10 MEQ Extended Release Oral Tablet, through Oral route, started on 2011-01-10, presumably until 2012-01-29, with quantity of 120.0, with intended 0 refill(s). Instructions: take 4 Tabs by mouth 2 times a day. \n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2011-01-09, presumably until 2011-01-09\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2011-01-12, presumably until 2011-01-28\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2011-01-14, presumably until 2012-01-29, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day as needed \n- furosemide 40 MG Oral Tablet, through Oral route, started on 2011-01-27, presumably until 2012-01-29, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- insulin detemir 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-01-13, presumably until 2020-04-28. Instructions: inject subcutaneous (under the skin). \n- citalopram 20 MG Oral Tablet, through Oral route, started on 2011-01-16, presumably until 2011-01-29. Instructions: take by mouth.\n- magnesium hydroxide 80 MG/ML Oral Suspension, through Oral route, started on 2011-01-17, presumably until 2011-01-29\n- 250 ML nitroglycerin 0.2 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- 10 ML furosemide 10 MG/ML Injection, started on 2011-01-13, presumably until 2011-01-26\n- 250 ML dopamine hydrochloride 1.6 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-14\n- warfarin sodium 4 MG Oral Tablet, through Oral route, started on 2011-01-22, presumably until 2011-01-27\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2011-01-09, presumably until 2011-01-13\n- pravastatin sodium 20 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-01-28. Instructions: take 20 mg by mouth daily.\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2011-01-11, presumably until 2011-01-14\n- insulin aspart, human 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2011-01-09, presumably until 2022-08-20. Instructions: inject subcutaneous (under the skin) 4 times a day before meals and bedtime. \n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, started on 2011-01-20, presumably until 2011-01-26\n- piperacillin 3000 MG / tazobactam 375 MG Injection, through Intravenous route, started on 2011-01-17, presumably until 2011-01-28\n- 50 ML sodium bicarbonate 84 MG/ML Prefilled Syringe, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- carvedilol 3.125 MG Oral Tablet, through Oral route, started on 2011-01-15, presumably until 2011-02-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 2.25 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-13\n- 50 ML potassium chloride 0.4 MEQ/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-11\n- carvedilol 6.25 MG Oral Tablet, through Oral route, started on 2011-01-14, presumably until 2011-01-14\n- sodium polystyrene sulfonate 250 MG/ML Oral Suspension, through Oral route, started on 2011-01-13, presumably until 2011-01-13\n- spironolactone 25 MG Oral Tablet, through Oral route, started on 2011-01-26, presumably until 2011-02-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day. \n- warfarin sodium 2 MG Oral Tablet, through Oral route, started on 2011-01-29, presumably until 2011-01-29, with quantity of 90.0, with intended 0 refill(s). Instructions: take 3 Tabs by mouth daily. Please have INR levels checked on Monday 02/01/2011 \n- pravastatin sodium 10 MG Oral Tablet, through Oral route, presumably until 2011-02-15. Instructions: take 20 mg by mouth daily. \n- 200 ML vancomycin 5 MG/ML Injection, through Intravenous route, started on 2011-01-17, presumably until 2011-01-28\n- warfarin sodium 1 MG Oral Tablet, through Oral route, started on 2011-01-25, presumably until 2011-01-25\n- 100 ML propofol 10 MG/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n- simethicone 80 MG Chewable Tablet, through Oral route, started on 2011-01-13, presumably until 2011-04-19, with quantity of 60.0, with intended 2 refill(s). Instructions: take 2 Tabs by mouth every 6 hours as needed \n- aspirin 300 MG Rectal Suppository, through Rectal route, started on 2011-01-11, presumably until 2011-01-12\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, started on 2011-01-10, presumably until 2011-02-15, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every morning with breakfast. \n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2011-01-12, presumably until 2011-01-12\n- acetaminophen 500 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2011-01-23, presumably until 2011-04-19, with quantity of 60.0, with intended 1 refill(s). Instructions: take 1-2 Tabs by mouth every 6 hours as needed for Pain. \n- 500 ML heparin sodium, porcine 2 UNT/ML Injection, through Intravenous route, started on 2011-01-11, presumably until 2011-01-12\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-10 14:38:57, ended at 2011-01-10 15:15:45\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Precordial pain\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-18 09:29:44, ended at 2011-01-18 10:42:10\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Coronary arteriosclerosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2011-01-29 10:00:00, ended at 2011-01-29 23:59:00\nThe patient in this visit was 61 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography\n\n### Condition\n- Congestive heart failure\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-01-29 00:00:00, ended at 2020-01-29 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Cancer Ag 19-9 [Units/volume] in Serum or Plasma: 2 (unit per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Office Visit, started at 2020-02-01 08:29:50, ended at 2020-02-01 10:34:41\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- allopurinol 300 MG Oral Tablet, through Oral route, started on 2020-01-28, presumably until 2020-01-28, with intended 0 refill(s). Instructions: take 1 Tablet (300 mg total) by mouth daily\n- furosemide 20 MG Oral Tablet, through Oral route, started on 2019-10-23, presumably until 2019-10-23, with intended 0 refill(s). Instructions: take 1 Tablet (20 mg total) by mouth AM\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2019-04-12, presumably until 2022-11-09, with intended 0 refill(s). Instructions: take 250 mg by mouth 2 times a day\n- omeprazole 40 MG Delayed Release Oral Capsule, through Oral route, started on 2019-10-25, presumably until 2022-03-01, with intended 0 refill(s). Instructions: take 40 mg by mouth daily\n- vitamin B complex, through Oral route, started on 2012-07-25, presumably until 2012-07-25, with intended 0 refill(s). Instructions: take 1 Capsule by mouth daily\n- 24 HR bupropion hydrochloride 150 MG Extended Release Oral Tablet, through Oral route, started on 2019-07-23, presumably until 2019-07-23, with intended 0 refill(s). Instructions: take 1 Tablet (150 mg total) by mouth AM\n- dorzolamide 20 MG/ML Ophthalmic Solution, through Intraocular route, started on 2019-08-17, presumably until 2019-08-17, with intended 0 refill(s). Instructions: instill 1 Drop to both eyes 2 times a day\n- spironolactone 25 MG Oral Tablet, started on 2017-08-15, presumably until 2017-08-15, with intended 0 refill(s). Instructions: Take one tablet by mouth one time daily\n- 3 ML insulin glargine 100 UNT/ML Pen Injector, through Subcutaneous route, started on 2017-08-19, presumably until 2017-08-19, with intended 0 refill(s). Instructions: inject 60 Units subcutaneous (under the skin) 2 times a day\n- 24 HR metformin hydrochloride 500 MG Extended Release Oral Tablet, through Oral route, started on 2019-12-30, presumably until 2019-12-30, with intended 0 refill(s). Instructions: take 500 mg by mouth 2 times a day\n- 0.5 ML dulaglutide 1.5 MG/ML Auto-Injector, through Subcutaneous route, started on 2020-01-07, presumably until 2020-01-07, with intended 0 refill(s). Instructions: inject subcutaneous (under the skin) every 7 days Every Mondays\n- rosuvastatin calcium 20 MG Oral Tablet, started on 2019-08-24, presumably until 2019-08-24, with intended 0 refill(s). Instructions: TAKE ONE TABLET BY MOUTH ONE TIME DAILY\n- losartan potassium 25 MG Oral Tablet, through Oral route, started on 2019-11-15, presumably until 2019-11-15, with intended 0 refill(s). Instructions: take 1 Tablet (25 mg total) by mouth 2 times a day\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-02-01 10:33:00, ended at 2020-02-01 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 47.1 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 26.9 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 21 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 41 (unit per liter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 46 (unit per liter)\n- Bilirubin.indirect [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.7 (percent)\n- Iron saturation [Mass Fraction] in Serum or Plasma: 13 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 10.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.38 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.43 (million per microliter)\n- Iron [Mass/volume] in Serum or Plasma: 46 (microgram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 16.3 (percent)\n- MCHC [Mass/volume] by Automated count: 31.0 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 4.67 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.4 (gram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.4 (gram per deciliter)\n- Bilirubin.direct [Mass/volume] in Serum or Plasma: 0.21 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 104 (unit per liter)\n- Ferritin [Mass/volume] in Serum or Plasma: 69.0 (nanogram per milliliter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 132 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.1 (percent)\n- Platelets [#/volume] in Blood by Automated count: 72 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.8 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.11 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 86.7 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 68.8 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Prothrombin time (PT): 13.9 (second)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-14 00:00:00, ended at 2020-02-14 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-02-18 00:00:00, ended at 2020-02-18 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 07:12:00, ended at 2020-03-31 08:24:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Bone and/or joint imaging; whole body\n\n### Condition\n- Liver cell carcinoma\n- Lumbar spondylosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 08:25:00, ended at 2020-03-31 10:25:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; without contrast material\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-03-31 13:22:00, ended at 2020-03-31 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n- Magnetic resonance (eg, proton) imaging, pelvis; without contrast material(s), followed by contrast material(s) and further sequences\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-04 00:00:00, ended at 2020-04-04 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Cirrhosis of liver\n- Nonalcoholic steatohepatitis\n- Portal vein thrombosis\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-04 00:00:00, ended at 2020-04-04 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-15 00:00:00, ended at 2020-04-15 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-04-18 00:00:00, ended at 2020-04-18 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-18 10:04:44, ended at 2020-04-18 10:16:59\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-04-22 07:47:00, ended at 2020-04-22 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Ultrasound, abdominal, real time with image documentation; complete\n- Duplex scan of arterial inflow and venous outflow of abdominal, pelvic, scrotal contents and/or retroperitoneal organs; limited study\n\n### Condition\n- Postoperative state\n- Steatosis of liver\n- Disorder of digestive system\n- Hepatosplenomegaly\n- Liver cell carcinoma\n- Acquired absence of organ\n- Disease of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-04-28 09:33:22, ended at 2020-04-28 10:35:04\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Essential hypertension\n- Malignant neoplasm of liver\n- Traumatic or non-traumatic injury\n- Obstructive sleep apnea syndrome\n- Generalized ischemic myocardial dysfunction\n- Hyperlipidemia\n- Primary diagnosis: COVID-19\n- Liver cell carcinoma\n\n### Drug\n- sulfamethoxazole 800 MG / trimethoprim 160 MG Oral Tablet, through Oral route, presumably until 2020-11-14, with intended 0 refill(s). Instructions: take 1 Tab by mouth 2 times a day\n- aspirin 81 MG Delayed Release Oral Tablet, through Oral route, with intended 0 refill(s). Instructions: take 1 Tablet (81 mg total) by mouth daily\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for non-invasive imaging or radiation therapy\n\n### Condition\n- Liver cell carcinoma\n- Essential hypertension\n- Atherosclerosis of coronary artery without angina pectoris\n\n### Drug\n- 2 ML sugammadex 100 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- magnesium chloride 0.00148 MEQ/ML / potassium chloride 0.0497 MEQ/ML / sodium acetate 0.0163 MEQ/ML / sodium chloride 0.0899 MEQ/ML / sodium gluconate 5.02 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 10 ML esmolol hydrochloride 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- cefazolin 1000 MG Injection, started on 2020-05-01, presumably until 2020-05-01\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 100 ML acetaminophen 10 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n- 2 ML ondansetron 2 MG/ML Injection, started on 2020-05-01, presumably until 2020-05-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Hospital, started at 2020-05-01 00:00:00, ended at 2020-05-01 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2020-05-01, presumably until 2020-05-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-05-01 08:40:00, ended at 2020-05-01 19:30:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.32 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 5.16 (million per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 45.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 58 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- INR in Blood by Coagulation assay: 1.1 (ratio)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.0 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.7 (millimole per liter)\n- Anion gap in Serum or Plasma: 13 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 98 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 27.5 (picogram)\n- MCV [Entitic volume] by Automated count: 88.6 (femtoliter)\n- Body height: 5' 6\" (inch (US))\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 223 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 31.1 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 26 (millimole per liter)\n\n### Procedure\n- Ablation, 1 or more liver tumor(s), percutaneous, radiofrequency\n- Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only\n- Computed tomography guidance for, and monitoring of, parenchymal tissue ablation\n- Collection of venous blood by venipuncture\n\n### Condition\n- Aortocoronary bypass graft present\n- Steatosis of liver\n- Hyperlipidemia\n- Old myocardial infarction\n- Supraventricular tachycardia\n- Chronic systolic heart failure\n- Primary diagnosis: Liver cell carcinoma\n- Generalized ischemic myocardial dysfunction\n- Chronic congestive heart failure\n- Hypertensive heart failure\n- Obesity\n- Type 2 diabetes mellitus without complication\n\n### Drug\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2020-05-01, presumably until 2020-05-01\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-06-24 00:00:00, ended at 2020-06-24 00:00:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-07-04 10:32:19, ended at 2020-07-04 10:56:47\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nonalcoholic steatohepatitis\n- Cirrhosis of liver\n- Primary diagnosis: Liver cell carcinoma\n- Portal vein thrombosis\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-08-05 07:00:00, ended at 2020-08-05 23:59:00\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-06 08:46:06, ended at 2020-08-06 09:13:34\nThe patient in this visit was 70 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2020-08-07 00:00:00, ended at 2020-08-07 00:00:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-08-15 10:36:58, ended at 2020-08-15 11:02:37\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Neoplasm defined only by topography: Liver\n- Portal vein thrombosis\n- Cirrhosis of liver\n- Nonalcoholic steatohepatitis\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-11-05 07:10:00, ended at 2020-11-05 23:59:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-11-14 09:54:20, ended at 2020-11-14 10:11:20\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n- Nonalcoholic steatohepatitis\n- Cirrhosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-01-12 00:00:00, ended at 2021-01-12 00:00:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Prostate specific Ag [Mass/volume] in Serum or Plasma: 0.56 (nanogram per milliliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2021-02-06 00:00:00, ended at 2021-02-06 00:00:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-02-12 12:59:00, ended at 2021-02-12 23:59:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Portal hypertension\n- Splenomegaly\n- Liver cell carcinoma\n- Cirrhosis of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2021-02-13 10:28:20, ended at 2021-02-13 10:49:11\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 5.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Nonalcoholic steatohepatitis\n- Cirrhosis of liver\n- Primary diagnosis: Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2021-05-08 06:57:00, ended at 2021-05-08 23:59:00\nThe patient in this visit was 71 years old, Asian, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Magnetic resonance (eg, proton) imaging, abdomen; without contrast material(s), followed by with contrast material(s) and further sequences\n\n### Condition\n- Cirrhosis of liver\n- Liver cell carcinoma\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "abfba416c551706ccd9b2ad7a2e8092272b4a5a72b4641e93b07d59ef6160e50", "prompt_hash": "e09c9d147f376dea3dbf056ee4074adc50a73687f64573586563b0eb3381644f", "target_hash": "85a39ab345d672ff8ca9b9c6876f3adcacf45ee7c1e2dbd2408fd338bd55e07e", "exact_match": 0.0, "f1_gu_yn": [1, 0], "recall_gu_yn": [1, 0]}
{"doc_id": 8, "doc": {"person_id": 115968156, "visit_occurrence_id": 169322226, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2020-12-20 14:50:00", "visit_end_datetime": "2020-12-20 23:59:00", "visit_length_in_hours": 9.15, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 104, "patient_first_visit_date": "2009-03-14 11:00:00", "patient_last_visit_date": "2022-11-08 16:25:00", "end_obs_date": "2021-12-20", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 1, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "recurrent", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "new", "type_ii_diabetes_one_year_diagnosis": 0, "breast_cancer_type": "recurrent", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "recurrent", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "recurrent", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "new", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 6, "cumulated_visit_num": 6, "cumulated_approximate_token_count": 3919, "visit_cumulated": "## Visit\nThis visit record, was from Inpatient Visit, started at 2009-03-14 11:00:00, ended at 2009-03-15 17:02:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 47 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 2.0 (ratio)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 251 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: J.CHU,Mondovi /ED @ 1153. (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 2.4 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 233 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 16.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 9.0 (millimole per liter)\n- Prothrombin time (PT): 22.1 (second)\n- Body height: 5' 11\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 3.3 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.04 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tachypnea\n- Congestive heart failure\n- Ischemic heart disease\n- Joint pain\n- Chronic kidney disease\n- Nausea and vomiting\n- Acute subendocardial infarction\n- Hyperlipidemia\n- Hypoxemia\n- Lung field abnormal\n- Benign hypertensive renal disease with renal failure\n- Chest pain\n- Disturbance in speech\n- Hypervolemia\n- Pain in limb\n- Late effects of cerebrovascular disease\n\n### Drug\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- warfarin sodium 5 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 5 mg by mouth. Sat and Sun schedule\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, presumably until 2021-12-03. Instructions: take 25 mg by mouth daily. \n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-03-13, presumably until 2009-03-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-03-14, presumably until 2009-03-15\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-14\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-03-15, presumably until 2009-07-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain. \n- baclofen 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2021-12-01. Instructions: take 10 mg by mouth 3 times a day. \n- lisinopril 20 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 20 mg by mouth daily. \n- 10 ML furosemide 10 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2010-03-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day. \n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2009-03-15, presumably until 2009-03-15\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2009-03-13, presumably until 2009-07-10. Instructions: take 300 mg by mouth 3 times a day. \n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-03-13, presumably until 2009-03-15\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, presumably until 2009-03-15. Instructions: take 2.5 mg by mouth daily. \n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- lovastatin 20 MG Oral Tablet, through Oral route. Instructions: take 20 mg by mouth every bedtime. \n- 2 ML ondansetron 2 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2009-03-15, presumably until 2009-03-15\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2009-03-13, presumably until 2009-03-13\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-03-13, presumably until 2009-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-10 00:00:00, ended at 2009-05-10 00:00:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Idiopathic interstitial pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-01-30 00:34:00, ended at 2017-01-30 06:03:00\nThe patient in this visit was 73 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 229 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.2 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.22 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.60 (thousand per microliter)\n- Prothrombin time (PT): 21.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.63 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 262 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Pain in left lower limb\n- Pain in right lower limb\n- Hypoglycemia\n- Primary diagnosis: Spasm\n- Pain in lower limb\n- Essential hypertension\n\n### Drug\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-01-30, presumably until 2017-01-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2018-06-20 09:01:00, ended at 2018-06-20 13:30:00\nThe patient in this visit was 74 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.4 (percent)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.7 (percent)\n- Prothrombin time (PT): 24.0 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.3 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Neck pain\n- Dysarthria\n- Cerebral artery occlusion\n- Injury of muscle and tendon at neck level\n- Muscle strain\n- Spasm\n- Headache\n- Essential hypertension\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2018-06-20, presumably until 2018-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-20 00:00:00, ended at 2020-12-20 00:00:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of breast upper outer quadrant\n- Primary diagnosis: Primary malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2009-03-14 11:00:00, ended at 2009-03-15 17:02:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 61 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.7 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood: 47 (percent)\n- INR in Platelet poor plasma by Coagulation assay: 2.0 (ratio)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.6 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.67 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 34.4 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 251 (thousand per microliter)\n- aPTT in Platelet poor plasma by Coagulation assay: 26.1 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Protein [Mass/volume] in Serum or Plasma: 7.9 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 38 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: J.CHU,Mondovi /ED @ 1153. (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 171 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.6 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.8 (milligram per deciliter)\n- Troponin I.cardiac [Mass/volume] in Serum or Plasma: 2.4 (nanogram per milliliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Creatine kinase [Enzymatic activity/volume] in Serum or Plasma: 233 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood by calculation: 16.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 90.3 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 9.0 (millimole per liter)\n- Prothrombin time (PT): 22.1 (second)\n- Body height: 5' 11\" (inch (US))\n- Eosinophils [#/volume] in Blood by Automated count: 0.07 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.6 (gram per deciliter)\n- Potassium [Moles/volume] in Blood: 3.3 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.5 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.77 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 7.04 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 86.9 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 105 (millimole per liter)\n- Sodium [Moles/volume] in Blood: 141 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Tachypnea\n- Congestive heart failure\n- Ischemic heart disease\n- Joint pain\n- Chronic kidney disease\n- Nausea and vomiting\n- Acute subendocardial infarction\n- Hyperlipidemia\n- Hypoxemia\n- Lung field abnormal\n- Benign hypertensive renal disease with renal failure\n- Chest pain\n- Disturbance in speech\n- Hypervolemia\n- Pain in limb\n- Late effects of cerebrovascular disease\n\n### Drug\n- warfarin sodium 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- warfarin sodium 5 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 5 mg by mouth. Sat and Sun schedule\n- hydrochlorothiazide 25 MG Oral Tablet, through Oral route, presumably until 2021-12-03. Instructions: take 25 mg by mouth daily. \n- 100 ML potassium chloride 0.1 MEQ/ML Injection, through Intravenous route, started on 2009-03-13, presumably until 2009-03-13\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2009-03-14, presumably until 2009-03-15\n- simvastatin 20 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-14\n- lidocaine hydrochloride 10 MG/ML Injectable Solution, started on 2009-03-13, presumably until 2009-03-13\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2009-03-15, presumably until 2009-07-10, with quantity of 30.0, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain. \n- baclofen 10 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2021-12-01. Instructions: take 10 mg by mouth 3 times a day. \n- lisinopril 20 MG Oral Tablet, through Oral route, presumably until 2021-12-01. Instructions: take 20 mg by mouth daily. \n- 10 ML furosemide 10 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- metoprolol tartrate 25 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2010-03-15, with quantity of 60.0, with intended 0 refill(s). Instructions: take 0.5 Tabs by mouth 2 times a day. \n- insulin lispro 100 UNT/ML Injectable Solution, through Subcutaneous route, started on 2009-03-15, presumably until 2009-03-15\n- gabapentin 300 MG Oral Capsule, through Oral route, started on 2009-03-13, presumably until 2009-07-10. Instructions: take 300 mg by mouth 3 times a day. \n- 0.8 ML enoxaparin sodium 100 MG/ML Prefilled Syringe, through Subcutaneous route, started on 2009-03-13, presumably until 2009-03-15\n- warfarin sodium 2.5 MG Oral Tablet, through Oral route, presumably until 2009-03-15. Instructions: take 2.5 mg by mouth daily. \n- aspirin 81 MG Chewable Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-13\n- lovastatin 20 MG Oral Tablet, through Oral route. Instructions: take 20 mg by mouth every bedtime. \n- 2 ML ondansetron 2 MG/ML Injection, started on 2009-03-13, presumably until 2009-03-13\n- 1 ML morphine sulfate 2 MG/ML Prefilled Syringe, started on 2009-03-15, presumably until 2009-03-15\n- nitroglycerin 0.4 MG Sublingual Tablet, through Sublingual route, started on 2009-03-13, presumably until 2009-03-13\n- clopidogrel 75 MG Oral Tablet, through Oral route, started on 2009-03-13, presumably until 2009-03-15\n- 1 ML morphine sulfate 4 MG/ML Prefilled Syringe, started on 2009-03-13, presumably until 2009-03-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2009-05-10 00:00:00, ended at 2009-05-10 00:00:00\nThe patient in this visit was 65 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Idiopathic interstitial pneumonia\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2017-01-30 00:34:00, ended at 2017-01-30 06:03:00\nThe patient in this visit was 73 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 25 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 31.9 (gram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 229 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 144 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.2 (second)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.17 (million per microliter)\n- Globulin [Mass/volume] in Serum: 4.2 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 36.8 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 23 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 7.7 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.22 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.83 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.7 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.4 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.06 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.8 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 5.60 (thousand per microliter)\n- Prothrombin time (PT): 21.8 (second)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.63 (milligram per deciliter)\n- Glucose [Mass/volume] in Blood: 262 (milligram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.6 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 38 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 28.2 (picogram)\n- Potassium [Moles/volume] in Serum or Plasma: 3.4 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- MCV [Entitic volume] by Automated count: 88.2 (femtoliter)\n\n### Procedure\n- Duplex scan of extremity veins including responses to compression and other maneuvers; complete bilateral study\n\n### Condition\n- Pain in left lower limb\n- Pain in right lower limb\n- Hypoglycemia\n- Primary diagnosis: Spasm\n- Pain in lower limb\n- Essential hypertension\n\n### Drug\n- 50 ML glucose 500 MG/ML Prefilled Syringe, through Intravenous route, started on 2017-01-30, presumably until 2017-01-30\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Emergency Room Visit, started at 2018-06-20 09:01:00, ended at 2018-06-20 13:30:00\nThe patient in this visit was 74 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 35.3 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 19.4 (percent)\n- MCV [Entitic volume] by Automated count: 88.3 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.26 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.1 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- MCH [Entitic mass] by Automated count: 29.3 (picogram)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.7 (percent)\n- Prothrombin time (PT): 24.0 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Leukocytes [#/volume] in Specimen by Automated count: 6.5 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 24 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 11.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 38.3 (second)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.98 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.65 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 4.54 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Platelets [#/volume] in Blood by Automated count: 218 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Neck pain\n- Dysarthria\n- Cerebral artery occlusion\n- Injury of muscle and tendon at neck level\n- Muscle strain\n- Spasm\n- Headache\n- Essential hypertension\n\n### Drug\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- acetaminophen 325 MG / oxycodone hydrochloride 5 MG Oral Tablet, through Oral route, started on 2018-06-20, presumably until 2018-06-20\n- lidocaine 0.05 MG/MG Medicated Patch, through Topical route, started on 2018-06-20, presumably until 2018-06-20\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Telehealth, started at 2020-12-20 00:00:00, ended at 2020-12-20 00:00:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of breast upper outer quadrant\n- Primary diagnosis: Primary malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2020-12-20 14:50:00, ended at 2020-12-20 23:59:00\nThe patient in this visit was 77 years old, Black or African American, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Overlapping malignant neoplasm of male breast\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "e8f389ba77b367cd0b94b9947d1992851710e01f83c6206c3ecfe6277ecfa47d", "prompt_hash": "d04225a0df77fdeca330445136835f397739292ee4eb4d72166dfcee4cfc0623", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
{"doc_id": 9, "doc": {"person_id": 115968294, "visit_occurrence_id": 61839720, "death_date": null, "visit_concept_name": "Outpatient Visit", "visit_start_datetime": "2014-04-10 14:30:00", "visit_end_datetime": "2014-04-10 23:59:00", "visit_length_in_hours": 9.483333333333333, "integrated_visit_record": "## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-10 14:30:00, ended at 2014-04-10 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n", "approximate_token_count": 91, "patient_first_visit_date": "2012-09-21 00:00:00", "patient_last_visit_date": "2022-06-22 00:00:00", "end_obs_date": "2015-04-10", "hypertension_type": "recurrent", "hypertension_one_year_diagnosis": 0, "obesity_type": "new", "obesity_one_year_diagnosis": 0, "asthma_type": "new", "asthma_one_year_diagnosis": 0, "hyperlipidemia_type": "recurrent", "hyperlipidemia_one_year_diagnosis": 0, "depressive_disorder_type": "new", "depressive_disorder_one_year_diagnosis": 0, "chronic_kidney_disease_type": "new", "chronic_kidney_disease_one_year_diagnosis": 0, "chronic_obstructive_pulmonary_disease_type": "new", "chronic_obstructive_pulmonary_disease_one_year_diagnosis": 0, "coronary_arteriosclerosis_type": "new", "coronary_arteriosclerosis_one_year_diagnosis": 0, "type_ii_diabetes_type": "recurrent", "type_ii_diabetes_one_year_diagnosis": 1, "breast_cancer_type": "new", "breast_cancer_one_year_diagnosis": 0, "prostate_cancer_type": "new", "prostate_cancer_one_year_diagnosis": 0, "pancreatic_cancer_type": "new", "pancreatic_cancer_one_year_diagnosis": 0, "lupus_type": "new", "lupus_one_year_diagnosis": 0, "acute_myocardial_infarction_type": "new", "acute_myocardial_infarction_one_year_diagnosis": 0, "ischemic_stroke_type": "new", "ischemic_stroke_one_year_diagnosis": 0, "heart_failure_type": "new", "heart_failure_one_year_diagnosis": 0, "dementia_type": "new", "dementia_one_year_diagnosis": 0, "intestinal_cancer_type": "new", "intestinal_cancer_one_year_diagnosis": 0, "gastric_cancer_type": "new", "gastric_cancer_one_year_diagnosis": 0, "lung_cancer_type": "new", "lung_cancer_one_year_diagnosis": 0, "liver_cancer_type": "recurrent", "liver_cancer_one_year_diagnosis": 0, "visit_sequence_number": 101, "cumulated_visit_num": 101, "cumulated_approximate_token_count": 32208, "visit_cumulated": "## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-21 00:00:00, ended at 2012-09-21 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-21 15:02:00, ended at 2012-09-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route. Instructions: take 5 mg by mouth daily.  \n- pioglitazone 15 MG Oral Tablet, through Oral route, presumably until 2013-04-04. Instructions: take 15 mg by mouth daily.  \n- cetirizine hydrochloride 10 MG Oral Tablet, through Oral route, presumably until 2012-10-19. Instructions: take  by mouth.  \n- pravastatin sodium 40 MG Oral Tablet, through Oral route, presumably until 2014-10-23. Instructions: take 40 mg by mouth daily.  \n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route. Instructions: take 0.4 mg by mouth Every Day.\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, presumably until 2012-10-19. Instructions: take  by mouth.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-25 00:00:00, ended at 2012-09-25 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-15 12:00:00, ended at 2012-10-15 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-16 12:29:00, ended at 2012-10-16 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Postprocedural state finding\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-19 08:55:00, ended at 2012-10-19 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.079\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2012-10-25 00:00:00, ended at 2012-10-25 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2012-10-25, presumably until 2012-10-25\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2012-10-25, presumably until 2012-10-25\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2012-10-25, presumably until 2012-10-25\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- cefazolin 1000 MG Injection, started on 2012-10-25, presumably until 2012-10-25\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2012-10-25, presumably until 2012-10-25\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2012-10-25, presumably until 2012-10-25\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2012-10-25, presumably until 2012-10-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- midazolam 1 MG/ML Injectable Solution, started on 2012-10-25, presumably until 2012-10-25\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2012-10-25, presumably until 2012-10-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2012-10-25 11:40:00, ended at 2012-10-31 11:15:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.18 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.50 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.72 (thousand per microliter)\n- Prothrombin time (PT): 14.6 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 181 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Body height: 5' 11\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 277 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 5.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 149 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Partial hepatectomy\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Excision of other bile duct\n- Anastomosis of hepatic duct to gastrointestinal tract\n- Excision of regional lymph nodes\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n- Foreign body granuloma of subcutaneous tissue\n- Benign prostatic hyperplasia without outflow obstruction\n- Inflammatory dermatosis\n- Primary malignant neoplasm of gallbladder\n- Type 2 diabetes mellitus without complication\n- Carcinoma in situ of liver and/or biliary system\n- Essential hypertension\n- Primary malignant neoplasm of biliary tract\n- Acquired absence of organ\n- Hyperlipidemia\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2012-10-28, presumably until 2012-10-28\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2012-10-30, presumably until 2012-10-30\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2012-10-26, presumably until 2012-10-31\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-28\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-11-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain.\n- hydrocortisone 5 MG/ML Topical Cream, through Topical route, started on 2012-10-29, presumably until 2012-11-09, with intended 0 refill(s). Instructions: Please apply thin film to rash once to twice daily.\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-10-31\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-10-30\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2012-10-26, presumably until 2012-10-28\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-10-31\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2012-10-26, presumably until 2012-10-29\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2012-10-30, presumably until 2012-12-07, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2012-10-26, presumably until 2012-10-31\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2012-10-26, presumably until 2012-10-31\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2012-10-26, presumably until 2012-10-29\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2012-10-26, presumably until 2012-10-31\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-11-09, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-09 07:23:00, ended at 2012-11-09 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.079\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2012-11-09, presumably until 2012-12-07, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-22 12:59:00, ended at 2012-11-22 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2012-11-22, presumably until 2014-04-10, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2012-11-22, presumably until 2014-04-10, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed. For nausea and vomiting.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2012-11-22, presumably until 2014-04-10, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-07 08:59:00, ended at 2012-12-07 09:49:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.1 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 141 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.31 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.53 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 205 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-07 09:50:00, ended at 2012-12-07 12:56:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n- Imaging of abdomen abnormal\n- Primary diagnosis: Disorder of gallbladder\n- Incisional hernia\n- Secondary malignant neoplasm of intra-abdominal organs\n- Disease of liver\n- Primary malignant neoplasm of gallbladder\n- Acquired absence of organ\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-07 12:57:00, ended at 2012-12-07 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n- Disorder of gallbladder\n- Lymphadenopathy\n- Hernia of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-13 07:57:00, ended at 2012-12-13 08:48:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 151 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.4 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.32 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.48 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.48 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 121 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 189 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of gallbladder\n- Hernia of anterior abdominal wall\n- Primary malignant neoplasm of gallbladder\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-13 08:49:00, ended at 2012-12-13 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2012-12-13, presumably until 2012-12-13\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2012-12-13, presumably until 2012-12-13\n- sodium chloride 9 MG/ML Injection, started on 2012-12-13, presumably until 2012-12-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-12-13, presumably until 2012-12-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-20 07:40:00, ended at 2012-12-20 07:56:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-20 07:57:00, ended at 2012-12-20 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.45 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 147 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 47.0 (percent)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 38.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 120 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.1 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-28 13:45:00, ended at 2012-12-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-02 10:12:00, ended at 2013-01-02 10:54:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.37 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 309 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.96 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-02 10:55:00, ended at 2013-01-02 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.75\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-03 09:30:00, ended at 2013-01-03 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-01-03, presumably until 2013-01-03\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-01-03, presumably until 2013-01-03\n- sodium chloride 9 MG/ML Injection, started on 2013-01-03, presumably until 2013-01-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-03, presumably until 2013-01-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-10 08:40:00, ended at 2013-01-10 09:05:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-01-10, presumably until 2013-01-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-01-10, presumably until 2013-01-10\n- sodium chloride 9 MG/ML Injection, started on 2013-01-10, presumably until 2013-01-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-10, presumably until 2013-01-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-10 09:06:00, ended at 2013-01-10 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 121 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.15 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.4 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 211 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33.5 (percent)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.42 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-24 08:18:00, ended at 2013-01-24 08:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.95 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 231 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 129 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 308 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.3 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-24 09:00:00, ended at 2013-01-24 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.748\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Primary diagnosis: Disorder of gallbladder\n- Constipation\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-01-24, presumably until 2013-01-24\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-01-24, presumably until 2013-01-24\n- sodium chloride 9 MG/ML Injection, started on 2013-01-24, presumably until 2013-01-24\n- docusate sodium 250 MG Oral Capsule, through Oral route, presumably until 2014-04-10. Instructions: take  by mouth daily.  \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-24, presumably until 2013-01-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-31 09:29:00, ended at 2013-01-31 09:31:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 11 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.06 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 35 (percent)\n- Platelets [#/volume] in Blood by Automated count: 295 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Manual count: 1.3 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Monocytes [#/volume] in Blood by Manual count: 0.4 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.3 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 50 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-31 09:32:00, ended at 2013-01-31 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-14 09:22:00, ended at 2013-02-14 09:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.6 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 48.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.44 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.30 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 188 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.13 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 164 (unit per liter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Blood chemistry abnormal\n- Abnormal glucose level\n- Disorder of gallbladder\n- Hematopoietic system finding\n- Primary malignant neoplasm of gallbladder\n- Constipation\n- Drug-induced neutropenia\n- Acquired absence of organ\n- Secondary malignant neoplasm of intra-abdominal organs\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-14 10:00:00, ended at 2013-02-14 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.748\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n- Constipation\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-02-14, presumably until 2013-02-14\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-02-14, presumably until 2013-02-14\n- sodium chloride 9 MG/ML Injection, started on 2013-02-14, presumably until 2013-02-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-14, presumably until 2013-02-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-28 10:20:00, ended at 2013-02-28 10:26:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.748\" (inch (US))\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-02-28, presumably until 2013-02-28\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-02-28, presumably until 2013-02-28\n- sodium chloride 9 MG/ML Injection, started on 2013-02-28, presumably until 2013-02-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-28, presumably until 2013-02-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-28 10:27:00, ended at 2013-02-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 165 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.05 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 160 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 48.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Constipation\n- Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-14 09:23:00, ended at 2013-03-14 09:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 155 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.5 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.33 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.7 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 178 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.95 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 136 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n- Constipation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-14 10:00:00, ended at 2013-03-14 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.669\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Constipation\n- Primary diagnosis: Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-03-14, presumably until 2013-03-14\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-03-14, presumably until 2013-03-14\n- sodium chloride 9 MG/ML Injection, started on 2013-03-14, presumably until 2013-03-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-14, presumably until 2013-03-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-26 13:56:00, ended at 2013-03-26 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Hernia of anterior abdominal wall\n- Disorder of gallbladder\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-28 09:20:00, ended at 2013-03-28 09:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 185 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.4 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.26 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 159 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Constipation\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-28 10:00:00, ended at 2013-03-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-04 12:48:00, ended at 2013-04-04 14:29:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-04 14:30:00, ended at 2013-04-04 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- capecitabine 500 MG Oral Tablet, started on 2013-04-04, presumably until 2013-07-04, with intended 0 refill(s). Instructions: xeloda 2000 mg po bid only with radiation therapy Monday through Friday x 5.5 wks, #224\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-05 13:31:00, ended at 2013-04-05 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-16 14:03:00, ended at 2013-04-16 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography guidance for placement of radiation therapy fields\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Acquired absence of organ\n- Hernia of anterior abdominal wall\n- Diarrhea\n- Primary malignant neoplasm of gallbladder\n- Carcinoma in situ of liver and/or biliary system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-22 13:45:00, ended at 2013-04-22 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n- Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 09:15:00, ended at 2013-04-23 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-24 14:19:00, ended at 2013-04-24 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-25 15:03:00, ended at 2013-04-25 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-26 14:11:00, ended at 2013-04-26 14:56:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-26 14:57:00, ended at 2013-04-26 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.48 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.40 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 129 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 97.3 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-29 13:06:00, ended at 2013-04-29 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-30 13:18:00, ended at 2013-04-30 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-01 13:24:00, ended at 2013-05-01 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-02 13:17:00, ended at 2013-05-02 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-03 13:13:00, ended at 2013-05-03 13:50:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-03 13:51:00, ended at 2013-05-03 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.48 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.29 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Platelets [#/volume] in Blood by Automated count: 154 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.26 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 13:40:00, ended at 2013-05-07 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-08 14:14:00, ended at 2013-05-08 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-09 13:22:00, ended at 2013-05-09 14:10:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-09 14:11:00, ended at 2013-05-09 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-10 13:31:00, ended at 2013-05-10 14:23:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-10 14:24:00, ended at 2013-05-10 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Platelets [#/volume] in Blood by Automated count: 148 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.11 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.34 (million per microliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.7 (percent)\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acquired absence of organ\n- Primary malignant neoplasm of gallbladder\n- Carcinoma in situ of liver and/or biliary system\n- Disorder of gallbladder\n- Hernia of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-13 13:14:00, ended at 2013-05-13 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Diarrhea\n- Hernia of anterior abdominal wall\n- Carcinoma in situ of liver and/or biliary system\n- Acquired absence of organ\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-14 13:16:00, ended at 2013-05-14 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-15 13:21:00, ended at 2013-05-15 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-16 13:26:00, ended at 2013-05-16 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-17 13:18:00, ended at 2013-05-17 14:29:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-17 14:30:00, ended at 2013-05-17 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.38 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.2 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.34 (million per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 127 (thousand per microliter)\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Collection of venous blood by venipuncture\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Disorder of gallbladder\n- Hernia of anterior abdominal wall\n- Diarrhea\n- Primary malignant neoplasm of gallbladder\n- Acquired absence of organ\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-20 11:40:00, ended at 2013-05-20 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-21 13:10:00, ended at 2013-05-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-22 13:19:00, ended at 2013-05-22 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-23 13:18:00, ended at 2013-05-23 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-24 00:00:00, ended at 2013-05-24 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Convalescence after radiotherapy\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-24 13:30:00, ended at 2013-05-24 14:09:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-24 14:10:00, ended at 2013-05-24 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 136 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 119 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.35 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 115 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Collection of venous blood by venipuncture\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Acquired absence of organ\n- Hernia of anterior abdominal wall\n- Diarrhea\n- Primary malignant neoplasm of gallbladder\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-27 13:17:00, ended at 2013-05-27 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-28 13:23:00, ended at 2013-05-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-29 13:20:00, ended at 2013-05-29 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-06 14:48:00, ended at 2013-06-06 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-21 16:08:00, ended at 2013-06-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.7 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.48 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.29 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 137 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 177 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.0 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-28 12:46:00, ended at 2013-06-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Convalescence after radiotherapy\n- Lung field abnormal\n- Hernia of anterior abdominal wall\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-07-04 00:00:00, ended at 2013-07-04 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n- Convalescence after radiotherapy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 13:39:00, ended at 2013-07-04 14:44:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Convalescence after radiotherapy\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 14:45:00, ended at 2013-07-04 15:43:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n- Convalescence after radiotherapy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 15:44:00, ended at 2013-07-04 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 256 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 149 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 154 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-05 13:32:00, ended at 2013-07-05 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-23 15:51:00, ended at 2013-07-23 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 327 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-07-31 00:00:00, ended at 2013-07-31 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-30 16:54:00, ended at 2013-08-30 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 242 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-27 13:55:00, ended at 2013-09-27 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 229 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.9 (femtoliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.22 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 174 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.37 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 196 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-30 16:00:00, ended at 2013-09-30 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-03 00:00:00, ended at 2013-10-03 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Convalescence after radiotherapy\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-03 14:00:00, ended at 2013-10-03 14:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- mupirocin 20 MG/ML Topical Cream, through Topical route, presumably until 2014-04-10. Instructions: by Topical route 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-03 15:00:00, ended at 2013-10-03 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-12-24 11:22:00, ended at 2013-12-24 13:07:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.37 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 249 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.6 (percent)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 198 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.8 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 210 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-12-24 13:08:00, ended at 2013-12-24 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of gallbladder\n- Postprocedural state finding\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-02 00:00:00, ended at 2014-01-02 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n- Convalescence after radiotherapy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-02 14:00:00, ended at 2014-01-02 14:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-02 15:00:00, ended at 2014-01-02 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-03 12:58:00, ended at 2014-01-03 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-31 00:00:00, ended at 2014-03-31 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-01 12:19:00, ended at 2014-04-01 14:37:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.44 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.70 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 259 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 173 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 180 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.9 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-01 14:38:00, ended at 2014-04-01 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Swelling / lump finding\n- Disorder of gallbladder\n- Lung field abnormal\n- Convalescence after radiotherapy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-10 13:30:00, ended at 2014-04-10 14:29:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-10 14:30:00, ended at 2014-04-10 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n"}, "target": "No", "arguments": {"gen_args_0": {"arg_0": "<|im_start|>user\nThis is a task about predicting if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year based on their recent EHR visit data: \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-21 00:00:00, ended at 2012-09-21 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-09-21 15:02:00, ended at 2012-09-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- finasteride 5 MG Oral Tablet, through Oral route. Instructions: take 5 mg by mouth daily.  \n- pioglitazone 15 MG Oral Tablet, through Oral route, presumably until 2013-04-04. Instructions: take 15 mg by mouth daily.  \n- cetirizine hydrochloride 10 MG Oral Tablet, through Oral route, presumably until 2012-10-19. Instructions: take  by mouth.  \n- pravastatin sodium 40 MG Oral Tablet, through Oral route, presumably until 2014-10-23. Instructions: take 40 mg by mouth daily.  \n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route. Instructions: take 0.4 mg by mouth Every Day.\n- diphenhydramine hydrochloride 25 MG Oral Capsule, through Oral route, presumably until 2012-10-19. Instructions: take  by mouth.  \n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2012-09-25 00:00:00, ended at 2012-09-25 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Consultation and report on referred slides prepared elsewhere\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-15 12:00:00, ended at 2012-10-15 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-16 12:29:00, ended at 2012-10-16 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen; with contrast material(s)\n\n### Condition\n- Postprocedural state finding\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-10-19 08:55:00, ended at 2012-10-19 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.079\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2012-10-25 00:00:00, ended at 2012-10-25 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Anesthesia for intraperitoneal procedures in upper abdomen including laparoscopy; partial hepatectomy or management of liver hemorrhage (excluding liver biopsy)\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- neostigmine methylsulfate 0.5 MG/ML Injectable Solution, started on 2012-10-25, presumably until 2012-10-25\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- 50 ML albumin human, USP 50 MG/ML Injection, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- glycopyrrolate 0.2 MG/ML Injectable Solution, started on 2012-10-25, presumably until 2012-10-25\n- 1 ML ephedrine sulfate 50 MG/ML Injection, started on 2012-10-25, presumably until 2012-10-25\n- cefoxitin 1000 MG Injection, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- cefazolin 1000 MG Injection, started on 2012-10-25, presumably until 2012-10-25\n- labetalol hydrochloride 5 MG/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- phenylephrine hydrochloride 10 MG/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- insulin, regular, human 100 UNT/ML Injectable Solution, started on 2012-10-25, presumably until 2012-10-25\n- 2 ML lidocaine hydrochloride 20 MG/ML Injection, started on 2012-10-25, presumably until 2012-10-25\n- rocuronium bromide 10 MG/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- 2 ML ondansetron 2 MG/ML Injection, started on 2012-10-25, presumably until 2012-10-25\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-10-25, presumably until 2012-10-25\n- midazolam 1 MG/ML Injectable Solution, started on 2012-10-25, presumably until 2012-10-25\n- 1 ML hydromorphone hydrochloride 2 MG/ML Injection, started on 2012-10-25, presumably until 2012-10-25\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Inpatient Visit, started at 2012-10-25 11:40:00, ended at 2012-10-31 11:15:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium.ionized [Moles/volume] in Serum or Plasma: 1.18 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.50 (million per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 8.72 (thousand per microliter)\n- Prothrombin time (PT): 14.6 (second)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 9 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 95 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 57 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 181 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Body height: 5' 11\" (inch (US))\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- INR in Platelet poor plasma by Coagulation assay: 1.2 (ratio)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 8.9 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 277 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Phosphate [Mass/volume] in Serum or Plasma: 5.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.34 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.8 (femtoliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 7.6 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 88.4 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- aPTT in Platelet poor plasma by Coagulation assay: 30.6 (second)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.9 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.3 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 149 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Magnesium [Mass/volume] in Serum or Plasma: 1.9 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 9.9 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.63 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Partial hepatectomy\n- Level IV - Surgical pathology, gross and microscopic examination Abortion - spontaneous/missed Artery, biopsy Bone marrow, biopsy Bone exostosis Brain/meninges, other than for tumor resection Breast, biopsy, not requiring microscopic evaluation of surgica\n- Excision of other bile duct\n- Anastomosis of hepatic duct to gastrointestinal tract\n- Excision of regional lymph nodes\n- Level V - Surgical pathology, gross and microscopic examination Adrenal, resection Bone - biopsy/curettings Bone fragment(s), pathologic fracture Brain, biopsy Brain/meninges, tumor resection Breast, excision of lesion, requiring microscopic evaluation of\n- Pathology consultation during surgery; first tissue block, with frozen section(s), single specimen\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n- Foreign body granuloma of subcutaneous tissue\n- Benign prostatic hyperplasia without outflow obstruction\n- Inflammatory dermatosis\n- Primary malignant neoplasm of gallbladder\n- Type 2 diabetes mellitus without complication\n- Carcinoma in situ of liver and/or biliary system\n- Essential hypertension\n- Primary malignant neoplasm of biliary tract\n- Acquired absence of organ\n- Hyperlipidemia\n\n### Drug\n- 1000 ML glucose 50 MG/ML / potassium chloride 0.02 MEQ/ML / sodium chloride 4.5 MG/ML Injection, through Intravenous route, started on 2012-10-28, presumably until 2012-10-28\n- bisacodyl 10 MG Rectal Suppository, through Rectal route, started on 2012-10-30, presumably until 2012-10-30\n- finasteride 5 MG Oral Tablet, through Oral route, started on 2012-10-26, presumably until 2012-10-31\n- calcium chloride 0.0014 MEQ/ML / potassium chloride 0.004 MEQ/ML / sodium chloride 0.103 MEQ/ML / sodium lactate 0.028 MEQ/ML Injectable Solution, through Intravenous route, started on 2012-10-25, presumably until 2012-10-28\n- acetaminophen 650 MG Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-11-09, with intended 0 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed for Pain.\n- hydrocortisone 5 MG/ML Topical Cream, through Topical route, started on 2012-10-29, presumably until 2012-11-09, with intended 0 refill(s). Instructions: Please apply thin film to rash once to twice daily.\n- pantoprazole 40 MG Delayed Release Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-10-31\n- Microencapsulated potassium chloride 20 MEQ Extended Release Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-10-30\n- pantoprazole 40 MG Injection, through Intravenous route, started on 2012-10-26, presumably until 2012-10-28\n- acetaminophen 325 MG Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-10-31\n- 5 ML metoprolol tartrate 1 MG/ML Injection, through Intravenous route, started on 2012-10-26, presumably until 2012-10-29\n- docusate sodium 250 MG Oral Capsule, through Oral route, started on 2012-10-30, presumably until 2012-12-07, with intended 0 refill(s). Instructions: take 1 Cap by mouth 2 times a day.\n- 0.5 ML heparin sodium, porcine 10000 UNT/ML Injection, started on 2012-10-26, presumably until 2012-10-31\n- atorvastatin 20 MG Oral Tablet, through Oral route, started on 2012-10-26, presumably until 2012-10-31\n- 1 ML ketorolac tromethamine 15 MG/ML Injection, started on 2012-10-26, presumably until 2012-10-29\n- tamsulosin hydrochloride 0.4 MG Oral Capsule, through Oral route, started on 2012-10-26, presumably until 2012-10-31\n- acetaminophen 325 MG / hydrocodone bitartrate 5 MG Oral Tablet, through Oral route, started on 2012-10-30, presumably until 2012-11-09, with intended 0 refill(s). Instructions: take 1-2 Tabs by mouth every 4 hours as needed for Pain.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-09 07:23:00, ended at 2012-11-09 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.079\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of intrahepatic bile duct\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- polyethylene glycol 3350 17000 MG Powder for Oral Solution, through Oral route, started on 2012-11-09, presumably until 2012-12-07, with intended 0 refill(s). Instructions: take 1 Packet by mouth daily as needed.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-11-22 12:59:00, ended at 2012-11-22 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2012-11-22, presumably until 2014-04-10, with intended 1 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n- lorazepam 1 MG Oral Tablet, through Oral route, started on 2012-11-22, presumably until 2014-04-10, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 6 hours as needed. For nausea and vomiting.\n- prochlorperazine 10 MG Oral Tablet, through Oral route, started on 2012-11-22, presumably until 2014-04-10, with intended 2 refill(s). Instructions: take 1 Tab by mouth every 8 hours as needed. For nausea and vomiting.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-07 08:59:00, ended at 2012-12-07 09:49:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.4 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.1 (femtoliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 141 (milligram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.31 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.53 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.1 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 19 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.7 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.49 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 205 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.31 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.49 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.9 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 1.0 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.7 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-07 09:50:00, ended at 2012-12-07 12:56:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of lung\n- Imaging of abdomen abnormal\n- Primary diagnosis: Disorder of gallbladder\n- Incisional hernia\n- Secondary malignant neoplasm of intra-abdominal organs\n- Disease of liver\n- Primary malignant neoplasm of gallbladder\n- Acquired absence of organ\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-07 12:57:00, ended at 2012-12-07 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Lung field abnormal\n- Disorder of gallbladder\n- Lymphadenopathy\n- Hernia of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-13 07:57:00, ended at 2012-12-13 08:48:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 15 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.0 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 151 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.1 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Monocytes/100 leukocytes in Blood by Automated count: 10.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.3 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 92.4 (femtoliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.32 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 50.5 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.48 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.48 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.6 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 121 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 189 (thousand per microliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of gallbladder\n- Hernia of anterior abdominal wall\n- Primary malignant neoplasm of gallbladder\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-13 08:49:00, ended at 2012-12-13 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2012-12-13, presumably until 2012-12-13\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2012-12-13, presumably until 2012-12-13\n- sodium chloride 9 MG/ML Injection, started on 2012-12-13, presumably until 2012-12-13\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2012-12-13, presumably until 2012-12-13\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-20 07:40:00, ended at 2012-12-20 07:56:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-20 07:57:00, ended at 2012-12-20 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 29.4 (picogram)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 135 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 32.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 42 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.45 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.47 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.7 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 147 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 17 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 47.0 (percent)\n- MCV [Entitic volume] by Automated count: 91.0 (femtoliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 38.6 (percent)\n- Platelets [#/volume] in Blood by Automated count: 120 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.20 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.2 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 100 (millimole per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.1 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 8.6 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2012-12-28 13:45:00, ended at 2012-12-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-02 10:12:00, ended at 2013-01-02 10:54:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.37 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.7 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 120 (unit per liter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.47 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.5 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 309 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.6 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.3 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- MCH [Entitic mass] by Automated count: 30.3 (picogram)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.3 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 1.96 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 46.0 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 40 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.0 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.2 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-02 10:55:00, ended at 2013-01-02 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.75\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-03 09:30:00, ended at 2013-01-03 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-01-03, presumably until 2013-01-03\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-01-03, presumably until 2013-01-03\n- sodium chloride 9 MG/ML Injection, started on 2013-01-03, presumably until 2013-01-03\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-03, presumably until 2013-01-03\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-10 08:40:00, ended at 2013-01-10 09:05:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-01-10, presumably until 2013-01-10\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-01-10, presumably until 2013-01-10\n- sodium chloride 9 MG/ML Injection, started on 2013-01-10, presumably until 2013-01-10\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-10, presumably until 2013-01-10\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-10 09:06:00, ended at 2013-01-10 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 50 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 127 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 30.2 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 54 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 121 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.2 (percent)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.05 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.15 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.4 (percent)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 1.2 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.2 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.3 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.40 (thousand per microliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 211 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 33.5 (percent)\n- MCV [Entitic volume] by Automated count: 91.7 (femtoliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.6 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.42 (million per microliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 40.5 (percent)\n- MCHC [Mass/volume] by Automated count: 32.9 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-24 08:18:00, ended at 2013-01-24 08:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.22 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.4 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.1 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 1.95 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 60 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 231 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.33 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 14.4 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.15 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.59 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.1 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.9 (femtoliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 129 (milligram per deciliter)\n- Platelets [#/volume] in Blood by Automated count: 308 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 28 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 47.3 (percent)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 32.3 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-24 09:00:00, ended at 2013-01-24 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.748\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Primary diagnosis: Disorder of gallbladder\n- Constipation\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-01-24, presumably until 2013-01-24\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-01-24, presumably until 2013-01-24\n- sodium chloride 9 MG/ML Injection, started on 2013-01-24, presumably until 2013-01-24\n- docusate sodium 250 MG Oral Capsule, through Oral route, presumably until 2014-04-10. Instructions: take  by mouth daily.  \n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-01-24, presumably until 2013-01-24\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-31 09:29:00, ended at 2013-01-31 09:31:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 53 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.4 (percent)\n- Lymphocytes [#/volume] in Blood by Manual count: 1.6 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 30.6 (picogram)\n- Monocytes/100 leukocytes in Blood by Manual count: 11 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.06 (million per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.4 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Manual count: 35 (percent)\n- Platelets [#/volume] in Blood by Automated count: 295 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Manual count: 0.0 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Manual count: 1 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 138 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.0 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Neutrophils [#/volume] in Blood by Manual count: 1.3 (thousand per microliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 175 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 18 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Monocytes [#/volume] in Blood by Manual count: 0.4 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 137 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.3 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- MCHC [Mass/volume] by Automated count: 33.6 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Manual count: 50 (percent)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-01-31 09:32:00, ended at 2013-01-31 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- No conditions.\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-14 09:22:00, ended at 2013-02-14 09:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.23 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.9 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 30.6 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 19 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.7 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.2 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.9 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.8 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 48.6 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.44 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.30 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.04 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 12.9 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 188 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.9 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.13 (million per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.71 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 16.8 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.0 (percent)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 164 (unit per liter)\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n\n### Condition\n- Blood chemistry abnormal\n- Abnormal glucose level\n- Disorder of gallbladder\n- Hematopoietic system finding\n- Primary malignant neoplasm of gallbladder\n- Constipation\n- Drug-induced neutropenia\n- Acquired absence of organ\n- Secondary malignant neoplasm of intra-abdominal organs\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-14 10:00:00, ended at 2013-02-14 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.748\" (inch (US))\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n- Constipation\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-02-14, presumably until 2013-02-14\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-02-14, presumably until 2013-02-14\n- sodium chloride 9 MG/ML Injection, started on 2013-02-14, presumably until 2013-02-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-14, presumably until 2013-02-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-28 10:20:00, ended at 2013-02-28 10:26:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.748\" (inch (US))\n\n### Procedure\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-02-28, presumably until 2013-02-28\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-02-28, presumably until 2013-02-28\n- sodium chloride 9 MG/ML Injection, started on 2013-02-28, presumably until 2013-02-28\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-02-28, presumably until 2013-02-28\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-02-28 10:27:00, ended at 2013-02-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Basophils/100 leukocytes in Blood by Automated count: 0.4 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 165 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.23 (million per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.2 (thousand per microliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.1 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.16 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.0 (picogram)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.9 (percent)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.7 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.05 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 5.0 (millimole per liter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 160 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.6 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.6 (percent)\n- MCHC [Mass/volume] by Automated count: 32.8 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 48.7 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.5 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 94.5 (femtoliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.6 (percent)\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Constipation\n- Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-14 09:23:00, ended at 2013-03-14 09:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 155 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 37 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.23 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.5 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 63 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Monocytes [#/volume] in Blood by Automated count: 0.69 (thousand per microliter)\n- Anion gap in Serum or Plasma: 11 (millimole per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.0 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 20 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.17 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 37.8 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.5 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.33 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.8 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 27.7 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Platelets [#/volume] in Blood by Automated count: 178 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 3.95 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 136 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- MCHC [Mass/volume] by Automated count: 33.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.0 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 52.4 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.3 (percent)\n\n### Procedure\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n- Constipation\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-14 10:00:00, ended at 2013-03-14 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.669\" (inch (US))\n\n### Procedure\n- Collection of venous blood by venipuncture\n- Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug\n- Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)\n- Intravenous infusion, hydration; each additional hour (List separately in addition to code for primary procedure)\n- Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)\n- Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)\n\n### Condition\n- Constipation\n- Primary diagnosis: Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- ondansetron 8 MG Oral Tablet, through Oral route, started on 2013-03-14, presumably until 2013-03-14\n- dexamethasone 4 MG Oral Tablet, through Oral route, started on 2013-03-14, presumably until 2013-03-14\n- sodium chloride 9 MG/ML Injection, started on 2013-03-14, presumably until 2013-03-14\n- 150 ML sodium chloride 9 MG/ML Injection, through Intravenous route, started on 2013-03-14, presumably until 2013-03-14\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-26 13:56:00, ended at 2013-03-26 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Hernia of anterior abdominal wall\n- Disorder of gallbladder\n- Lung field abnormal\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-28 09:20:00, ended at 2013-03-28 09:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 142 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.0 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 185 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 28.4 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 51.6 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 13 (milligram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Hemoglobin [Mass/volume] in Blood: 12.7 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.24 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 35 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.14 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.3 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 38.4 (percent)\n- MCH [Entitic mass] by Automated count: 31.7 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.70 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 16.0 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.26 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 66 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 159 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.7 (percent)\n- MCHC [Mass/volume] by Automated count: 33.0 (gram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.00 (million per microliter)\n- Anion gap in Serum or Plasma: 4 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 101 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.2 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 136 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Constipation\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-03-28 10:00:00, ended at 2013-03-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-04 12:48:00, ended at 2013-04-04 14:29:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.984\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-04 14:30:00, ended at 2013-04-04 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- capecitabine 500 MG Oral Tablet, started on 2013-04-04, presumably until 2013-07-04, with intended 0 refill(s). Instructions: xeloda 2000 mg po bid only with radiation therapy Monday through Friday x 5.5 wks, #224\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-05 13:31:00, ended at 2013-04-05 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.669\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-16 14:03:00, ended at 2013-04-16 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography guidance for placement of radiation therapy fields\n- Therapeutic radiology simulation-aided field setting; complex\n\n### Condition\n- Acquired absence of organ\n- Hernia of anterior abdominal wall\n- Diarrhea\n- Primary malignant neoplasm of gallbladder\n- Carcinoma in situ of liver and/or biliary system\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-22 13:45:00, ended at 2013-04-22 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Therapeutic radiology treatment planning; complex\n- Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-23 09:15:00, ended at 2013-04-23 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Basic radiation dosimetry calculation, central axis depth dose calculation, TDF, NSD, gap calculation, off axis factor, tissue inhomogeneity factors, calculation of non-ionizing radiation surface and depth dose, as required during course of treatment, onl\n- Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-24 14:19:00, ended at 2013-04-24 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-25 15:03:00, ended at 2013-04-25 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-26 14:11:00, ended at 2013-04-26 14:56:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-26 14:57:00, ended at 2013-04-26 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.1 (percent)\n- MCHC [Mass/volume] by Automated count: 32.6 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 115 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.48 (million per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.55 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.6 (percent)\n- MCH [Entitic mass] by Automated count: 31.8 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.40 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 67.8 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.9 (milligram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.5 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 129 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 4.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 8 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 27 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.8 (percent)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 43.6 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.1 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 138 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.0 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.7 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 97.3 (femtoliter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-29 13:06:00, ended at 2013-04-29 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-04-30 13:18:00, ended at 2013-04-30 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-01 13:24:00, ended at 2013-05-01 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Radiation treatment management, 5 treatments\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-02 13:17:00, ended at 2013-05-02 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-03 13:13:00, ended at 2013-05-03 13:50:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-03 13:51:00, ended at 2013-05-03 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 99 (unit per liter)\n- MCHC [Mass/volume] by Automated count: 33.3 (gram per deciliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.48 (thousand per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.8 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.1 (percent)\n- Magnesium [Mass/volume] in Serum or Plasma: 2.2 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 134 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.7 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 12.0 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 14 (unit per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: <0.5 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.29 (million per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Platelets [#/volume] in Blood by Automated count: 154 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 18 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 30 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 8.2 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.41 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.3 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 31.9 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.26 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.6 (percent)\n- Eosinophils [#/volume] in Blood by Automated count: 0.28 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.9 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n\n### Procedure\n- No procedures.\n\n### Condition\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-07 13:40:00, ended at 2013-05-07 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-08 14:14:00, ended at 2013-05-08 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-09 13:22:00, ended at 2013-05-09 14:10:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-09 14:11:00, ended at 2013-05-09 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-10 13:31:00, ended at 2013-05-10 14:23:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-10 14:24:00, ended at 2013-05-10 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Platelets [#/volume] in Blood by Automated count: 148 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 14.5 (percent)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.2 (picogram)\n- Neutrophils [#/volume] in Blood by Automated count: 2.11 (thousand per microliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.24 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.5 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.2 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 66.7 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.5 (percent)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.29 (thousand per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 9.3 (percent)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.8 (percent)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.34 (million per microliter)\n- MCV [Entitic volume] by Automated count: 95.7 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.50 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.7 (percent)\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Collection of venous blood by venipuncture\n\n### Condition\n- Acquired absence of organ\n- Primary malignant neoplasm of gallbladder\n- Carcinoma in situ of liver and/or biliary system\n- Disorder of gallbladder\n- Hernia of anterior abdominal wall\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-13 13:14:00, ended at 2013-05-13 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Diarrhea\n- Hernia of anterior abdominal wall\n- Carcinoma in situ of liver and/or biliary system\n- Acquired absence of organ\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-14 13:16:00, ended at 2013-05-14 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-15 13:21:00, ended at 2013-05-15 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-16 13:26:00, ended at 2013-05-16 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-17 13:18:00, ended at 2013-05-17 14:29:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-17 14:30:00, ended at 2013-05-17 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- Hemoglobin [Mass/volume] in Blood: 14.2 (gram per deciliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.38 (thousand per microliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.7 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 7.2 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 69.2 (percent)\n- Eosinophils/100 leukocytes in Blood by Automated count: 7.7 (percent)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- MCHC [Mass/volume] by Automated count: 34.1 (gram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 15.3 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.34 (million per microliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.53 (thousand per microliter)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.25 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 95.9 (femtoliter)\n- Platelets [#/volume] in Blood by Automated count: 127 (thousand per microliter)\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Collection of venous blood by venipuncture\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Disorder of gallbladder\n- Hernia of anterior abdominal wall\n- Diarrhea\n- Primary malignant neoplasm of gallbladder\n- Acquired absence of organ\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-20 11:40:00, ended at 2013-05-20 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-21 13:10:00, ended at 2013-05-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-22 13:19:00, ended at 2013-05-22 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-23 13:18:00, ended at 2013-05-23 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Radiation treatment management, 5 treatments\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-05-24 00:00:00, ended at 2013-05-24 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Convalescence after radiotherapy\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-24 13:30:00, ended at 2013-05-24 14:09:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-24 14:10:00, ended at 2013-05-24 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.4 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 136 (milligram per deciliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.5 (percent)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 119 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 72 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.27 (thousand per microliter)\n- MCH [Entitic mass] by Automated count: 32.8 (picogram)\n- MCV [Entitic volume] by Automated count: 96.6 (femtoliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.1 (percent)\n- MCHC [Mass/volume] by Automated count: 34.0 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.4 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.15 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 3.46 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.35 (million per microliter)\n- Globulin [Mass/volume] in Serum: 2.8 (gram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.3 (gram per deciliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 3.4 (percent)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.6 (percent)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 42.0 (percent)\n- Neutrophils/100 leukocytes in Blood by Automated count: 78.9 (percent)\n- Platelets [#/volume] in Blood by Automated count: 115 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.7 (gram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.9 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 6.1 (percent)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 83 (unit per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.51 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n\n### Procedure\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n- Collection of venous blood by venipuncture\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n\n### Condition\n- Acquired absence of organ\n- Hernia of anterior abdominal wall\n- Diarrhea\n- Primary malignant neoplasm of gallbladder\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-27 13:17:00, ended at 2013-05-27 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-28 13:23:00, ended at 2013-05-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-05-29 13:20:00, ended at 2013-05-29 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy\n- Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-06 14:48:00, ended at 2013-06-06 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-21 16:08:00, ended at 2013-06-21 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 16 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.7 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 6.8 (gram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.13 (thousand per microliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 3.7 (percent)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.48 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.5 (millimole per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 43 (unit per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.01 (thousand per microliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 32 (millimole per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.29 (million per microliter)\n- Globulin [Mass/volume] in Serum: 3.1 (gram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 152 (milligram per deciliter)\n- MCH [Entitic mass] by Automated count: 32.5 (picogram)\n- Platelets [#/volume] in Blood by Automated count: 137 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 98 (unit per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 177 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.2 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 8.7 (milligram per deciliter)\n- MCV [Entitic volume] by Automated count: 96.4 (femtoliter)\n- Sodium [Moles/volume] in Serum or Plasma: 141 (millimole per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 17.6 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 10.5 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 13.9 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.36 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 72.0 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.6 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-06-28 12:46:00, ended at 2013-06-28 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n\n### Condition\n- Convalescence after radiotherapy\n- Lung field abnormal\n- Hernia of anterior abdominal wall\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-07-04 00:00:00, ended at 2013-07-04 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n- Convalescence after radiotherapy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 13:39:00, ended at 2013-07-04 14:44:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Convalescence after radiotherapy\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 14:45:00, ended at 2013-07-04 15:43:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n- Convalescence after radiotherapy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-04 15:44:00, ended at 2013-07-04 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 8.8 (milligram per deciliter)\n- Globulin [Mass/volume] in Serum: 3.5 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 256 (unit per liter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 100 (unit per liter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.4 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 149 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 140 (millimole per liter)\n- Chloride [Moles/volume] in Serum or Plasma: 104 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 154 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-05 13:32:00, ended at 2013-07-05 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 11.26\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-07-23 15:51:00, ended at 2013-07-23 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Creatinine [Mass/volume] in Serum or Plasma: 0.8 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 139 (milligram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 10 (milligram per deciliter)\n- Anion gap in Serum or Plasma: 7 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 327 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Globulin [Mass/volume] in Serum: 3.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.2 (millimole per liter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 79 (unit per liter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.5 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 102 (millimole per liter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.6 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 48 (unit per liter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-07-31 00:00:00, ended at 2013-07-31 00:00:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-08-30 16:54:00, ended at 2013-08-30 23:59:00\nThe patient in this visit was 72 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Calcium [Mass/volume] in Serum or Plasma: 9.0 (milligram per deciliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 65 (unit per liter)\n- Globulin [Mass/volume] in Serum: 3.3 (gram per deciliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 34 (unit per liter)\n- Protein [Mass/volume] in Serum or Plasma: 7.1 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 242 (unit per liter)\n- Anion gap in Serum or Plasma: 9 (millimole per liter)\n- Glucose [Mass/volume] in Serum or Plasma: 128 (milligram per deciliter)\n- Sodium [Moles/volume] in Serum or Plasma: 143 (millimole per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 28 (millimole per liter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.0 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.4 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 106 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-27 13:55:00, ended at 2013-09-27 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 229 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.6 (percent)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.3 (milligram per deciliter)\n- MCHC [Mass/volume] by Automated count: 34.2 (gram per deciliter)\n- Protein [Mass/volume] in Serum or Plasma: 6.9 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 29 (millimole per liter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 15.2 (percent)\n- MCH [Entitic mass] by Automated count: 32.1 (picogram)\n- Monocytes [#/volume] in Blood by Automated count: 0.45 (thousand per microliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 65.3 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 142 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- MCV [Entitic volume] by Automated count: 93.9 (femtoliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.19 (thousand per microliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 13.3 (percent)\n- Globulin [Mass/volume] in Serum: 3.4 (gram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 107 (millimole per liter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 5.7 (percent)\n- Monocytes/100 leukocytes in Blood by Automated count: 13.2 (percent)\n- Neutrophils [#/volume] in Blood by Automated count: 2.22 (thousand per microliter)\n- Platelets [#/volume] in Blood by Automated count: 174 (thousand per microliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 55 (unit per liter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.4 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 15 (milligram per deciliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.52 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.3 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.37 (million per microliter)\n- Glucose [Mass/volume] in Serum or Plasma: 196 (milligram per deciliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-09-30 16:00:00, ended at 2013-09-30 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Secondary malignant neoplasm of liver\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2013-10-03 00:00:00, ended at 2013-10-03 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Convalescence after radiotherapy\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-03 14:00:00, ended at 2013-10-03 14:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- mupirocin 20 MG/ML Topical Cream, through Topical route, presumably until 2014-04-10. Instructions: by Topical route 2 times a day.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-10-03 15:00:00, ended at 2013-10-03 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Primary diagnosis: Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-12-24 11:22:00, ended at 2013-12-24 13:07:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.3 (percent)\n- Protein [Mass/volume] in Serum or Plasma: 7.3 (gram per deciliter)\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 23 (unit per liter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 31 (millimole per liter)\n- MCV [Entitic volume] by Automated count: 91.1 (femtoliter)\n- Monocytes [#/volume] in Blood by Automated count: 0.47 (thousand per microliter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.37 (thousand per microliter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.5 (gram per deciliter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 249 (unit per liter)\n- Anion gap in Serum or Plasma: 5 (millimole per liter)\n- Hemoglobin [Mass/volume] in Blood: 13.1 (gram per deciliter)\n- MCHC [Mass/volume] by Automated count: 33.7 (gram per deciliter)\n- Potassium [Moles/volume] in Serum or Plasma: 3.9 (millimole per liter)\n- Basophils [#/volume] in Blood by Automated count: 0.03 (thousand per microliter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.28 (million per microliter)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 20.6 (percent)\n- MCH [Entitic mass] by Automated count: 30.7 (picogram)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 36 (unit per liter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.7 (percent)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.7 (milligram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.7 (percent)\n- Glucose [Mass/volume] in Serum or Plasma: 198 (milligram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 39.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 3.8 (thousand per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 12 (milligram per deciliter)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 3.8 (gram per deciliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Calcium [Mass/volume] in Serum or Plasma: 9.3 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Lymphocytes [#/volume] in Blood by Automated count: 0.79 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 12.2 (percent)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 61.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 210 (thousand per microliter)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Disorder of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2013-12-24 13:08:00, ended at 2013-12-24 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Disorder of gallbladder\n- Postprocedural state finding\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-01-02 00:00:00, ended at 2014-01-02 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n- Convalescence after radiotherapy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-02 14:00:00, ended at 2014-01-02 14:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-02 15:00:00, ended at 2014-01-02 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-01-03 12:58:00, ended at 2014-01-03 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Case Management Visit, started at 2014-03-31 00:00:00, ended at 2014-03-31 00:00:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-01 12:19:00, ended at 2014-04-01 14:37:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 33 (unit per liter)\n- Erythrocytes [#/volume] in Blood by Automated count: 4.44 (million per microliter)\n- Urea nitrogen [Mass/volume] in Serum or Plasma: 14 (milligram per deciliter)\n- Basophils [#/volume] in Blood by Automated count: 0.02 (thousand per microliter)\n- Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (MDRD): >60 (milliliter per minute per square meter)\n- Neutrophils [#/volume] in Blood by Automated count: 2.70 (thousand per microliter)\n- Sodium [Moles/volume] in Serum or Plasma: 139 (millimole per liter)\n- Anion gap in Serum or Plasma: 6 (millimole per liter)\n- Bilirubin.total [Mass/volume] in Serum or Plasma: 0.5 (milligram per deciliter)\n- Creatinine [Mass/volume] in Serum or Plasma: 0.9 (milligram per deciliter)\n- Eosinophils [#/volume] in Blood by Automated count: 0.18 (thousand per microliter)\n- Potassium [Moles/volume] in Serum or Plasma: 4.6 (millimole per liter)\n- Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma: 259 (unit per liter)\n- Lymphocytes [#/volume] in Blood by Automated count: 1.13 (thousand per microliter)\n- MCV [Entitic volume] by Automated count: 93.1 (femtoliter)\n- Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma: 71 (unit per liter)\n- Albumin [Mass/volume] in Serum or Plasma: 3.8 (gram per deciliter)\n- Carbon dioxide, total [Moles/volume] in Serum or Plasma: 30 (millimole per liter)\n- Erythrocyte distribution width [Ratio] by Automated count: 15.1 (percent)\n- Lymphocytes/100 leukocytes in Blood by Automated count: 24.8 (percent)\n- Chloride [Moles/volume] in Serum or Plasma: 103 (millimole per liter)\n- Globulin [Mass/volume] in Serum: 4.0 (gram per deciliter)\n- Hematocrit [Volume Fraction] of Blood by Automated count: 41.4 (percent)\n- Monocytes [#/volume] in Blood by Automated count: 0.54 (thousand per microliter)\n- Monocytes/100 leukocytes in Blood by Automated count: 11.8 (percent)\n- Platelets [#/volume] in Blood by Automated count: 173 (thousand per microliter)\n- Protein [Mass/volume] in Serum or Plasma: 7.8 (gram per deciliter)\n- Basophils/100 leukocytes in Blood by Automated count: 0.5 (percent)\n- Calcium [Mass/volume] in Serum or Plasma: 9.1 (milligram per deciliter)\n- Glucose [Mass/volume] in Serum or Plasma: 180 (milligram per deciliter)\n- Hemoglobin [Mass/volume] in Blood: 14.0 (gram per deciliter)\n- Eosinophils/100 leukocytes in Blood by Automated count: 4.0 (percent)\n- Leukocytes [#/volume] in Specimen by Automated count: 4.6 (thousand per microliter)\n- MCHC [Mass/volume] by Automated count: 33.9 (gram per deciliter)\n- Neutrophils/100 leukocytes in Blood by Automated count: 58.9 (percent)\n- MCH [Entitic mass] by Automated count: 31.6 (picogram)\n\n### Procedure\n- Collection of venous blood by venipuncture\n\n### Condition\n- Disorder of gallbladder\n- Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-01 14:38:00, ended at 2014-04-01 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- Computed tomography, abdomen and pelvis; with contrast material(s)\n- Computed tomography, thorax, diagnostic; with contrast material(s)\n\n### Condition\n- Primary malignant neoplasm of gallbladder\n- Swelling / lump finding\n- Disorder of gallbladder\n- Lung field abnormal\n- Convalescence after radiotherapy\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-10 13:30:00, ended at 2014-04-10 14:29:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- Body height: 5' 10.512\" (inch (US))\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n<|VISIT_SEPARATOR|> \n\n## Visit\nThis visit record, was from Outpatient Visit, started at 2014-04-10 14:30:00, ended at 2014-04-10 23:59:00\nThe patient in this visit was 73 years old, White, Not Hispanic or Latino, MALE.\n\n### Measurement\n- No measurements.\n\n### Procedure\n- No procedures.\n\n### Condition\n- Primary diagnosis: Primary malignant neoplasm of gallbladder\n\n### Drug\n- No drugs.\n\n\n\nAbove are the patient's recent EHR visit records (including the current visit) in chronological order.\n\nYou are a medical AI assistant analyzing patient data to predict future diagnoses given the patient's recent and current EHR visit records provided above.\n\nINSTRUCTIONS:\n- Predict if the patient will receive a recurrent diagnosis of Hyperlipidemia within the next year (we know this patient has had this condition in their medical records up to the current visit)\n- the condition of hyperlipidemia means itself and any of its descendant conditions in the medical ontology hierarchy\n- Do not provide any explanation, reasoning, or additional text.\n- You must respond with exactly one word only: Yes or No\n\nAnswer:<|im_end|>\n<|im_start|>assistant\n", "arg_1": {"until": ["<im_end>"], "max_gen_toks": 2048, "do_sample": false, "temperature": 0.0}}}, "resps": [["No"]], "filtered_resps": ["No"], "filter": "binary_yn", "metrics": ["exact_match", "f1_gu_yn", "recall_gu_yn"], "doc_hash": "c36128e1b9e07a66bd3579d0f4c4af005fc6459621f425526a1bec8893722f86", "prompt_hash": "3370b23fa7121b978438fae5c4436cd596a5aa0c44ffb2e1959a76566be7825f", "target_hash": "1ea442a134b2a184bd5d40104401f2a37fbc09ccf3f4bc9da161c6099be3691d", "exact_match": 1.0, "f1_gu_yn": [0, 0], "recall_gu_yn": [0, 0]}
